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 Summary  III
Summary 
Prions have been extensively studied since they represent a new class of infectious 
agents in which a protein, PrPSc (prion scrapie), appears to be the sole component of 
the infectious particle. They are responsible for transmissible spongiform 
encephalopathies (TSEs), which affect both, humans and animals. Human prion 
diseases occur in infectious, sporadic or genetic forms. The "protein only" hypothesis 
argues that the key event in the pathogenesis represents the conversion of the normal 
host protein, PrPc, into its pathogenic isoform PrPSc. Prion diseases have been 
associated with the accumulation of this abnormally folded protein and its neurotoxic 
effects. However, it is not known if PrPc loss of function is an important factor since 
the normal biological function of PrPc, a cell surface-anchored glycoprotein 
predominantly expressed in neuronal cells, and the cellular processes in which this 
protein is involved remain obscure.  
 
Recently, the human 37 kDa laminin receptor precursor (LRP), which represents the 
precursor of the human 67 kDa high-affinity laminin receptor (LR), was identified as 
a binding partner for the cellular prion protein in a yeast two-hybrid screen. In order 
to characterize the possible role of LRP/LR as a cell surface receptor for PrPc, cell 
culture studies were performed to investigate the cellular localization of PrP and 
LRP/LR and to analyse the binding and internalization behaviour of PrP depending on 
the presence of LRP/LR on the cell surface of neuronal and non-neuronal cells. 
Immunofluorescence analysis of non-permeabilized murine neuroblastoma cells 
demonstrated that PrP and LRP/LR co-localize on the surface of these cells. In 
addition, baby hamster kidney (BHK) cells transfected with recombinant Semlik-
Forest virus RNAs overexpressed human PrP and human LRP at their cell surface, the 
latter one orientated as a type II transmembrane protein with its C-terminus outside 
and its N-terminus inside the cell. Co-localization of both proteins was observed on 
BHK cells co-transfected with LRP and PrP encoding recombinant SFV RNAs. Cell 
binding and internalization assays with recombinant human PrP demonstrated the 
LRP/LR-dependent binding and endocytosis of externally added human PrP. An 
increased, dose-dependent cell binding of recombinant PrP was demonstrated by BHK 
cells overexpressing full-length human LRP on their cell surface. Trypsin treatment of 
the cell surface revealed the LRP dependent internalization of GST-tagged and 
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untagged, glycosylated PrP. In contrast to wild-type LRP, the expression of an LRP 
mutant lacking its transmembrane domain led to the secretion of this mutant from 
transfected BHK cells and totally abolished the binding and internalization of 
exogenous, recombinant PrP. This LRP mutant could function as a decoy recetor in 
therapy of TSEs. The strict LRP/LR specificity of the PrP binding to neuronal cells 
was verified by testing the displacement capacity of a series of different antibodies in 
the LRP-PrP binding reaction. Only LRP and PrP specific antibodies were able to 
block totally the binding of human GST-fused PrP to N2a and NT2 cells whereas 
various control antibodies used for competition showed no effect. Mapping analyses 
in the yeast two-hybrid system and cell-binding assays identified direct and heparan 
sulfate proteoglycan (HSPG)-dependent interaction sites mediating the binding of 
cellular PrP to the 37-kDa/67-kDa LRP/LR. The relationship between the 37-kDa 
LRP and the 67-kDa high-affinity LR is unknown so far. Both forms were observed in 
plasma membrane fractions of N2a cells. We conclude from these data that the 37-
kDa/67-kDa laminin receptor acts as the main cell surface receptor for PrP. 
 
High-level expression and purification of recombinant, glycosylated prion proteins in 
mammalian cells is essential for a better understanding of the physiological function 
of PrPc and biochemical processes responsible for prion diseases. Due to the presence 
of important organelles, membranes and other cellular cofactors which are necessary 
for the correct processing, trafficking and localization of prion proteins mammalian 
cell culture systems such as the Semliki-Forest virus (SFV) system allow the synthesis 
and characterization of wild-type as well as mutant PrP to get a better insight into the 
biology of these proteins. Therefore, the SFV system was used to generate 
recombinant highly glycosylated human wild-type and human disease-associated 
mutant prion proteins as well as FLAG-tagged human and bovine PrP in cultured 
BHK cells. Both mutated variants, which are related to the human prion diseases fatal 
familial insomnia (FFI) and Creutzfeldt-Jakob disease (CJD) reveal proteinase K (PK) 
resistance, one of the most typical biochemical properties characteristic for the 
infectious scrapie isoform of the prion protein. The subcellular location of both PrP 
mutants at the cell surface and in intracellular compartments of transfected BHK cells 
was similar to that of wild-type PrP without any significant differences regarding the 
cellular distribution and expression level. In addition, FLAG-tagged prion proteins 
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were expressed with high efficiency in BHK cells showing the typical glycosylation 
pattern allowing the rapid and simple purification via anti-FLAG antibody 
chromatography. 
 
PrP dimers could play an essential role in the PrPc  PrPSc conversion process and 
might be involved in PrP interspecies transmission. Recently, crystallization of the 
prion protein in a dimeric form was reported. Size exclusion chromatography showed 
that native soluble homogeneous FLAG tagged prion proteins from hamster, man and 
cattle expressed in the baculovirus system were predominantly dimeric. The PrP/PrP 
interaction was confirmed in rec. SFV-RNA transfected BHK cells co-expressing 
FLAG and oligohistidine tagged human PrP. The yeast two-hybrid system identified 
the octarepeat region and the C-terminal structured domain (aa90-aa230) of PrP as 
PrP/PrP interaction domains. 
 
The identification of the 37-kDa/67-kDa laminin receptor as the receptor for the 
cellular prion protein might represent an important step for a better understanding of 
the molecular biology of prion diseases and might lead to the development of 
powerful therapeutics such as LRP/LR specific antibodies for the treatment of these 
unconventional diseases. 
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2 Chapter I 
1. Prion diseases in humans and animals 
Transmissible spongiform encephalopathies (TSE) represent a special form of fatal 
neurodegenerative diseases affecting humans and animals. Human TSEs include Creutzfeldt-
Jakob disease (CJD), fatal familial insomnia (FFI), Gerstmann-Sträussler-Scheinker syndrome 
(GSS) and Kuru. The most known prion diseases in animals are Scrapie in sheep, bovine 
spongiform encephalopathie (BSE) in cattle and chronic wasting disease (CWD) in elk and 
deer (for review see (Lasmézas and Weiss, 2000; Prusiner et al., 1998; Weissmann and 
Aguzzi, 1997)). The causative agent of these disorders is termed prion which is defined as a 
proteinaceous infectious particle constituted of the abnormal pathogenic isoform, PrPSc, of 
the host-encoded cellular prion protein, PrPc (for review see (Prusiner, 1998)). The alteration 
in protein conformation is thought to be the basic event for the generation of pathogenesis 
produced by a misfolded, oligomeric protein in the absence of any specific nucleic acids 
(Kellings et al., 1992). Therefore, based on the "protein-only" hypothesis, prions represent a 
new class of infectious pathogens (for review see (Prusiner, 1991)). 
 
1.1. History and Epidemiology 
TSEs have a long and exciting history. Scrapie, the prototype of prion diseases in animals 
affecting sheep appeared for the first time in the United Kingdom (UK) and in Germany over 
200 years ago (for review see (Prusiner, 1997)). The observation that the affected animals 
scrape on hedges in the early stage of the disease resulted in the term Scrapie. During the 
progression of the disease these sheeps staggered, collapsed and finally died. The pathological 
examination of the brain revealed spongiform degeneration accompanied by amyloid-like 
plaques, astrocytosis and gliosis (for review see (Lasmézas and Weiss, 2000)).  
In the 1950s Carlton Gajdusek, the later Nobelist, discovered aborigines in New Guinea 
suffering from a human form of TSE that resulted from tribal cannibalism and which was 
later termed Kuru (Gajdusek and Zigas, 1957). One typical characteristic of this degenerative 
disorder was the appearance of "kuru-type" plaques in the brain of affected persons. The 
prohibition of this kind of cannibalistic ritual act by law decreased dramatically the incidence 
rates of people suffering from Kuru.  
In the 1920s the two German physicians Creutzfeldt and Jakob described brain lesions in 
humans similar to those observed in the brains from Kuru-affected aborigines such as 
spongiosis, astrocytosis and gliosis. This human prion disease was termed Creutzfeldt-Jakob 
disease (CJD) (Creutzfeldt, 1920) and occured with up to 85% sporadically and with up to 
15% familial (Masters, 1981). Two further human TSEs have been identified which differ 
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from classical CJD (sporadic and familial cases) in their clinical and pathological criteria and 
are strictly genetically linked: the Gerstmann-Sträussler-Scheinker syndrome (GSS) 
(Gerstmann, 1928) and the fatal familial insomnia (FFI) (Tateishi et al., 1995). 
 
The BSE epidemic and crisis started in the UK in 1985 when the first suspected cases of this 
disease were observed. In November 1987 the first case of BSE was histologically confirmed 
(Wells et al., 1987). In the following years the number of cases increased continuously and 
the crises raised its maximum in the late 1992 and in the beginning of 1993 with 3500 
confirmed new infections each month (source: ministery of agriculture, fisheries and food 
(MAFF), UK). What was the reason for this epidemic affecting cattles in the UK? According 
to the sheep origin hypothesis, the causative pathogens were transmitted from Scrapie-
infected sheep to cattle by feeding cattle with meat and bone meal prepared from sheep 
cadaver including the affected ones. Simultaneously, the sterilization temperature was 
reduced from 130 to 110°C and solvent extractions of fat were suppressed resulting finally in 
an insufficient inactivation of the agent and the possibility to cross the species barrier from 
sheep to cattle (for review see (Edenhofer et al., 1997)). After the UK-prohibition of feeding 
meat and bone-meal to ruminants in July 1988, the so-called feed-ban, followed by  the 
specified bovine offal ban (SBO) in November 1989, the number of BSE-affected cattles 
decreased dramatically yielding in about 50 confirmed newly infected BSE-cases per month 
in January 2002 in England (source: MAFF, UK). Some infected animals born after the feed 
ban might have been infected due to the vertical transmission of the infectious agent from the 
mother cow to the calf. Up to now, BSE-cases have been confirmed in 23 countries 
worldwide (Table I). Some of these cases have been imported from the UK as indicated in 
Table I. 
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Table I. Total numbers of confirmed BSE cases worldwide since 1987* 
Country Total 
number 
Country Total 
number 
United Kingdom 181552 Japan 3 
Ireland 877** Czech. Republic 2 
Portugal 597 Oman 2 
France 529 Lichtenstein 2 
Switzerland 406 Slovenia 2 
Germany 151** Austria 1 
Spain 87 Finland 1 
Belgium 69 Luxembourg 1 
Italy 54** Greece 1 
Netherland 29 Falkland Islands 1 
Denmark 8 Canada 1 
Slovakia 5   
*   http://ourworld-top.cs.com/j1braakman/BSE.htm (updated 26 january 2002) 
** including imported cases from the UK 
 
 
1.2. Sporadic, familial and transmitted (including iatrogenic) TSEs 
Human prion diseases are fatal neurodegenerative disorders which have a sporadic, genetic or 
infectious origin. Genetic TSEs are autosomal dominant diseases caused by defined mutations 
within the prion protein gene (Prn-p). Prn-p represents a single-copy gene which is located on 
the short arm of chromosome 20 in humans (Sparkes et al., 1986). The 15 kb gene consists of 
two short, non-coding exons and a 2,4 kb exon 3 which contains the 759 bp coding region 
followed by a 1,64 kb non-translated 3 region (Kretzschmar et al., 1986; Puckett et al., 
1991). All mammalian genomes analysed so far contain a prion protein gene. In addition, the 
primary structure of PrP is highly conserved between different  species (Schätzl et al., 1995). 
Approximately 10-15% of all human prion diseases are familial. So far, three classical genetic 
human prion diseases have been described: Creutzfeldt-Jakob disease (CJD), fatal familial 
insomnia (FFI) and Gerstmann-Sträussler-Scheinker syndrome (GSS) (for review see 
(Lasmézas and Weiss, 2000; Prusiner, 1998; Weissmann and Aguzzi, 1997). Whereas 85% of 
all CJD cases occur sporadically in the absence of any mutations, FFI, GSS and 15% of CJD 
are dominantly inherited caused by several defined mutations within the Prn-p gene. Genetic 
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linkage has been identified for several amino acid substitutions in the core region of PrP as 
well as some insertions and one deletion within the octarepeat region of the molecule (Figure 
1). Here, the spontaneous (de novo) conversion of PrPc to a misfolded pathogenic isoform 
(PrPSc) in the absence of exogenous prions has been supposed (Young, 1999) but the exact 
mechanism by which these mutations provoke the conformational changes is still unknown. 
Destabilization of the PrPc structure or effects on the thermodynamic stability of PrP caused 
by a few disease-specific amino acid replacements are suggested (Liemann and Glockshuber, 
1999; Riek et al., 1998; Swietnicki et al., 1998; Zhang et al., 2000). For all known mutations 
within the Prn-p gene a genotyp-phenotyp association exists. In contrast to the classic CJD 
phenotype which features a rapidly progressing dementia, GSS is a more slowly progressing 
disease (incubation time for GSS: 3 to 10 years; for CJD: ~1 year) in which ataxia is the 
predominant clinical sign and dementia usually occurs at a later stage (Ghetti et al., 1995). 
Polymorphism at codon 129 of the prion protein gene is implicated both in susceptibility and 
phenotype of human prion diseases. In conjunction with the point mutation at residue 178, the 
valine/methionine polymorphism at position129 determines whether this mutation leads to the 
clinical phenotype of CJD or of FFI (Goldfarb et al., 1992).  
In infectious prion diseases such as Kuru as well as new-variant and iatrogenic CJD 
(transmission via treatment with contaminated human growth hormone or by surgery 
performed by physicians), exogenous PrPSc is thought to impress its conformation on 
endogenous host PrPc, thereby generating more PrPSc in an auto-catalytic reaction (Prusiner 
et al., 1990). Sporadic CJD, which comprise most cases of the disease may result from rare, 
spontaneous conversion of wild-type PrPc to PrPSc or from somatic mutations within the 
Prn-p gene (Cohen et al., 1994). 
 
 
Fig. 1: PrP mutations, polymorphisms and structural elements of the human prion protein. 
Pathogenic mutations are shown below, polymorphisms and structural elements above the PrP 
scheme. H:-helix; S: -pleated sheet; N: asparagine-linked glycosylation site; GPI: glycosyl 
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phosphatidylinositol  anchorage site; -S-S-: disulfide bridge between aa 179 and 214. 
Pathogenic mutations are marked coloured according to the different phenotypes occuring in 
genetic human prion diseases (GSS: pink; CJD: blue; FFI: green; dementia: bold black; PrP 
cerebral amyloid angiopathy (PrP-CAA) : black). 
 
 
1.3. Transmission studies and occurence of new variant CJD 
Despite extensive investigations of the bovine Prn-p gene in affected cattle, neither natural 
polymorphisms nor defined mutations within the PrP encoding gene have been associated 
with the susceptibility to BSE. Therefore, the most probable origin of BSE represents the 
transmission of the Scrapie agent to cattle via insufficiently treated Srapie-affected foodstuff 
feeded to cows, although sporadic BSE cases prior to the first reports of BSE cases cannot be 
excluded. A variety of transmission experiments have demonstrated that TSE agents are able 
to cross the species barrier dependent on the degree of homology in the Prn-p gene between 
infected donor and recipient. Several species such as cattle, goats, pigs, sheep, mice, mink, 
marmosets and macaques have been infected with the BSE agent by the parenteral route 
(Baker et al., 1993; Fraser et al., 1992; Lasmézas et al., 1996). The transmission by the oral 
route was only successful to cattle, goats, sheep, mice and mink. However, one of the most 
interesting questions concerns the transmission of this pathogenic agent to humans and the 
relationship between the BSE crises and the occurance of new variant CJD (vCJD) cases in 
March 1996 in Great Britain (Will et al., 1996). Until January 2002 113 definite and probable 
cases of vCJD have been reported in the UK (referred to the CJD surveillance unit in 
Edinburgh). Although BSE has mainly affected the UK, two definite cases and two probable 
cases of vCJD have been described in France even though these people have never been in the 
UK (Chazot et al., 1996; Deslys et al., 1997). All these patients show common features which 
differ from those noted for the classical form of CJD (sporadic and familial CJD). They were 
remarkable young with a mean age of 29 years in comparison to about 65 years observed for 
patients suffering from sporadic CJD. The duration of illness for vCJD (from the onset of the 
disease until death) was about 15 month, in contrast to the sporadic form of the disease with a 
duration period of 6 months. In addition, clinical aspects were different for both diseases. 
Sequencing of the open reading frames of the Prn-p genes of vCJD patients revealed no 
mutations and all patients were homozygous for methionine at codon 129 (Zeidler et al., 
1997). However, it cannot be concluded that heterozygocity at this codon protects against 
infection and leads to vCJD immunity. It seems that people who are homozygous for 
methionine at this position are more prone to develop the disease than people who are 
heterozygous. In the caucasian population 40% are homozygous for methionine, 50% 
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heterozygous for methionine/valine and 10% homozygous for valine (Collinge, 1999). Very 
recently, an altered frequency of the human leukocyte antigen (HLA) class-II type DQ7 was 
observed in patients suffering from vCJD compared to control persons (sporadic or familial 
CJD-patients or non-infected people) revealing that the HLA-DQ7 antigen is clearly 
underrepresented in patients with vCJD but not in those with the classical form of disease and 
therefore seems to protect against vCJD (Jackson et al., 2001a). This apparently protective 
genetic factor should aid differential diagnosis and may have important implications for the 
understanding of host susceptibility towards infections with BSE prions.  
One of the most amazing features represents the neuropathology of vCJD patients. The brains 
exhibit amyloid plaques surrounded with vacuoles, so-called florid plaques, which are similar 
to those described for some Kuru patients (in addition to kuru-type plaques found in the 
brains of those affected persons) but which have never been observed in the brains of classical 
CJD patients. The location and distribution of florid plaques is similar for all vCJD patients 
examined so far. The most affected locations in the brain are cerebrum and cerebellum. 
Spongiosis, astrocytosis, gliosis and neuronal loss are detected mainly in basal ganglia and 
thalamus. It is noteworthy that PrP depositions consist of proteinase K resistant material and 
are observed in the absence of confluent spongiform changes in the surrounding neurophils 
(Chazot et al., 1996; Will et al., 1996). It has been supposed that the origin of vCJD happened 
during the late eighties and the beginning nineties where presumably high amounts of BSE-
contaminated material has entered the food chain. This might explain why most of the 
affected people originate from the UK, the country in which the BSE epidemic appeared. In 
addition, experminantal data i.e. transmission studies with transgenic animals carrying the 
human Prn-p gene (Hill et al., 1997; Scott et al., 1999), molecular analysis of prion strain 
variation (Collinge et al., 1996) and inoculation experiments with mice infected with BSE- 
and vCJD-prions showing the same lesion profiles and incubation times (Bruce et al., 1997; 
Lasmezas et al., 2001) demonstated that the same agent causes both BSE and vCJD.  
 
 
2. Prion, the causative agent of TSEs 
Prions represent a new class of pathogenic agents in which a protein denoted PrPSc appears to 
be the sole component ot the infectious particle causing transmissible spongiform 
encephalopathies in humans and animals. The mechanism of disease propagation is thought to 
involve the interaction of PrPSc with its normal cellular isoform PrPc. Thereby, PrPc 
undergoes a posttranslational structural conversion resulting finally in the abnormally folded 
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PrPSc. Prion diseases have been associated with the accumulation of this misfolded protein 
and its neurotoxic effects, however, it remains unclear whether the PrPc "loss of function" 
represents a crucial factor.  
 
2.1. The physiological role of PrPc 
The physiological role of the cellular prion protein is poorly understood. In order to 
characterize the function of PrPc, a series of PrP-deficient (PrP0/0) mice have been generated 
by several groups differing in their strategy to knock-out the PrP encoding gene. Surprisingly, 
some of these mouse lines developed completely normal without any visible phenotype 
(Bueler et al., 1992; Lledo et al., 1996; Manson et al., 1994). These results were amazing 
since PrP is expressed predominantly in the brain and since the Prn-p gene is highly 
conserved among species (85-97% among mammals (Gabriel et al., 1992)). Therefore 
researchers expected dramatic physiological deficiencies in those animals. In contrast, two 
further independently generated mouse lines in which the PrP gene has been ablated by other 
strategies revealed late-onset ataxia associated with a loss of cerebellar Purkinje cells (Moore 
et al., 1999; Sakaguchi et al., 1996). These observations have been interpreted as evidence 
that PrP might play a role in the long-term survival of Purkinje cells. However, the discovery 
of a PrP-like gene, Prn-d, which is located 16 kb downstream of the Prn-p gene and encodes 
for doppel (Dpl) revealed that the loss in Purkinje neurons and ataxia in these mice were 
caused by Dpl overexpression, an unexpected consequence of the target inactivation of the 
Prn-p locus (Moore et al., 1999). Other reports using PrP0/0 mice described a role of PrPc in 
synaptic processes (Collinge et al., 1994) or described an alteration in circadian activity 
rythms and sleep (Tobler et al., 1996).  
In addition, an involvement of PrP in the metabolism of copper has been reported (Hornshaw 
et al., 1995). Several studies indicated that PrPc can bind copper (cooperative binding of four 
Cu2+ per PrPc molecule) via the histidine-containing octapeptide repeats in the amino-
terminal domain of the prion protein (Brown et al., 1997; Viles et al., 1999). However, the 
exact functional relationship between copper and PrPc is still unclear. Recently, a Cu/Zn 
superoxide dismutase (SOD) activity has been described for recombinant PrP and for PrP 
immunoprecipitated from mouse brain tissues (Brown et al., 1999). These results suggest that 
PrPc harbors an enzymatic activity that depends on the incorporation of copper as an essential 
cofactor and finally might contribute to cellular resistance against oxidative stress. 
  
 Chapter I 9 
In contrast, very recent data have shown that PrPc might play a role in signal transduction and 
triggers cell signaling increasing the phosphorylation levels of the tyrosine kinase Fyn 
(Mouillet-Richard, 2000). Caveolin-1 and Clathrin were described as possible intermediate 
factors which might connect PrPc on the outer membrane to the intracellular kinase Fyn. 
However, the ligand i.e. a transmembrane receptor which might be responsible for the 
generation of the signal and which might mediate the PrPc dependent activation of Fyn has 
not been identified by this group (Mouillet-Richard, 2000). Two other PrP interacting partners 
were found which are implicated in neuronal signaling processes, the neuronal 
phosphoprotein synapsin Ib and the adaptor protein Grb2 (Spielhaupter and Schätzl, 2001). 
These findings further strengthen the putative role of the prion protein in signal transduction. 
Despite of numerous studies suggesting various possibilities for the physiological role of 
PrPc, its exact function as a cellular membrane-localized protein is still unclear. The only 
proven phenotype of PrPc remains its absolute necessity for an organism towards a PrPSc 
infection since PrP-ablated mice were totally resistant towards an infection with mouse-
adapted Scrapie strains (Bueler et al., 1993). 
 
2.2. Biochemical and structural features of PrPc 
Mammalian PrP genes encode proteins which contain a N-terminal signal peptide, a series of 
five proline- and glycine-rich octapeptide repeats, a central highly conserved hydrophobic 
segment, and a C-terminal hydrophobic region that represents a signal for the addition of a 
glycosyl phosphatidylinositol (GPI) anchor (Figure 1). PrPc is synthesized in the rough 
endoplasmic reticulum (ER) and transits through the Golgi on its way to the cell surface. 
During biosynthesis the PrP precursor becomes processed as follows: (i) the N-terminal signal 
peptide is removed, (ii) two N-linked oligosaccharide chains are added, (iii) a single disulfide 
bond is formed and (iv) a GPI anchor becomes attached (Endo et al., 1989; Stahl et al., 1987; 
Turk et al., 1988). The N-linked oligosaccharide chains, of the high mannose-type, are 
initially added within the ER and are subsequently modified in the Golgi resulting in an 
endoglycosidase H resistance. The GPI anchor is added in the ER after cleavage of the 
hydrophobic C-terminal signal sequence. After its passage through the secretory pathway 
PrPc remains on the cell surface where it is attached to the plasma membrane via the GPI-
moiety. 
The conversion of PrPc to its pathogenic, infectious isoform, PrPSc, is accompanied by 
conformational changes. Spectroscopic studies revealed that PrPc has a high -helical content 
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whereas PrPSc is rich in -sheets (Table II). These two isoforms also differ biochemically 
with PrPSc displaying reduced solubility in non-denaturing detergents and partial resistance 
towards proteinase K digestion (Meyer et al., 1986; Oesch et al., 1985). Whereas PrPc is 
completely sensitive to proteinase K digestion, PrPSc is degraded to a truncated highly 
infectious form termed PrP27-30 which lacks about 60 amino acid residues at the N-terminus 
compared to PrPSc (Table II). Which form of PrP is the dominant one in an affected 
individual is thought to depend on the presence of cellular proteinases in the individual tissue 
or organ. 
 
Table II. Characteristics of PrPc, PrPSc and PrP27-30  
Characteristics PrPc PrPSc PrP27-30 
Secondary structure 
  - -Helix 
  - -Sheet 
 
42% 
3% 
 
30% 
43% 
 
21% 
54% 
Proteinase K status sensitive partially resistant resistant 
Infectivity status non infectious infectious infectious 
 
 
Recently the three-dimensional structure of soluble, recombinant PrPc from mouse (Riek et 
al., 1996; Riek et al., 1997), Syrian hamster (Donne et al., 1997), human (Zahn et al., 2000; 
Zhang et al., 2000) and cattle (Lopez Garcia et al., 2000) (Figure 2) have been determined by 
nuclear magnetic resonance (NMR) spectroscopy, revealing that the core region of the protein 
forms a globular domain with three -helices and a short two-stranded antiparallel -sheet, 
while the N-terminal segment remains flexibly disordered in solution. The three-dimensional 
structures of prion proteins of different species are quite similar. However, the highest degree 
in structural identity has been observed between human and bovine PrP (Lopez Garcia et al., 
2000). The role of the flexible N-terminal segment is not yet fully understood: a role in 
binding/uptake of copper ions which might stimulate the endocytosis of PrP (Pauly and 
Harris, 1998) or the interaction with a ligand required for signal transduction (Shmerling et 
al., 1998) have been suggested.  
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Fig. 2: NMR structure of recombinant, soluble bovine PrP from residue 23 to 230 modified 
from (Lopez Garcia et al., 2000). The globular domain extending from aa 125-227 contains 
three -helices (green) and a short antiparallel -strand (cyan). Helix 2 and helix 3 are linked 
by one disulfide bond. Segments with non-regular secondary structures within the core region 
are in yellow, and the flexible disordered "tail" of residues 23-121 is represented by 108 
yellow dots for each amino acid residue. (The native mature boPrP stretches from aa 25 to 
242. Lopez-Garcia published a structure of boPrP from aa 23 to 230). 
 
 
Very recently, the crystal structure of the human prion protein reveals dimer formation 
resulting from the three-dimensional swapping of the C-terminal helix 3 and the 
rearrangement of the disulfide bond (Knaus et al., 2001). An interchain two-stranded 
antiparallel -sheet is generated at the interface of the dimer by residues located in helix 2 in 
the monomeric NMR structure (Knaus et al., 2001). As suggested in the nucleation dependent 
polymerization model of prion propagation, the occurence of such PrP-dimers could 
accelerate the generation of a nucleus that might act as a seed for the formation of highly 
ordered PrPSc aggregates. 
 
2.3. Replication mechanisms of prions ("protein-only" and "nucleation dependent 
polymerization" hypothesis ) 
In the mid-sixties Alper and Griffith suspected that the scrapie agent could replicate in the 
absence of any specific nucleic acid (Alper et al., 1967; Alper et al., 1966; Griffith, 1967). 15 
years later Stanley Prusiner stamped the term "prion" (proteinaceous infectious particle) and 
mentioned in his "protein-only" hypothesis that the prion is an infectious protein that causes 
the disease (Prusiner, 1982). In contradiction to classical agents of infectious diseases such as 
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viruses, bacteria and fungi, prions are stated to replicate in the absence of any nucleic acid. 
The replication scheme is quite simple: an infectious PrPSc molecule binds to the 
endogeneous PrPc most likely in the endocytotic pathway of the Scrapie-infected cell forming 
a heterodimer. This event created the term "heterodimer" model. Due to the direct interaction 
of both molecules, PrPc is forced to undergo structural changes yielding in an increase in its 
-sheet content and thereby is converted into PrPSc. In a chain reaction further PrPc 
molecules are converted into the pathogenic, but thermodynamically more stable isoform 
resulting in prion propagation and finally astrocytosis, gliosis, vacuolization and apoptosis. 
For this striking and completely new replication mechanism, S.B. Prusiner received the Nobel 
Prize for Medicine in 1997. Another favored model, the nucleation dependent polymerization 
or crystal seed model claims the existence of a nucleus consisting of a few PrPSc molecules 
(Lansbury and Caughey, 1995). Different crystals originate from different species or strains. 
Here, the most important factor for prion propagation represents the similarities between PrPc 
and one PrPSc monomer in the seed. The higher the similarities between both molecules the 
better the polymerization proceeds. This model offers an explanation for the existance of 
different scrapie strains within the same species and the existance of species barriers. 
Although the "protein-only" hypotheses (encompassing the heterodimerization and the 
nucleation-dependent polymerization model) are favoured by the majority of scientists in the 
field, there are further hypotheses such as the virino and the viral ones that assume the 
existance of a so far undiscovered nucleic acid or virus specific for the Scrapie agent 
(Dickinson and Outram, 1988; Dickinson et al., 1989; Manuelidis et al., 1988; Özel et al., 
1994). 
 
 
3. Trafficking of PrP and the role of a cell surface receptor 
PrPc is a cell-surface glycoprotein which is expressed in the rough endoplasmic reticulum 
(ER) of neuronal (or other scrapie-infectable) cells. Recently, Prusiner and Lingappa localized 
three forms of PrP at this compartment which differ in their topology: the carboxy terminal 
transmembrane protein CtmPrP, the amino terminal transmembrane protein NtmPrP and the 
secretory form of the prion protein SecPrP (Hegde et al., 1998). In contrast to SecPrP, CtmPrP 
and NtmPrP span the membrane once via a conserved, hydrophobic domain, CtmPrP with the 
C-terminus and NtmPrP in the opposite orientation with the N-terminus directed towards the 
lumen of the ER (Hegde et al., 1998). It has been proposed that both membrane-spanning 
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forms occur as key intermediates in infectious and inherited prion diseases but the exact 
mechanism by which these forms are produced is still unclear. The classical isoform, SecPrP, 
traffics through the secretory pathway via the golgi apparatus and secretory granules to the 
cell surface where it is GPI-anchored to the plasma membrane (Figure 3). The subcellular 
trafficking of PrPc has been widely studied employing transfected cell lines that express the 
protein. The results demonstrate that PrPc does not remain on the cell surface, but rather 
constitutively cycles between the plasma menbrane and an endocytic compartment (Shyng et 
al., 1993). This endocytic pathway is of great interest because it is thought that the conversion 
of PrPc to PrPSc takes place in certain endocytic compartments. Clathrin-coated pits and 
vesicles are suggested to be the morphological structures responsible for the endocytic uptake 
of PrPc (Shyng et al., 1994). This observation is surprising for a GPI-anchored protein like 
PrPc that lacks a cytoplasmic domain which is thought to interact directly with adapter 
proteins and clathrin. Therefore, Harris postulated the existence of a PrPc receptor, a 
transmembrane protein with a coated-pit localization signal in its cytoplasmic domain and a 
PrP-binding site in its extracellular domain, which mediates the endocytosis of PrP and direct 
the complex into clathrin-coated pits (Harris et al., 1996). In contrast, it has been speculated 
that the internalization is mediated receptor-independent by caveolae-like membranous 
domains (Anderson, 1993; Vey et al., 1996). Other reports proposed that PrP is associated to 
cholesterol and sphingolipid enriched domains (Gorodinsky et al., 1995; Taraboulos et al., 
1995) and that different kind of such specialized microdomains ("rafts") exist on the surface 
of neuronal cells in which PrPc might be enriched (Madore et al., 1999). 
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Fig. 3: Trafficking of cellular PrP. PrPc is synthesized in the rough endoplasmic reticulum 
and after the passage through the golgi apparatus and secretory granules, it reaches the cell 
surface where it is anchored to the plasma membrane via its GPI-moiety. PrPc becomes 
internalized via clathrin-coated pits or caveolae-like membranous domains and enters the 
endocytic pathway encompassing endosomes, lysosomes and endolysosomes, compartments 
in which the PrPc  PrPSc conversion process might occur. 
 
 
The presence of a specific so far unidentified cell-surface receptor for PrP with a molecular 
weight of 66 kDa has been deduced by means of complementary hydropathy (Martins et al., 
1997). Simultaneously, the human 37-kDa laminin receptor precursor (LRP), the precursor of 
the 67 kDa high-affinity laminin receptor (LR), was identified as an interaction partner of 
PrPc in a yeast two-hybrid screen (Rieger et al., 1997). Several reasons exist which favour 
LRP/LR as a possible cellular prion protein receptor (for review see (Gauczynski et al., 
2001a; Rieger et al., 1999), Chapter II, respectively). (i) Both molecules are well-represented 
on the surface of neuronal cells (Rieger et al., 1997). (ii) LRP is clearly increased in several 
organs and tissues of Scrapie-infected mice and hamsters such as brain, spleen and pancreas 
compared to uninfected control animals revealing a correlation between the LRP level and the 
occurance of infectivity and PrPSc accumulation in those organs (Rieger et al., 1997). (iii) 
Mapping analyses of the LRP/PrP interaction site performed in the yeast two-hybrid system 
  
 Chapter I 15 
demonstrated that the laminin-binding site encompassing residues 161 to 180 (Castronovo et 
al., 1991b) can also function as a binding domain for PrPc (Hundt et al., 2001; Rieger et al., 
1997) (Chapter IV). The 37-kDa LRP is thought to be the precursor of the 67-kDa high-
affinity LR which was first isolated from solid tumors and exhibit a high binding capacity to 
laminin, a glycoprotein of the extracellular matrix mediating cell attachment, movement, 
differentiation and growth (Beck et al., 1990; Rao et al., 1989; Rao et al., 1983). The 
mechanism how the high-molecular LR is formed by the 37-kDa precursor is still unclear. 
Heterodimerization caused by the interaction of LRP with an additional so far unknown 
protein or acylation of the precursor has been suggested (Buto et al., 1998; Castronovo et al., 
1991a). In addition, yeast two-hybrid analyses revealed that LRP does not interact with itself 
disproving the theorie that the high-molecular form of the receptor represents a homodimer of 
the 37-kDa form (Hundt et al., 2001) (see Chapter IV). Like PrPc, LRP/LR is well conserved 
throughout evolution showing a high degree of homology among mammalian species (Rao et 
al., 1989). Within the life cycle of prions, we suggest that this surface-located transmembrane 
protein may be involved in the receptor-mediated endocytosis of the GPI-anchored PrPc and 
potentially of exogenous PrPSc. In order to further characterize the role of LRP/LR as a 
binding partner for the prion protein, cell-binding/internalization assays for PrP were 
performed with various cultured cell lines revealing the LRP/LR-dependent internalization of 
recombinant PrP by neuronal and non-neuronal cells (Gauczynski et al., 2001b) (see Chapter 
III). Two binding sites were identified: a direct binding domain identified by yeast two-hybrid 
mapping studies and a heparansulfate proteoglycan (HSPG)-dependent interaction site 
identified by cell-binding assays using a series of recombinant PrP peptides as well as various 
mutated LRP molecules (Hundt et al., 2001) (see Chapter IV). Furthermore, we found that 
PrP co-localizes with LRP/LR at the surface of neuroblastoma cells and with LRP on 
transfected BHK cells co-expressing both proteins. On the basis of all these data, we conclude 
that LRP/LR acts as the cellular prion protein receptor playing an essential role in the normal 
cell cycle of PrP by mediating its endocytosis. It might be conceivable that the internalization 
process of PrPSc proceeds also receptor-dependent. After the entry into the nerve cell, either 
directly or receptor-dependent, the pathogenic PrP isoform comes in contact with PrPc 
probably during the endocytotic pathway involving endosomes, lysosomes and 
endolysosomes, compartments in which finally the conversion of PrPc and the aggregation of 
PrPSc is thought to take place. A first contact between PrPc and PrPSc on the cell surface is 
also conceivable. Here a PrPc and LRP/LR mediated internalization of PrPSc is imaginable 
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(as shown in the diploma thesis from Susanne El-Gogo, February 2002, "Bindungs- und 
Internalisierungsstudien des murinen Scrapie prion proteins PrP27-30 an Säugerzellen mit 
Hilfe des Semliki-Forest-Virus Systems" performed in the Weiss laboratory, Gene Center, 
Munich). The involvement of an additional, so far unknown protein termed protein X (Telling 
et al., 1995) which might represent a molecular chaperone such as Hsp60 (Edenhofer et al., 
1996) in the conversion process cannot be excluded.  
Due to the capability of LR to bind laminin and elastin, two proteins of the extracellular 
matrix, the interaction with PrP may induce a signal essential in cell survival. Recently, it has 
been shown that PrPc might play a role in signal transduction by activating the intracellular 
tyrosine kinase Fyn and might trigger cell signaling (Mouillet-Richard, 2000). However, the 
ligand i.e. a transmembrane receptor which might be responsible for the generation of the 
signal and which might mediate the PrPc dependent activation of Fyn has not been identified 
so far (Mouillet-Richard, 2000). The plasma membrane-spanning LRP/LR might represent 
such a protein which connect, either directly or indirectly via HSPGs, the GPI-anchored PrP 
with the intracellular plasma-membrane-associated Fyn kinase (Hundt et al., 2001).  
The identification of the cellular prion receptor might not only allow a better understanding of 
the cellular processes in normal and in Scrapie infected cells, but might also represent a point 
of attack for anti-prion drugs interfering with the receptor mediated binding and endocytosis 
of PrPc and/or PrPSc. A possible strategy would be the blockage of the PrPc /PrPSc entry by 
using LRP-specific antibodies which are raised against the PrP binding domains (Figure 4). 
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Fig. 4: Life cycle of the prion protein (1-3) and the anti-prion effect of antibodies raised 
against the cellular prion receptor (4). PrPc is synthesized within the neuronal cell and 
transported to the plasma membrane via the secretory pathway. After its exposure to the cell 
surface, PrPc binds to its receptor and becomes internalized. The conversion of the normal 
prion protein to its infectious form might occur spontaneously or PrPSc mediated within 
compartments of the endocytic pathway of the cell leading to PrPSc aggregation and finally to 
cell death. Antibodies which specifically bind to this transmembrane receptor protein prevent 
the entry of the cellular and presumably the pathogenic prion protein and therefore protect the 
cell against the infection. (The graphic is adapted from FOCUS 46/2001, p.176 and therefore 
labeled in German. We thank the FOCUS Magazine for providing us with this image).  
 
 
4. Therapeutics for prion diseases 
Until now, no effective therapy is available that cure a patient or an animal suffering from a 
manifested TSE. A variety of classical drugs used in human therapy have been tested but 
among them, only a few delay the appearance of the disease in animals experimentally 
infected with PrPSc. The research in this field is mainly hampered by the uncertainties 
remaining about the replication mechanisms of the TSE agent and furthermore the exact mode 
of action of life-prolonging therapeutic drugs is widely unknown. 
Polyanions such as heteropolyanion 23 (HPA-23), Dextran Sulfate 500 (DS-500), heparin and 
pentosan polysulfate (SP54) have been shown to be efficient in experimental Scrapie. 
Although HPA-23 and DS-500 probably act on the early replication phase of the agent in the 
lymphoreticular system (LRS), their application is limited due to a toxicity at therapeutic 
doses. In addition, they are only effective when administered at the time of infection (Ehlers 
and Diringer, 1984; Kimberlin and Walker, 1983; Kimberlin and Walker, 1986) (in detail see 
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Chapter II). To date, the polyanion pentosan polysulfate (SP54) represents one of the most 
promising candidates in the field of anti-scrapie drugs; first, SP54 was effective at extreme 
low doses and secondly, it was clearly less toxic. SP54 is thought to be effective during the 
very early events of pathogenesis by interfering with the uptake of PrPSc by nerve endings 
(Farquhar et al., 1999; Ladogana et al., 1992) (see Chapter II). Preliminary experiments 
suggest, that SP54 might interfere with the PrPSc/LRP-LR interaction process on the cell 
surface resulting in the blockage of binding and presumably internalization of the Scrapie 
prion protein (as shown in the diploma thesis from Susanne El-Gogo, February 2002, 
"Bindungs- und Internalisierungsstudien des murinen Scrapie prion proteins PrP27-30 an 
Säugerzellen mit Hilfe des Semliki-Forest-Virus Systems" performed in the Weiss laboratory, 
Gene Center, Munich). 
Congo Red, normally used as a diagnostic dye for amyloids, inhibits PrPSc accumulation and 
prion replication in chronically, scrapie-infected mouse neuroblastoma (ScN2a) cells 
(Caughey et al., 1993a) and in hamsters inoculated with the pathogenic agent (Ingrosso et al., 
1995) (see Chapter II). Congo Red may also act during the early phases of infection; its 
ability to insert into amyloid proteins suggests that it binds directly to PrPSc and therefore, 
interfers with PrPSc formation and replication (Caspi et al., 1998). 
Amphotericin B (AmB), widely used for the treatment of fungal infections, and its derivative 
MS-8209 belongs to the group of polyene macrolide antibiotics which increase the incubation 
period of Scrapie infected rodents probably by the direct prevention of PrP conversion or 
interference with the uptake of PrPSc (Adjou et al., 1995; Pocchiari et al., 1989) (see Chapter 
II). Whereas the application of AmB is hardly restricted due to its acute nephrotoxicity, the 
derivative MS-8209 shows at least a five times lower toxicity and a higher solubility without 
a loss of efficiency in delaying the disease and PrPSc accumulation (Adjou et al., 1999) . 
Very recently, potential anti-prion effects of quinacrine and chlorpromazine, tricyclic 
derivatives of acridine and phenothiazine, were observed in ScN2a cells (Korth et al., 2001). 
They represent a new class of pharmacotherapeutics for prion diseases consisting of a 
tricyclic ring structure and an aliphatic side chain at the middle ring moiety (Figure 5). The 
mechanism by which these reagents inhibit PrPSc formation is unknown, but both compounds 
require only a few days of treatment before PrPSc disappear in chronically infected N2a cells. 
Since quinacrine and chlorpromazine have already been used in humans as anti-malarial and 
anti-psychotic drugs and are known to penetrate the blood-brain barrier, they are auspicious 
candidates for the treatment of CJD and other prion diseases. 
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Fig. 5: Structure of the anti-prion compounds chlorpromazine and quinacrine. They consist of 
a tricyclic scaffold with an aliphatic side chain extending from the middle ring moiety. 
 
 
Recent data showed that exposure of Scrapie infected N2a cells to anti-PrP antibodies or to 
the enzyme phosphatidylinositol-specific phospholipase C (PIPLC) which cleaves PrPc off 
the cell surface causes rapid loss of PrPSc and even cures the chronically Scrapie-infected 
cultures (Enari et al., 2001; Peretz et al., 2001). Therefore, the level of PrPSc is determined 
by the rates of its formation from PrPc and its degradation. Expression of anti-prion protein 
antibodies in transgenic mice resulted in the prevention of pathogenesis of Scrapie prions 
introduced by intraperitoneal injection in the spleen and brain (Heppner et al., 2001). These 
observations encourage the use of antibodies in the prevention and treatment of prion 
diseases. 
A better understanding of the cellular processes regarding the uptake of the Scrapie agent into 
the cell and the exact conversion mechanisms within the cell might be necessary for the 
efficient application of therapeutic drugs to prevent the PrPSc replication, PrPSc 
accumulation and cell death. Therefore, the identification of a cellular receptor that mediates 
the binding and internalization of PrPc/PrPSc is important to develop compounds such as 
specific antibodies which block the early step of infection i.e. the entry of PrPc/PrPSc into the 
cell. In addition, a precise transport of such therapeutics to the affected tissues might be 
essential. PEGylated polycyanoacrylate nanoparticles have been suggested as a vector for an 
efficient drug delivery in prion diseases leading to a higher uptake by the spleen and the brain 
which both represent target tissues of PrPSc accumulation in Scrapie-infected animals (Calvo 
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et al., 2001). Those particles are very useful for anti-prion drugs which do not pass the blood-
brain barrier.  
 
 
5. Generation of recombinant proteins by the Semliki Forest virus (SFV) 
system in cultured cells 
Cell culture models are useful tools to study the biology of PrPc, to get a better understanding 
of the nature of the pathogenic isoform PrPSc including its propagation and to screen for 
potential therapeutic drugs and diagnostic tools.  
In this work the Semliki Forest virus (SFV) expression system was utilized to (i) generate 
recombinant soluble PrP (Chapter V), (ii) synthesize human PrP mutants which are associated 
with familial prion diseases (Chapter V) and (iii) perform binding and internalization assays 
for the identification of the cellular prion protein receptor (Chapter III and IV). While 
prokaryotic and yeast expression systems are highly efficient and easy to use, expression 
systems for higher eukaryotic cells are still hampered by difficulties such as insufficient levels 
of protein production, restriction in host range and/or complexity of the system. Although the 
baculovirus system is one of the most efficient expression systems regarding protein 
production, its application, however, is strictly restricted to insect cells which are known to 
glycosylate proteins different from animal cells. Therefore, in order to generate correctly 
processed and glycosylated proteins such as prion proteins, the SFV system offers a variety of 
advantages which overcome those obstacles. The SFV system supplies a multitude of 
advantages for the expression of recombinant proteins in mammalian cells: (i) a large-scale 
production for up to 72 hours post transfection/infection, (ii) a broad host range,  (iii) 
modifications such as glycosylations and (iv) the easy and fast transfection procedure with in 
vitro-transcribed RNA (for review see (Tubulekas et al., 1997)). An efficient production of a 
series of cytoplasmic, membrane-associated and secreted proteins e.g. the mouse 
dihydrofolate reductase (a cytoplasmic protein), the human transferrin receptor (a membrane 
protein) and the chicken lysozyme (a secreted protein) has been demonstrated (Liljestrom and 
Garoff, 1991).  
The Semliki Forest virus is an enveloped RNA virus that belongs to the alphavirus group of 
the familiy Togaviridae and infects a variety of mammalian and insect cells. SFV expression 
vectors are based on a cDNA copy of the viral genome which consists of capped and 
polyadenylated single-stranded RNA of positive polarity and encodes its own RNA 
polymerase. Here, viral structural genes are deleted and replaced by the gene of interest. The 
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recombinant plasmid serves as a template for in vitro synthesis of recombinant RNA which is 
then transfected with an efficiency of up to 100 % into the cell. Due to the viral replicase 
which leads to an efficient production of recombinant RNA within the cell, a high-level 
synthesis of the foreign protein proceeds (for review see (Tubulekas et al., 1997)). Another 
possibility is the infection of cell lines with recombinant high-titer virus particles. Different 
cell lines and primary cell cultures were infected with such alphaviral particles resulting in the 
high-level production of a variety of CNS-related recombinant proteins such as Presenilin, 
APP, COX-2, Neurokinin, Dopamine, Serotonin etc. (for review see (Lundstrom, 1999)). The 
ability to infect primary neurons has made SFV an useful tool in neurobiology (Cook et al., 
1996; Olkkonen et al., 1993; Simons et al., 1995; Ulmanen et al., 1997). 
The SFV cell culture system is suitable to express high amounts of glycosylated wild-type 
and mutant disease-associated prion proteins in cultured mammalian cells on the one hand 
and allows localization and functional studies of recombinant proteins and their relationship 
to other cellular components on the other hand. Furthermore, the possibility to infect or 
transfect cell cultures simultaneously with several recombinant virus stocks or RNAs offers 
the investigation of protein-protein interaction. (Co-)localization studies and cell-binding 
assays with transfected or co-transfected cells overexpressing different proteins, separately or 
simultaneously, were performed to analyse the correlation between PrP and its cellular 
receptor LRP/LR to get a better understanding in the biology of prion proteins and the cellular 
processes in which they are involved (Gauczynski et al., 2001b; Hundt et al., 2001). In 
addition, recombinant SFV particles expressing various Prn-p genes were used to inoculate 
PrP-deficient PrP0/0 mice for the generation of a series of monoclonal antibodies raised 
against human prion proteins (Krasemann et al., 1996a; Krasemann et al., 1996b; Krasemann 
et al., 1999). 
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I. Introduction 
 
The prion protein PrP represents a central player in transmissible spongiform 
encephalopathies (TSEs), also known as prion diseases (for review see Lasmézas and Weiss, 
2000). The physiological role of the cellular isoform of PrP termed PrPc is speculative so far 
(for review see (Weissmann, 1996)) and might involve control of circadian activity rhythms 
and sleep (Tobler et al., 1996), maintenance of cerebellar Purkinje cell (Sakaguchi et al., 
1996), and normal synaptic functions (Collinge et al., 1994; Fournier et al., 1995; Kitamoto et 
al., 1992). Because several reports do not describe any phenotype for PrP (Bueler et al., 1992; 
Lledo et al., 1996; Manson et al., 1994) the only proved role of PrPc is its necessity for the 
development of TSEs (Bueler et al., 1993) such as bovine spongiform encephalopathy (BSE) 
in cattle, new variant Creutzfeldt-Jakob (nvCJD) in humans or scrapie in sheep. A recent 
report describes a superoxide dismutase (SOD) activity for PrPc (Brown et al., 1999) 
suggesting that PrP might play a role in the cellular resistance to oxidative stress. 
In the last 20 years of the past twentieth century, researchers worldwide were eagerly 
searching for molecules able to interact specifically with the prion protein in the hope of 
identifying interactors (1) that play an important role in the life cycle of prions or (2) that 
could be developed into powerful TSE therapeutics. 
This chapter summarizes PrP interacting molecules that might be relevant for PrP 
pathogenesis or TSE therapy. In the first section we describe putative prion protein receptors 
including the role of heparan sulfate proteoglycans (HSPGs). A cellular model will be 
presented that describes the possible role of prion receptors and prion proteins, including the 
recently identified PrP-like protein termed doppel (Moore et al., 1999). The model 
emphasizes the possible role of PrP and its receptor regarding PrP internalization as well as 
signal transduction and physiological function, in particular, the 37 kDa laminin receptor 
precursor (LRP), an up to now unidentified 66 kDa cell surface protein, and cadherins, which 
are then discussed as prion receptors that might trigger the entry of PrP into scrapie infectable 
cells. Next, we summarize the role of molecular chaperones, including chemical chaperones 
that may catalyze or hamper the conversion process of PrPc to PrPSc. In this context, we 
emphasize a possible function for protein X, an as yet unknown protein predicted by S.B. 
Prusiner to be necessary for the PrP conversion process. The occurrence of PrP dimers under 
native and denaturing conditions observed in different cell systems and in vitro represents 
another aspect of PrP interactions, in this case an interaction of PrP with itself. The possible 
role of such PrP dimers in the complex scenario of PrP oligomerization and multimerization 
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processes is discussed. In the section V we report on a series of PrP interacting molecules 
identified using different biochemical approaches such as ligand blotting and yeast two-
hybrid techniques. Among these are the PrP ligand proteins (Pli) encompassing Pli 3-8, Pli 45 
and 110 as well as Bcl-2, which belongs to a family of proapoptotic and antiapoptotic 
molecules. The role of Bcl-2 in the light of neurodegeneration and apoptosis is discussed. The 
interaction between laminin and PrP-mediating neuritogenesis is reported. The last section 
describes molecules, mainly of nonproteinaceous origin, which act as therapeutics for the 
treatment of TSEs. These include polyanions such as heteropolyanion 23, dextran sulfate 500, 
pentosan polysulfate (SP54), and heparin. Other groups of anti-TSE therapeutics include 
Congo red, polyene antibiotics such as AmB and MS-8209, IDX, porphorins, phtalocyanes 
and the protein clusterin. The possible modes of action of these molecules such as interfering 
with the PrPc/PrPSc conversion process followed by PrP accumulation, interfering with the 
cellular uptake of PrPc/PrPSc, overstabilization of PrPSc, or competing with cellular 
glycosamino-glycans for the binding to PrPc are discussed. The last group of PrP interacting 
molecules represent nucleic acids including RNA aptamers, the latter as a possible tool for the 
diagnosis of TSEs. 
 
 
II. Cell Surface Receptors 
 
A. The Role of a Cellular Prion Protein Receptor 
To understand the pathogenesis of diseases such as TSEs, it is necessary to clarify how the 
biological system works under physiological conditions. The main principle of the "protein-
only“ hypothesis is that the cell-membrane glycoprotein PrPc is converted into its pathogenic 
isoform PrPSc, a process that involves conformational changes of the protein (Prusiner et al., 
1998). During this transformation PrP acquires additional regions of ß-sheets in the 
polypeptide chain, resulting in a partially resistance to proteases. The cellular pathway of PrPc 
is of major interest because here the conversion of PrPc to PrPSc might take place. PrPc is 
synthesized in the rough endoplasmatic reticulum (rER). It is passaged via the Golgi and 
secretory granules to the cell surface where it is anchored to the plasma membrane by its 
glycosylphosphatidylinositol (GPI) moiety (Rogers et al., 1991). According to an endocytic 
recycling pathway, the surface-PrPc is internalized by clathrin-coated pits (Shyng et al., 1994) 
or caveolae-like domains (CLDs) (Vey et al., 1996). The endocytosis of PrPc could be 
mediated by a transmembrane protein, which might connect the GPI-anchored PrP to clathrin. 
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Harris postulated the existence of an endocytic PrP-receptor that carries a coated-pit 
localization signal in its cytoplasmic domain and whose extracellular domain binds the N-
terminal part of PrPc (Harris, 1999; Harris et al., 1996). He observed that deletions within the 
N-terminal region of PrPc result in a decrease of internalization of the protein and 
consequently in a reduction of the PrPc concentration in coated pits (Harris, 1999; Shyng et 
al., 1995). In addition, Harris observed that chicken PrP binds to the surface of mammalian 
cells via heparan sulfates on the cell surface (Shyng et al., 1995). Several researchers 
described an interaction between heparan sulfates and PrP (Brimacombe et al., 1999; 
Caughey et al., 1994; Chen et al., 1995; Gabizon et al., 1993). Heparan sulfates have been 
shown to be a component of amyloid plaques in prion diseases (Gabizon et al., 1993). 
Recently, it has been demonstrated that the addition of heparin competes with the binding of 
copper to PrP which occurs in the octarepeat region (Brown et al., 1997; Brimacombe et al., 
1999), suggesting that this region of PrP binds to heparin. The recently observed superoxide 
dismutase (SOD) activity of PrPc is dependent on the presence of the octarepeat region 
(Brown et al., 1999) confirming the important role of this domain for PrP. HSPGs make up 
proteoglycan moieties consisting of proteins carrying glycosaminoglycan (GAGs) chains 
made of anionic polysaccharide chains. Heparan sulfate, the main GAG-constituent of 
HSPGs, like heparin, consists of disaccharide repeating units of O-/N-sulforyl and N-
acetylglucosamine (or N-acetylgalactosamine) and O-sulforyliduronic acid except that it 
harbors fewer N- and O-sulfate groups and more N-acetyl groups. The proteoglycans HSPGs 
are thought to play an important role on the cell surface within the life cycle of prions. 
The process by which exogenous PrPSc enters the cell is unclear so far. The uptake of 
the infectious agent could also be mediated by a receptor protein or might occur receptor 
independent. The conversion of PrPc to PrPSc may take place after internalization in cellular 
compartments such as endosomes, lysosomes, or endolysosomes. This conversion process is 
thought to be influenced by an unknown protein termed protein X (Telling et al., 1995), 
which could represent a molecular chaperone such as Hsp60 (Edenhofer et al., 1996). In 
addition, it has been suggested that several proteins possessing a GPI-anchor are excluded 
from coated pits and internalized by caveolae (Anderson, 1993). Furthermore, it has been 
reported that PrPc and PrPSc are present in CLDs isolated from scrapie-infected neuroblastoma 
cells and brains of scrapie-infected hamsters, and it is speculated that the conversion of PrPc 
into PrPSc could also take place in these compartments (Vey et al., 1996). To understand the 
mechanism of this conversion event as well as the physiological function of the cellular prion 
protein, it is important to investigate the involvement of a possible receptor protein as well as 
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of proteins showing biological properties similar to PrP, such as the recently discovered PrP-
like protein designated doppel (Dpl) (Moore et al., 1999). 
The discovery of doppel does not only represent the first PrP-related protein (Moore et al., 
1999), it also could explain some curious, surprising observations within several lines of 
Prnp0/0 mice, which differ only in the strategy used to generate PrPc-deficiency. Creating an 
internal insertion or deletion within the PrP exon 3, two lines of mice were generated showing 
normal development without any pathological phenotype (Bueler et al., 1992; Lledo et al., 
1996; Manson et al., 1994). However, in two other cell lines the entire coding sequence of 
PrP as well as a ~1 kb region 5' to exon 3 including the exon 3 splice acceptor site were 
deleted (Sakaguchi et al., 1996). These Prnp0/0 mice showed progressive symptoms of ataxia 
and Purkinje cell degeneration in the cerebellum. It is suggested that Dpl is involved in a 
physiological process in a manner leading to this pathological phenotype. Doppel is the first 
PrP-like protein to be described in mammals (Moore et al., 1999). It consists of 179 amino 
acid residues showing ~25 % identity with all known prion proteins. The Dpl locus, Prnd, is 
located 16 kb downstream of the PrP gene, Prnp, generating two major transcripts of 1.7 and 
2.7 kb. Like PrP, Dpl mRNA is expressed during the embryogenesis but, in contrast to PrP, it 
is poorly expressed in the adult central nervous system (CNS) and at high levels in the testis 
of mice. However, Dpl is upregulated in the CNS of the two Prnp0/0 lines that develop late-
onset ataxia and Purkinje cell death but not in the normally developed Prnp0/0 lines (Moore et 
al., 1999). Therefore, it was assumed that Dpl may provoke neurodegeneration in PrP-
deficient mice, an observation that might explain why some lines of Prnp0/0 mice develop 
cerebellar dysfunction and Purkinje cell death, whereas others do not. Moore et al. suggested 
that Dpl and PrP may share some biological functions owing to the similarities between these 
two proteins (Moore et al., 1999). Would it be possible that PrP and Dpl bind to each other or 
would it be also possible that they compete for binding to a common receptor? Dpl synthesis 
is thought to occur in the secretory pathway to yield a globular, N-glycosylated, membrane-
associated protein comparable to PrPc, but in contrast to it containing no octarepeat region in 
its N-terminal domain (Moore et al., 1999). 
In addition, expression of moderate levels of N-terminal truncated PrP with deletions of 
amino acid residues 32-121 or 32-134 caused ataxia and specific degeneration of the granular 
layer of the cerebellum in PrP0/0 mice, whereas mice expressing shorter truncations of PrP, up 
to residue 106, show no pathological changes (Shmerling et al., 1998). This granule cell 
dysfunction was completely abrogated by introducing a single copy of a wild-type murine PrP 
gene into mice. It is speculated that the truncated PrP may compete with some other molecule 
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with a function similar to that of PrP for a common ligand or receptor. It was assumed that in 
wild-type mice PrP interacts with a presumed receptor promoting signal transduction (Fig. 
1A), and the same signal is elicited by interaction of the receptor with π, a conjectural protein 
that has the functional properties of PrP, but is not closely related to it on DNA level (Fig. 1B) 
(Shmerling et al., 1998). This would explain why the absence of PrPc has no obvious 
phenotypic consequences. It is postulated that truncated PrP can interact with the receptor 
without giving rise to a signal (Fig. 1C). The affinity of the receptor for truncated PrP would 
have to be stronger compared to π, but would be less compared to intact PrP. Only N-terminal 
truncated PrP where the deletion extends to or beyond residue 121 shows cerebellar 
dysfunction leading to the conclusion that the globular domain of cellular PrP binds to a 
receptor, whereas the flexible tail of the N-terminus spanning residues 23 to 120 is  
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Fig. 1: Model of PrPc- and receptor-mediated signal transduction. In the normal cell, PrPc and 
receptor molecules from the same cell or from different cells can interact and promote signal 
transduction (A). The same signal might be elicited by the binding of a conjectural protein 
designated π, which possesses the functional properties of PrPc explaining why some lines of 
PrP0/0 mice develop normally (B). In the absence of PrPc, N-terminal truncated PrP can also 
interact with the receptor competing with the binding of π, however, without giving rise to a 
signal and leading to ataxia and degeneration of the granular layer of the cerebellum. A 
similar event is thought to take place in PrP-deficient mice, which are showing a pathological 
phenotyp. In these mice a PrP-like protein called doppel (Dpl) is upregulated in the CNS. It is 
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speculated that this protein may bind with higher affinity to the receptor than π does, resulting 
in ataxia and degeneration of Purkinje cells (C).  
 
 
responsible for activation (Shmerling et al., 1998). One possible interpretation for the 
pathological phenotype caused by the expression of N-terminal truncated PrP is that such PrP-
mutants assumes a Dpl-like conformation that is neurotoxic and results in the killing of the 
granular layer in the cerebellum (Moore et al., 1999). The association of Dpl overexpression 
with degeneration of Purkinje cells which were rescued by overexpression of wild-type PrP, 
suggest that Dpl and PrP interact perhaps directly or indirectly by competing as ligands for a 
common receptor. Therefore, both proteins may play a role in cell contact processes (Fig. 1).  
Recently, a signal transduction activity of the prion protein by achieving tyrosine 
kinase Fyn was described (Mouillet-Richard et al., 2000). Since PrPc locates GPI-anchored at 
the cell surface, whereas Fyn-kinase is associated with the inner plasma membrane of the cell, 
a transmembrane receptor might mediate the PrPc dependent activation of the Fyn-kinase. 
In this section we describe the different candidates, identified so far, that may act as prion 
protein receptors. Distinct strategies and methods were used to identify the putative receptor 
molecule. Further investigations are necessary to clarify the identity of a physiological PrPc-
receptor and to reveal its role in the normal cellular process of PrPc as well as in the 
pathogenesis of prion-diseases. Identification and characterization of this receptor are also 
important in designing drugs that could be used to prevent the initial uptake of the infectious 
agent into cells. 
 
B. A 66 kDa Membrane Protein as a Potential Prion Receptor 
Employing complementary hydropathy a 66 kDa membrane protein that could act as a 
cellular prion protein receptor, was recently identified (Table I) (Martins et al., 1997). By 
means of this strategy, a hypothetical peptide mimicking the receptor binding site should bind 
to the neurotoxic domain of prion proteins. Here a peptide encoded by the DNA strand 
complementary to that of the human PrP gene, spanning amino acid residues 114 to 129, was 
chemically synthesized and used to immunize mice in order to generate antibodies directed 
against this complementary prion peptide. The available mouse antisera were used to 
investigate the localization of the putative receptor by immunofluorescence and confocal 
microscopy approaches, resulting in the detection of an antigen at the cell membrane of 
primary mouse neurons. In Western blot analysis of membrane extracts from mouse brain, the 
antiserum recognized a specific protein of 66 kDa. In vitro and in vivo binding assays were 
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performed demonstrating that PrPc and the 66 kDa membrane protein could bind to each other 
(Martins et al., 1997). Flow cytometry studies revealed that purified membrane extracts, 
prepared from mouse brain, inhibited in vivo recognition of cellular PrP in cultured 
neuroblastoma cells (N2a) by anti-PrP antiserum. This process could be reversed by 
pretreatment of such membrane extracts with antiserum raised against the complementary 
prion peptide and the putative receptor protein. Furthermore, both the complementary prion 
peptide and the antiserum against it were able to block the neurotoxic effects mediated by the 
human prion peptide 106-126 towards cultured neuronal cells. Martins et al. suggested that a 
specific receptor for prion proteins could be responsible for their internalization and for the 
cellular responses mediated by PrPc. They speculated that, as PrPc tends to accumulate in 
postsynaptic vesicles (Askanas et al., 1993), both PrPc and its receptor are involved in 
interneuronal cell adhesion causing neuronal networking (Martins et al., 1997). 
According to Martins et al. in the normal cell, PrPc and receptors from the same cell or from 
different cells can interact and mediate signal transduction, triggering their physiological 
function. They postulated that the infectious agent should interact with the same receptor 
following internalization, facilitating the conversion of PrPc into PrPSc and leading to PrPSc 
accumulation and finally cell death (Martins, 1999). Further investigations leading to the 
identification of the 66 kDa protein are necessary to clarify the role of this putative receptor in 
the normal process of PrPc, as well as in the pathogenesis of TSEs. 
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Table I. PrP binding proteins, identity and characteristics 
 
PrP binding 
Protein 
cDNA 
identified 
Known 
homology 
Surface 
protein 
Method of 
identification 
 
Reference 
Pli45c Yes GFAP No ligand blot Oesch et al, 1990 
Pli110c Yes PSF No ligand blot Oesch et al, 1990 
Pli3c Yes human ESTs No PrP-AP 
screening 
Yehiely et al, 1997 
Pli4c Yes None No PrP-AP 
screening 
Yehiely et al, 1997 
Pli5c Yes guinea pig 
organ of corti, 
rat and human 
ESTs 
No PrP-AP 
screening 
Yehiely et al, 1997 
Pli6c Yes Mouse Aplp1 
(amyloid 
precurser like 
protein) 
Yes PrP-AP 
screening 
Yehiely et al, 1997 
Pli7c Yes Mouse Nrf2       
(p45 NF-E2 
related factor) 
No PrP-AP 
screening 
Yehiely et al, 1997 
Pli8c Yes None No PrP-AP 
screening 
Yehiely et al, 1997 
37-kDa laminin 
receptor 
precursora 
Yes 37 kDa 
laminin-
receptor 
precursor 
Yes yeast-two-hybrid 
screening 
Rieger et al, 1997 
66-kDa proteina No None Yes complementary 
hydropathy 
Martins et al,  
1997 
Cadherinsa Yes Cadherins Yes PrP-AP 
screening 
Cashman and 
Dodelet, 1997 
Bcl2c Yes Bcl-2 No yeast-two-hybrid 
screening 
Kurschner and 
Morgan, 1995 
Chaperons
b Yes several 
molecular 
chaperons 
No various methods DebBurman et al, 
1997 
Edenhofer et al, 1996
Tatzelt et al, 1996 
a See Section II. 
b See Section III. 
c See Section V. 
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C. The 37 kDa Laminin Receptor Precursor (37 kDa LRP) 
In a yeast two-hybrid screen, we identified a specific molecule as an interaction partner for 
the prion protein: the 37 kDa laminin receptor precursor (37 kDa LRP) (Table I) (Rieger et 
al., 1997). We speculated that this protein could act as a potential receptor for the cellular PrP. 
This interaction was confirmed by coinfection and cotransfection studies in insect and 
mammalian cells, respectively (Rieger et al., 1997). Furthermore, investigations of the LRP 
level in several organ and tissues of scrapie-infected mice and hamsters demonstrated that 
LRP occurs in higher amounts only in those organs that exhibit infectivity and PrPSc 
accumulation such as brain, spleen and pancreas compared with uninfected control animals 
(Rieger et al., 1997). This was confirmed by cell culture experiments demonstrating an 
increased amount of LRP in scrapie-infected mouse neuroblastoma (N2a) cells compared with 
uninfected cells. Mapping of the 37 kDa LRP with different peptide fragments identified a 
transmembrane domain containing amino acids 86-101 (Castronovo et al., 1991b) and a 
laminin-binding domain comprising amino acids 161-180 (Castronovo et al., 1991b), which is 
thought to be directed towards the extracellular space (Fig.2). Mapping of the LRP/PrP 
interaction site performed in the yeast two-hybrid system demonstrated that the laminin-
binding domain can also function as a PrP binding site (Rieger et al., 1997) (Fig. 2). 
 
 
Fig. 2: Schematic view of the prion protein (PrP) and the 37 kDa laminin receptor precursor 
(LRP) on the surface of a scrapie-infectable cell. PrP is anchored by GPI (Blochberger et al., 
1997) and is thought to colocalize with LRP. The putative transmembrane region of LRP 
stretches from aa 86 to aa101 (Castronovo et al., 1991b). The laminin binding domains from 
aa 161 to 180 (Castronovo et al., 1991b) encompassing the palindromic sequence 
LMWWML, which appeared during evolution from the non-laminin-binding ribosomal 
protein p40 (Ardini et al., 1998), to the laminin-binding LRP on the cell surface is identical to 
the PrP binding domain (Rieger et al., 1997). 
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LRP is thought to be the precursor of the 67 kDa laminin receptor (67 kDa LR) because 
attempts to isolate the gene for the 67 kDa LR resulted in the identification of a cDNA 
fragment which encoded a 37 kDa polypeptide (Rao et al., 1989; Yow et al., 1988). This was 
confirmed by pulse-chase experiments carried out with antibodies directed against the 37 kDa 
protein (Castronovo et al., 1991; Rao et al., 1989). The 67 kDa laminin receptor was first 
isolated from tumor cells (Lesot et al., 1983; Malinoff and Wicha, 1983; Rao et al., 1983) 
owing to its high binding capacity to laminin, a glycoprotein of the extracellular matrix that 
mediates cell attachment, movement, differentiation and growth (Beck et al., 1990). 
Engelbreth-Holm-Swarm (EHS) laminin (Beck et al., 1990), which has been proved to bind to 
the 37 kDa LRP (Rieger et al., 1997) (Table II), consists of three polypeptide chains: A or  
(440 kDa), B1 or , and B2 or  (each 220 kDa), linked via disulfide bonds, resulting in the 
typical cross-structure (Beck et al., 1990). Several other classes of laminin binding proteins 
have been described including integrins (Albelda and Buck, 1990) and -galactoside binding 
lectins such as galectin-3 (Bao and Hughes, 1995; Ochieng et al., 1993; Yang et al., 1996) 
equivalent to CBP-35 (Laing et al., 1989). Immunoblotting assays performed with a 
polyclonal serum directed against galectin-3 revealed that the 67 kDa LR carries galectin-3 
epitopes, whereas the 37 kDa LRP does not (Buto et al., 1998). 
The 37 kDa LRP/67 kDa LR is a multifunctional protein (Table II) and its amino acid 
sequence is well conserved throughout evolution, showing a high degree of homology among 
mammalian species (Rao et al., 1989). The evolutionary analysis of the sequence identified as 
the laminin-binding site [which we proved to correspond to the PrP binding domain (Rieger et 
al., 1997)] suggested that the aquisition of the laminin binding capability is linked to the 
palindromic sequence LMWWML, which appeared during evolution concomitantly with 
laminin binding (Ardini et al., 1998). This protein evolved from the ribosomal protein p40, 
which participated in protein synthesis on 40 S ribosomes without any laminin-binding 
activity (Auth and Brawerman, 1992) to a cell surface receptor binding laminin (Rieger et al., 
1997), elastin (Hinek et al., 1988; Salas et al., 1992) and carbohydrates (for review see 
(Ardini et al., 1998; Mecham, 1991; Rieger et al., 1999)). In addition, interaction of the 
epitope-tagged laminin binding protein LBP/p40 with nuclear structures was observed in 
cultured cells (Sato et al., 1996). In vitro analysis revealed that LBP/p40 binds tightly to 
chromatin DNA through association with histones H2A, H2B and H4 suggesting that this 
protein may play an essential role in the maintenance of nuclear structures (Kinoshita et al., 
1998). 
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The laminin receptor family is highly conserved in a wide spectrum of eucaryotic cells 
(Keppel and Schaller, 1991; Wewer et al., 1986), including yeast (Demianova et al., 1996), 
and is encoded by archaean genomes (Ouzonis et al., 1995). 37 kDa LRP acts as a receptor 
for the Venezuelan equine encephalitis virus on mosquito cells (Ludwig et al., 1996), whereas 
the 67 kDa LR functions as a receptor for the Sindbis virus on mammalian cells (Wang et al., 
1992) (Table II). The mechanism of how the 37 kDa precursor protein forms the mature 67 
kDa isoform is still unclear. Homodimerization of the 37 kDa LRP (Landowski et al., 1995) 
or the involvement of an additional component (Castronovo et al., 1991a) has been discussed. 
Recent studies suggested that the 67 kDa LR is a heterodimer stabilized by fatty acid-
mediated interactions (Buto et al., 1998). Very recently, it has been proved that the 67 kDa 
LR (also termed laminin binding protein, p67 LBP) is expressed on a subset of activated 
human T lymphocytes and, together with the integrin, very late activation antigen-6, mediates 
strong cellular adherence to laminin (Canfield and Khakoo, 1999). In summary, the 37 kDa 
LRP/67 kDa LR polymorphism remains a mystery. Both forms may act as a receptor for 
prions on the surface of scrapie infectable cells.  
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Table II Characteristics of the 37 kDa laminin receptor precursora (LRP)/67 kDa laminin 
receptorb (LR) 
  
 Characteristics 
Isolation 37 kDa LRP/p40 cDNA (Rao et al., 1989; Yow  et al., 1988) 
67 kDa LR isolated from solid tumors (Lesot et al., 1983; Malinoff and 
Wicha, 1983; Rao et al., 1983) 
Occurrence of the 37 
LRP/p40 gene 
Saccharomyces cerevisiae (Davis et al., 1992), Arabidopsis thaliana 
(Garcia-Hernandez et al., 1994), Drosophila melanogaster (Melnick et al., 
1993), Urechis caupo (Rosenthal and Wordeman, 1995), Chlorohydra 
viridissima (Keppel and Schaller, 1991), Haloarcula marismortui (Ouzonis 
et al., 1995), Candida albicans (Lopez-Ribot et al., 1994), mammals (Ardini 
et al., 1998) 
Cellular localization of 
37 kDa LRP 
At the cell surface of mosquito cells (Ludwig et al., 1996) , of Candida 
albicans (Lopez-Ribot, 1994) and of mammalian cells such as Madin-Darby 
canine kidney cells (MDCK) (Salas et al., 1992); in the cytoplasm on 40S 
ribosomes (Auth and Brawerman, 1992); in the nucleus (Sato et al., 1996) 
Molecular weight 37,000 (laminin receptor precursor protein) 
67,000 (mature laminin receptor protein) 
Binding partners of 
-37 kDa LRP 
 
 
--67 kDa LR 
 
Laminin (Rieger et al., 1997), PrPc (Rieger et al., 1997), the Venezuelan 
equine encephalitis (VEE) virus (Ludwig et al., 1996); association of 
LBPc/p40 with histones H2A, H2B and H4 (Kinoshita et al., 1998) 
Laminin (Beck et al., 1990), elastin and carbohydrates (for review: (Ardini 
et al., 1998; Mecham, 1991; Rieger et al., 1999), the Sindbis virus (Wang et 
al., 1992) 
Functional domains  Transmembrane domain: aa 86-101 (Castronovo et al., 1991b), 
Laminin binding domain: aa 161-180 (Castronovo et al., 1991b); 
PrPc binding domain: aa 157 and 180 (Rieger et al., 1997) 
Functions of 
- 37 kDa LRP 
 
 
 
 
- 67 kDa LR  
 
Receptor for laminin (Rieger et al., 1997), PrPc (Rieger et al., 1997) and the 
Venezuelan equine encephalitis virus (Ludwig et al., 1996); as ribosomal 
protein LRP/p40 involved in protein synthesis (Auth and Brawerman, 
1992); possible role of LBPc/p40 in maintenance of nuclear structures 
(Kinoshita et al., 1998) 
Receptor for laminin (Beck et al., 1990), elastin, carbohydrates (for review: 
(Ardini et al., 1997; Mecham, 1991; Rieger et al., 1997)) and the Sindbis 
virus (Wang et al., 1992); crucial role in the metastatic potential of solid 
tumors (Castronovo, 1991b) 
a Laminin receptor precursor, LRP 
b Laminin receptor, LR 
c Laminin binding protein, LBP (equivalent to LRP) 
 
 
 
Mammalian genomes contain multiple copies of the LRP gene, in particular 6 copies in the 
mouse and 26 copies in the human genome (Fernandez et al., 1991; Jackers et al., 1996a) a 
fact that has hampered the identification of the active gene for a long time. To date, only the  
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gene for the chicken and the human gene encoding LRP have been isolated (Clausse et al., 
1996; Jackers et al., 1996b). The gene encoding 37 kDa LRP belongs to a multicopy gene 
family and contains seven exons and six introns (Jackers et al., 1996b). 
The 37 kDa LRP/p40 gene has been identified in different species including Saccharomyces 
cerevisiae (Davis et al., 1992), Arabidopsis thaliana (Garcia-Hernandez et al., 1994), 
Drosophila melanogaster (Melnick et al., 1993), the sea urchin Urechis caupo (Rosenthal and 
Wordeman, 1995), Chlorohydra viridissima (Keppel and Schaller, 1991), the fungus Candida 
albicans (Lopez-Ribot et al., 1994) and the archaebacterium Haloarcula marismortui 
(Ouzonis et al., 1995), as well as in mammals (Ardini et al., 1998; for review: Rieger et al., 
1999).The 37 kDa LRP also acts as a receptor for alphaviruses such as the Venezuelan equine 
encephalitis (VEE) virus on the surface of mosquito cells (Ludwig et al., 1996), has been 
identified on the cell surface of the fungus Candida albicans (Lopez-Ribot et al., 1994). and 
has been proved to be located on the surface of Madin-Darby canine kidney (MDCK) cells 
from dogs, which might be involved in cell attachment, spreading and polarization (Salas et 
al., 1992). These findings clearly demonstrate the location of the 37 kDa LRP on the cell 
surface. 
Within the life cycle of prions, LRP may play a role in the physiological function of PrPc, as 
well as in the pathogenesis of prion diseases. We assume that LRP is involved in the 
internalization process of PrPc via cavolae-like domains (Vey et al., 1996) or clathrin-coated 
pits (Shyng et al., 1994) (Fig. 3). Involvement of clathrin-coated pits in the endocytosis of a 
GPI-anchored protein such as PrPc is surprising because PrPc has no cytoplasmic domain that 
can interact directly with the intracellular components of coated pits (Harris, 1999). Here a 
receptor protein could be responsible for making the connection between the surface-
anchored PrP to clathrin. The uptake of PrPSc is thought to be mediated directly by a receptor 
protein such as LRP, but could also be mediated in an indirect manner dependent on the 
presence of cellular PrP. We assume that internalized PrPSc interacts with PrPc during the 
endocytic pathway (Fig. 3). PrPc is probably converted into PrPSc within the endosome, 
lysosomes or endolysosome influenced by an unknown protein termed protein X (Telling et 
al., 1995) which could represent a molecular chaperone such as Hsp60 (Edenhofer et al., 
1996). Recently, a homology of the amino terminus of LRP with members of the Hsp70 
family was observed (Ardini et al., 1998) suggesting that LRP/p40 might be involved in 
protein folding. Although we demonstrated a specific interaction between PrP and members 
of the Hsp60 family including GroEL (Edenhofer et al., 1996), no binding of PrP to members 
of the Hsp70 family was observed, which suggest no homology to the Hsp60 family 
 Chapter II 38
(Edenhofer et al., 1996). However, it cannot be excluded that a hypothetical chaperone 
activity of LRP might be involved in the PrPc/PrPSc conversion reaction, which is thought to 
occur in endosomes, lysosomes or endolysosomes of the endocytic pathway in the life cycle 
of prions. Other proteins encompassing an GPI-anchor were internalized by caveolae 
(Anderson, 1993). It has been suggested that PrPc and PrPSc are internalized by CLDs, a 
compartment where the conversion of PrPc to PrPSc might also take place (Vey et al., 1996). 
PrPSc accumulation leads to neuronal cell death resulting in vacuolization and death of the 
organism. 
The role of LRP within the life cycle of prions mediating PrP internalization and its 
involvement in pathological mechanisms within the complex scenario of transmissible 
spongiform encephalopathies has to be further investigated. 
 
 
Fig. 3: Model of the life cycle of prions. PrPc is synthesized in the rough endoplasmatic 
reticulum (ER), and after passing through the secretory pathway including the Golgi and 
secretory vesicles, reaches the surface of a PrPSc infectable cell where it is anchored via a 
glycosylphosphatidyl inositol (GPI) moiety. Endocytosis of PrPc and possibly PrPSc via 
clathrin coated vesicles could be mediated by the 37 kDa laminin receptor precursor (LRP). 
The uptake of the infectious agent could also be LRP independent. The conversion of the 
internalized PrPc to PrPSc is thought to take place in the endosomes, lysosomes or 
endolysosomes. Molecular chaperones could be involved in this conversion process. PrP 
replication and aggregation can occur in neuronal cells of the brain but also in the cells 
constituting the lymphoreticular system. Alternatively, endocytosis and conversion of PrPc 
into PrPSc could happen in caveolae-like domains (CLDs). 
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D. The Cadherins 
Two cell surface proteins were isolated from murine cells and characterized as so-called prion 
protein binding proteins (PrPBPs) (Table III) (Cashman and Dodelet, 1997). Mouse and 
human PrPs expressed as fusion proteins to human placental heat-stable alkaline phosphatase 
(PrP-AP) bound with high affinity to the surface of many primary cells and cell lines, 
particularly to the mouse muscle cell line G8, whereas no binding of AP alone could be 
observed. Frog oocytes showing little or no intrinsic PrP-AP surface binding were 
microinjected with in vitro transcribed mRNA generated from pooled plasmid clones of a G8 
cDNA library. Following selection of clones that showed specific binding to PrP-AP, 
sequence analysis revealed the cDNA inserts in two clones, one encoded a portion of 
protocadherin-43 spanning amino acid residues 67 to 252 and exhibited the highest level of 
PrP-AP binding activity, the other one encoded a portion of OB-cadherin-1 (the N-terminal 
cadherin repeat) and showed a moderate PrP-AP binding (Cashman and Dodelet, 1997). 
Protocadherin-43 described by Sano et al. (1993) and OB-cadherin-1 described by Okazaki et 
al. (1994) belong to a group of cell adhesion proteins designated Cadherins. Cadherins are a 
family of transmembrane glycoproteins involved in Ca2+ dependent cell-cell adhesion that 
occurs in many tissues mediating development patterning and tissue organization. They 
contain a large N-terminal extracellular region consisting of repetitive subdomains including 
the Ca2+-binding sites. Ca2+-binding is required for cadherin interaction and cell-cell adhesion, 
a process that results from lateral clustering of cadherin cis dimers and their trans association 
with cis dimers on the apposed cell (Steinberg and McNutt, 1999). The C-terminus consists of 
a transmembrane region and a highly conserved cytoplasmic domain, through which 
cadherins interact with intracellular adhesions proteins such as catenins and stabilize the 
internal structure of the cell. 
Binding of PrP-AP to cultured cells was significantly reduced in the presence of the calcium 
chelator EDTA, indicating that for optimum binding, the presence of divalent cations such as 
Ca2+ might be required. Binding of mouse, human and bovine cellular PrP as well as PrPSc 
from BSE-affected brain to the candidate receptor was observed (Cashman et al., 1999).  
Prion proteins could act as novel ligands for cadherin proteins. Cadherins participate in cell-
layer segregation and morphogenesis in development, also in maintenance of cell-cell 
recognition in mature tissues, and may participate in disorders in which recognition is 
deficient, such as metastatic cancer. It is also possible that they are involved in muscle and 
immunological disorders as well as in neurodegenerative diseases such as TSEs (Cashman 
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and Dodelet, 1997). The possible role of cadherins as cell surface receptors for prion proteins, 
however, has still to be confirmed. 
 
 
III. Molecular Chaperones of Mammals 
 
The crucial event in prion diseases involves the conformational change of the cellular form of 
the prion protein into the pathogenic isoform. This change causes a dramatic alteration within 
the structure. Structural variations of a protein often require a catalysing agent. Molecular 
chaperones are prominent candidates that could promote this reaction. 
The protein-only hypothesis indicates that the scrapie form of the prion protein can promote 
the conversion of the cellular form. This leads to the conclusion that prions themselves can act 
as chaperones (Liautard, 1991). Thermokinetic analysis of protein folding shows that a 
misfolded chaperone gives rise to new misfolded chaperones, which fit very well to the 
protein-only hypothesis in which PrPSc triggers the formation of PrPSc.  
Besides this theory, other proteins can act as promotors for the prion conversion reaction. In 
1996 chemical reagents were investigated and were shown to affect formation and 
propagation of PrPSc. Cellular osmolytes and proteinaceous chaperones were tested in this 
context (Tatzelt et al., 1996b). Chaperones that can prevent the formation of PrPSc (Fig. 4) 
might act as powerful tools for the generation of anti-TSE therapeutics. 
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Fig. 4: Influence of molecular and chemical chaperones on the conversion process of PrPc to 
PrPSc. Molecular chaperones such as Hsp104 and GroEL promote the conversion reaction 
whereas the chemical chaperones TMAO, DMSO and sucrose prevent PrPSc formation.  
 
 
Molecular chaperones also represent a biochemical and mechanistical link between the 
mammalian prions and the “prion-like” proteins in yeast. In this light heat-shock protein 
Hsp104 has an effect on the conversion of hamster PrP (DebBurman et al., 1997) and on the 
regulation of the yeast nonchromosomal element [PSI+] (Chernoff et al., 1995) suggesting 
that the prion concept is of general importance in mammalian and nonmammalian systems. 
Studies on the transmission of human prion proteins to transgenic mice indicates the existance 
of an unknown protein termed “protein X”, which binds to PrP (Telling et al., 1995) and 
might act as a molecular chaperone. 
 
A. Heat-Shock Proteins 
A number of cellular proteins function in vivo as chaperones that catalyse the formation of 
proteins with an intact secondary, tertiary and quaternary structure. Heat shock proteins 
(Hsps) are prominent representatives of these chaperones and were first discovered because of 
their specific induction during the cellular response to heat shock (Gething and Sambrook, 
1992). Nevertheless, the majority of the Hsps are expressed constitutively and their functions 
are diverse. Hsps stabilize unfolded protein precursors, rearrange protein oligomers and 
dissolve protein aggregates in an ATP-dependent manner. 
Hsps are thought to play an important role in the conversion of the cellular prion protein PrPc 
to the pathogenic isoform PrPSc (Table III). In 1995 the expression levels of Hsp72, Hsp28 
and Hsp73 in normal and scrapie-infected mouse neuroblastoma cells were investigated 
(Tatzelt et al., 1995). After heat shock Hsp72 and Hsp28 were both detectable in normal, but 
not in scrapie-infected cells. The constitutively expressed Hsp73, however, was expressed at 
comparable levels in both cell types, indicating that Hsp73 could possibly assist the formation 
of PrPSc. The lack of Hsp72 and Hsp28 in scrapie-infected cells suggests that chaperones do 
not catalyse a refolding of PrPSc into PrPc in these cells. Together, both facts might lead to an 
increase of PrPSc concentrations in scrapie-infected cells. 
We identified Hsp60 as a PrP binding molecule employing a HeLa cDNA library in prey and 
hamster PrP in bait position of the yeast-two-hybrid system (Edenhofer et al., 1996). In vitro 
binding studies with recombinant PrP confirmed the specificity of the PrP-Hsp60 interaction. 
Mapping analysis employing a series of PrP peptides identified the C-terminus of PrP (aa 180 
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to aa 210) encompassing -helix 2 and parts of -helix 3 (179-193 and 200-217) (Riek et al., 
1996; Donne et al., 1997; Riek et al., 1997) as the Hsp60 binding domain on PrP. GroEL, the 
prokaryotic homolog of Hsp60 revealed the same binding domain as Hsp60 on PrP. This 
indicates that eukaryotic as well as prokaryotic chaperones interact with the prion protein and 
suggest an important role of heat shock proteins in the conversion process of prion proteins.  
 
Table III Function of heat shock proteins and their effect on the prion protein 
 
Heat shock 
protein 
Reference First reported function in prion 
diseases 
Effect on PrP conversion 
Hsp28 Tatzelt et al., (1995) Role in Ca2+-dependent 
thermoresistance  
No effect on PrP 
conversion/PrPSc 
diminishes synthesis of 
Hsp28 
Hsp40 DebBurman et al., (1997) Co-chaperone of Hsp70s No effect on PrP 
conversion 
Hsp60 Edenhofer et al., (1996) Stabilization of prefolded 
structures and folding 
Binding to haPrP, binding 
domain: aa 180-210 
Hsp70 DebBurman et al., (1997) Completion of translocation in 
mitochondria 
No influence on PrP 
conversion 
Hsp72 Tatzelt et al., (1995) Prevents aggregation and 
accelerates refolding of 
damaged proteins  
No effect on PrP 
conversion/PrPSc 
diminishes synthesis of 
Hsp72 
Hsp73 Tatzelt et al., (1995) Cytosolic heat shock protein  Assists PrPSc formation? 
Hsp90 DebBurman et al., (1997) Stabilizing of inactive precursor 
forms in the cytosol 
No influence on PrP 
conversion 
Hsp104 DebBurman et al., (1997) Thermotolerance and ethanol 
tolerance in yeast 
Promotes conversion of 
PrPc 
GroEL Edenhofer et al., (1996) 
and DebBurman et al., 
(1997) 
Antifolding before translocation Binding to haPrP, binding 
domain: aa 180-210, 
promote conversion of 
PrPc 
GroES DebBurman et al., (1997) Form functional complex with 
GroEL 
No influence on PrP 
conversion 
 
 
GroEL and the heat shock protein Hsp104 are able to affect the in vitro conversion of hamster 
PrP, confirming the importance of GroEL for the PrP conversion reaction (DebBurman et al., 
1997). However, this process requires the presence of exogenous added PrPSc, suggesting that 
the conversion process and further aggregation seem to require a nucleation seed. Molecular 
chaperones may probably be not sufficient for this reaction. Other heat shock proteins like 
GroES, Hsp40, Hsp70 and Hsp90 do not show any effect in the conversion process. Hsp104 
links mammalian prion proteins and the prion-like yeast protein Sup35. Hsp104 could therby 
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either promote sup35* or sup35 formation dependening on Hsp104 concentrations. Hsp104 
might influence the regulating process of the [PSI+] element in S.cerevisiae (Patino et al., 
1996). In conclusion, heat shock proteins might influence the structure of mammalian and 
yeast prions. 
 
B. Protein X 
The transmission of human prion proteins to transgenic mice depends on the species of the 
endogenous expressed transgenic prion protein and the homozygocity/heterocygocity status of 
the expressed transgene. In contrast to transgenic mice ablated for the mouse Prnp gene or 
transgenic mice expressing low levels of a chimeric transgene, which are susceptible towards 
human prions, transgenic mice expressing the human PrP transgene are completely resistant 
towards human prions. This phenomenon reflecting the species barrier can be explained by a 
species specific factor termed protein X, which is thought to participate in prion formation. 
Protein X might act as a chaperone facilitating or hampering the conversion of PrPc to PrPSc. 
The fact that transgenic mice hyperexpressing human PrP are resistant to human prions 
(Telling et al., 1995), together with the finding that transgenic mice expressing chimeric 
MHu2MPrPc retain human PrP susceptibility suggests that protein X could bind to the cellular 
form of the prion protein and the affinity of protein X to prion proteins of different species 
may vary. The binding of protein X to the prion protein may result in the PrP conversion 
reaction. Differences in the amino acid sequence of PrP of different species may be the main 
reason for both effects. The main differences between mouse and human PrP are thought to 
reside in the carboxy-terminus of PrP. An epitope mapping of the binding site for protein X 
on PrP (Kaneko et al., 1997b) by substitution of the basic residues at aa position 167, 171 or 
218 preventing PrPSc formation suggests that the binding site for protein X on PrP resides 
within this region. Amino acid 218 is located within the third -helix of the mouse prion 
protein and residues 167 and 171 reside within an adjacent loop. The stoichiometry of the 
protein X/ PrPc complex is unknown to date. The fact that the protein X/PrPc interaction was 
abolished by mutations preventing the PrPSc formation might be useful for the development of 
anti-TSE therapeutic agents. A prerequiste for that, however, is the identification of protein X. 
 
C. Chemical Chaperones 
In contrast to “classical” chaperones consisting of proteins, chemical chaperones represent 
chemical compounds of small molecular weight that are able to stabilize proteins and correct 
misfolded ones (Welch and Brown, 1996) (Fig. 4). Chemical chaperones such as glycerol, 
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trimethylamine-N-oxide (TMAO) and dimethylsulfoxide (DMSO) might stabilize the native 
conformation of a protein by direct interaction. These compounds termed „cellular osmolytes“ 
are produced in cells in response to osmotic shock (Somero, 1986). Glycerol, TMAO and 
DMSO were tested to determine their influence on the formation of PrPSc in ScN2a cells 
(Tatzelt et al., 1996b). All reduced the extent of PrP conversion into its detergent insoluble 
form. The stabilizing effect of the native form of a protein was also demonstrated for other 
proteins such as the cystic fibrosis transmembrane regulator (CFTR) (Brown et al., 1996). 
The presence of chemical chaperones might have an effect on the hydration of proteins. 
Because self-association or tighter packaging of the prion protein is enhanced, PrPSc fails to 
interact with PrPc so that no PrPc/PrPSc heterodimer is formed leading to an inhibition of the 
PrP conversion process (Gekko and Timasheff, 1981). In the case that chemical chaperones 
might be transported to the brain bypassing the blood-brain barrier (BBB), they might be 
useful as therapeutic agents in TSE-therapy. 
The influence of chemical chaperones has also been demonstrated in cell-free conversion 
assays (DebBurman et al., 1997). The conversion of hamster PrP using partially denatured 
PrPSc was only inhibited by DMSO. Glycerol and cyclodextrin compounds had no effect, 
whereas molecular chaperones (Hsp104) were able to block the conversion process. Chemical 
chaperones such as glycerol and cyclodextrin, acting as co-chaperones, might have an 
influence on molecular chaperones that are lacking in a cell-free system. 
 
 
IV. Interaction between prion proteins 
 
According to the protein-only hypothesis, proposed by Prusiner (Fig. 5) the interaction of the 
cellular prion protein with the pathological isoform seems to be the crucial step in the 
conversion of PrPc to PrPSc. The existence of the hypothetical PrPc/PrPSc heterodimer may 
require the presence of a homodimer consisting of two PrPc molecules. This homodimer is 
thought to be in equilibrium with the PrPc monomers. It is unclear to date whether the 
spontanous conversion reaction involves PrPc monomers or the PrPc homodimers.  
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Fig. 5: Scheme of the conversion process of PrPc to PrPSc. Three possibilities for the 
conversion of PrPc into PrPSc do exist. An exogenous PrPSc triggers the conversion of PrP 
monomers leading directly to the hypothesized heterodimer consisiting of PrPc and PrPSc. 
Genetic predisposition of an individual leads to a spontanous conversion of PrPc to PrPSc. The 
conversion process might proceed after formation of a dimeric PrPc or might occur with a 
monomeric PrPc. The central PrPSc heterodimer forms a PrPSc homodimer aggregating into 
amyloid fibrils. 
 
In 1986 a 54 kDa protein was identified under denaturing conditions that may act as a dimeric 
PrP precursor for the scrapie protein (Bendheim and Bolton, 1986). A 60 kDa form of a 
recombinant hamster prion protein was detected in murine neuroblastoma cells in 1995 
(Priola et al., 1995). It appears as a dimer under denaturing conditions analyzed by SDS-
PAGE and under native conditions analyzed by immunoprecipitation. The linkage of both 
prion proteins might occur via hydrogen bonding, electrostatic interactions or covalent 
linkage involving lysins at the N-terminus of the protein. The observed dimer formation might 
be due to the hyperexpression of PrP with high PrP concentrations.  
The multimer formation of the prion protein and structural changes during this process has 
been investigated by fluorescence correlation spectroscopy (FCS) (Post et al., 1998). Prion 
aggregates mainly constituted of PrP27-30 were converted by sonication to monomeric PrP 
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with an high -helical content in the presence of 0.2% SDS. The oligomerization process was 
then initiated by the reduction of the SDS-concentration. Formation of -sheet structured 
dimers was the initial step followed by oligomerization of these dimers within 10 minutes. 
After 1 hour PrP was aggregated. Whether the conversion reaction arises before the 
dimerization event or wether dimerization represents the initial step of the conversion process 
remains speculative. 
Prion proteins with mutations in the octarepeat region causing familial CJD show abnormal 
aggregation properties (Priola and Chesebro, 1998). Hamster PrPs encompassing two, four 
and six octarepeats were expressed in mouse neuroblastoma cells. The fact that PrP dimers 
were detectable even under harsh denaturing conditions present in SDS-gel electrophoresis 
suggest that the PrP monomers were covalently linked rather than stabilized by noncovalent 
linkages such as hydrophobic interactions. However, covalently linked PrP dimers have still 
to be confirmed by other systems. 
Because of the lack of convincing experimental data, only a few models describe the PrP-
dimerization process. One of them proposes the highly conserved region from aa 109 to aa122 
as a major dimerization domain (Warwicker and Gane, 1996) calculated by a computational 
search for potential PrP interaction interfaces. Mutations such as alanine to valine at position 
117 of human PrP associated with Gerstmann-Sträussler-Scheinker syndrome reside within 
this region, and might alter the stability of the dimer, facilitating the conversion of PrPc to 
PrPSc. In addition to the dimerization process, the association of the prion protein to the 
membrane could play an important role in TSE pathogenesis (Warwicker, 1999). The putative 
membrane-binding domain might be the first -helix. The agglomeration of the prion protein 
on the membrane might influence the orientation and configuration of PrP facilitating the PrP 
interaction process. 
Whether PrP dimers that have also been observed by us (Hundt, Gauczynski, Riley, and 
Weiss, manuscript in preparation) might play an important role in the PrP oligo-
/multimerization process and whether PrP/PrP interfering agents might hamper the entire PrP 
aggregation process have still to be investigated. 
 
 
V. Other PrP interacting molecules 
 
This section first describes PrP interacting molecules identified by ligand blots, yeast two-
hybrid techniques or in vitro selection. Members of the PrP ligand family Pli are described 
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followed by Bcl-2 belonging to the family of proapoptotic and antiapoptotic molecules. 
Second, molecules are summarized acting as therapeutics in TSEs. With the exception of the 
protein clusterin, all the other molecules are of nonproteinaceous origin including polyanions, 
Congo red, polyene antibiotics, IDX, porphorins and phtalocyanes. Finally, nucleic acids such 
as RNA aptamers are described in their function as PrP-interacting molecules.  
 
A. PrP Ligands (Pli´s) 
1. Pli 45 and Pli 110 
Two PrP binding proteins were identified in 1990, using ligand blots (Oesch et al., 1990). 
These two proteins identified from hamster brain were termed PrP ligands Pli 45 and Pli 110. 
To investigate the interaction of purified PrP with other proteins the authors used radiolabeled 
PrP27-30 and PrPc, respectively, for the binding of proteins from hamster brain that were 
separated by SDS-PAGE and blotted to nitrocellulose (ligand blots).Two major bands became 
visible by autoradiography using purified PrP27-30 and immunopurified PrPc. The molecular 
weight of the identified proteins were 45,000 and 110,000, respectively, and both proteins 
bound to PrPSc and PrPc derived from hamster brain. Other PrP binding proteins ranging from 
32-200 kDa were also observed. The stability of the complexes formed by Pli 45 and PrP 27-
30 on nitrocellulose were investigated by intense washing steps and 50% of the radiolabelled 
PrP27-30 was washed off after 60 hours, corresponding to a dissociation rate constant of 
kD=3x10-6 s-1. Pli 45 revealed a sequence homology of 94.6% to murine GFAP (glial fibrillary 
acidic protein) at the cDNA level, suggesting that Pli 45 and GFAP are the same proteins. 
Comparitive immunochemistry studies, using polyclonal Pli45- and GFAP specific antibodies 
revealed the same staining pattern as monoclonal anti-GFAP antibodies in scrapie-infected 
sheep brain. In addition, both antibodies recognized recombinant GFAP expressed in 
Escherichia coli, suggesting that Pli 45 and GFAP are indeed the same proteins. 
Pli 45 was found exclusively in brain, whereas Pli 110 is present in several tissues, such as 
brain, lung, liver, spleen and pancreas. Pli 110 was shown to be identical with PTP-associated 
splicing factor (PSF) (Oesch, 1994). Because studies with GFAP0/0 mice revealed that GFAP 
is not essential for scrapie development (Gomi et al., 1995; Tatzelt et al., 1996) and PSF is an 
essential splicing factor, located in the nucleus (Patton et al., 1993), it seems that Pli45 and 
Pli110 do not play a crucial role in prion diseases. 
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2. Pli3-Pli8 
Seven years after the identification of the first two PrP-binding proteins Pli 45 and Pli 110 six 
other PrP ligands were found (Table I) (Yehiely et al., 1997). The authors used a different 
system than that used for the identification of Pli 45 and Pli 110. Here, PrP was designed as a 
fusion protein with alkaline phosphatase (AP) and secreted by NIH 3T3 cells. PrP-AP was 
then used as a probe for screening the mouse brain cDNA library gt11. Sequence analysis of 
nine clones revealed the six unique sequences, Pli3 to Pli8. Two cDNA clones showed 
homology to known sequences, to the mouse amyloid precursor-like protein (Aplp1) denoted 
Pli6 and to the mouse p45 NF-E2 related factor 2 (Nrf2), termed Pli7. All six Plis revealed the 
consensus sequence GXXXXXX(E/P)XP, which is not unique to PrP binding proteins, but 
was identified in many other protein sequences. Hence, the authors conclude that it might 
represent a functional motif. Negative charge might also play a role in PrP binding, as four 
cDNA clones showed an excess of glutamic acids and aspartic acids over lysines and 
arginines. Each cDNA clone identified a single copy gene and the chromosomal location of 
each clone was identified in this work.  
Polyclonal antibodies directed against the polypeptides Pli3 and Pli5 were generated and 
purified. Both antibodies recognized proteins from N2a cells and mouse brain on Western 
blots. Anti-Pli3 antiserum detected a 70 and a 100 kDa polypeptide, whereas anti-Pli5 
antiserum detected a 45 kDa polypeptide. All three identified polypeptides were believed to 
be novel PrP-binding proteins. Antisera to Nrf2 (Pli7) and Aplp1 (Pli6) were also used as 
probes on N2a cell lysates and mouse brain homogenates. For anti-Nrf2 antiserum, a 66 kDa 
protein was found, that corresponds to the predicted size of mouse Nrf2. Aplp1 antiserum 
recognized polypeptides of about 85 and 95 kDa molecular mass, which are likely to be two 
different forms of Aplp1. The protein levels of Pli3 and Pli5 appeared similar in scrapie-
infected and noninfected brain and N2a cells, whereas higher levels of Pli5 mRNA could be 
found in ScN2a cells. The protein levels of Nrf2 were found to be slightly decreased in ScN2a 
cells, whereas Aplp1 protein levels remained unchanged in ScN2a cells and infected mouse 
brain. Higher mRNA levels for both Aplp1 and Pli5 were found in ScN2a cells. 
Aplp2 is a member of the APP-like (amyloid precursor protein) family, playing an important 
role in the pathogenesis of Alzheimer disease (AD). The major component of the senile 
plaques that are observed in AD is the A peptide, which is derived from the APP protein 
(Glenner and Wong, 1984; Masters et al., 1985). PrP and Aplp1 are both membrane proteins; 
hence it is likely that they could interact on the cell surface.  
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B. Bcl-2 
Bcl-2 (Table I) represents a well-known member of a rapidly enlarging protein family of 
proapoptotic and antiapoptotic molecules, including at least 15 related proteins (Adams and 
Cory, 1998). In 1995 the role of Bcl-2 was investigated using a yeast two-hybrid screen 
(Kurschner and Morgan, 1995). LexA-Bcl-2 in the bait and a murine cerebellar cDNA-VP16 
fusion library in the prey position identified potential Bcl-2 binding proteins. Surprisingly the 
prion protein and not bax, which is known to heterodimerize with Bcl-2 (Oltvai et al., 1993), 
was pulled out by this screen. The sequenced cDNA clone contained a fusion between the 
VP16 domain and mouse PrP, encompassing aa72 to aa245, denoted PrP-VP16. Usinging 
LexA-PrP in the bait and Bcl-2-VP16 in the prey position of the yeast two-hybrid system 
resulted also in an interaction between PrP and Bcl-2. Interactions with other members of the 
Bcl-2 family, such as Bax or A1 were not observed. The PrP mutation P102L, associated with 
human Gerstmann-Sträusler-Scheinker syndrome was investigated, and it was shown that this 
mutation did not alter the binding behavior of PrP to Bcl-2. Interestingly, the PrP-Bcl-2 
interaction could not be confirmed by coimmunoprecipitation assays, suggesting that this 
protein interaction can be observed only in the yeast-two-hybrid system.  
Bcl-2 and Bax act as antiapoptotic and proapoptotic molecules in apoptosis, respectively. 
Moreover, the ratio of Bax-Bcl-2 heterodimers to homodimers of each protein is important for 
the regulation of apoptosis (Oltvai and Korsmeyer, 1994; O´Dowd et al., 1988; Yang and 
Korsmeyer, 1996). Hence the authors concluded that PrP might play a role in disrupting the 
Bax:Bcl-2 ratio by trapping Bcl-2 and favoring Bax-Bax homodimers, which would lead to 
cell death by apoptosis (Fig.6). The trapping of Bcl-2 by PrP might occur during trafficking of 
PrP before exposure to the cell membrane. Although Bcl-2 and PrP are both membrane 
associated, the physiological cellular location of Bcl-2 is different from that of PrP. Bcl-2 is 
thought to be an inner mitochondrial membrane protein (Hockenbery et al., 1990; Motoyama 
et al., 1998) or might reside on the mitochondrial outer membrane, the endoplasmatic 
reticulum, or the nuclear membrane (Krajewski et al., 1993; Lithgow et al., 1994) , and is not 
present on the cell surface membrane. 
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Fig. 6: Schematic view of Bcl-2::Bax, Bcl-2::PrP and Bax::Bax transitions and their possible 
role in cellular functions. 
 
C. Laminin 
Laminin (LN) is a glycoprotein of the extracellular matrix (ECM) [for review see Beck et al., 
(1990)] that mediates cell attachment, communication, differentiation, movement and neurite 
outgrowth promotion (Hunter et al., 1989). Laminin is the first ECM protein detected during 
embryogenesis. In later development and in mature tissue, laminin serves as an ubiquitious 
and major noncollagenous component of basement membranes (Beck et al., 1990). Laminin 
was first isolated from Engelbreth-Holm-Swarm (EHS) tumor (Timpl et al., 1979) and from 
extracellular deposits of murine parietal yolk sac (PYS) carcinoma cells (Chung et al., 1979). 
A specific binding between laminin and the amyloid precursor protein (APP), the precursor of 
the amyloid peptide involved in Alzheimer`s disease, has been identified (Narindrasorasak et 
al., 1992). APP and -amyloid peptide (1-40) interaction with the extracellular matrix 
promotes neurite outgrowth, suggesting that the complex might play a normal physiological 
role in the brain (Kibbey et al., 1993; Koo et al., 1993). Recently, a direct interaction between 
the cellular prion protein (PrPc) and laminin was reported (Graner et al., 2000). An 
involvement of the PrPc-laminin interaction in neuritogenesis induced by NGF plus laminin in 
the PC-12 cell line was further suggested (Graner et al., 2000). Neuritogenesis, induced either 
by laminin or its -1-derived peptide in primary cultures from rat or either wild-type or PrP 
null mice hippocampal neurons, might imply that PrPc could be the main cellular receptor for 
the particular -1 domain located to the carboxy terminus of laminin (Graner et al., 2000). 
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D. Therapeutics 
1. Polyanions 
Polyanions (Table IV), including heteropolyanion 23 (HPA-23), Dextran Sulfate 500 (DS 
500), pentosan polysulfate (SP54) and heparin are known to bind the prion protein and/or 
prevent PrPSc accumulation in animals and cell systems (Brimacombe et al., 1999; Caughey 
and Raymond, 1993; Diringer and Ehlers, 1991; Ehlers and Diringer, 1984; Farquhar et al., 
1999; Gabizon et al., 1993; Kimberlin and Walker, 1983; Kimberlin and Walker, 1986; 
Ladogana et al., 1992). The first polyanion denoted as an anti-scrapie drug was HPA-23 
(Kimberlin and Walker, 1983; Kimberlin and Walker, 1986). The effect of HPA-23 was 
tested in several different scrapie strains, such as 139A, ME7, 22A and 263K. HPA-23 was 
effective in all these strains and prolonged the lifetimes of the animals significantly after 
scrapie injection. Less effect was observed when scrapie material was injected 
intraperitoneally or if the drug was given more than 48 hours after scrapie infection. Injection 
before to infection with scrapie is not effictive, owing to the rapid metabolization or excretion 
of HPA-23. HPA-23 is thought to interfere with early replication of PrPSc in the 
lymphoreticular system, reducing the efficiency of scrapie infection. These results, together 
with the brain toxicity of this molecule suggest, that HPA-23 has limited therapeutic value. 
Two high-molecular-weight polyanions, carrageenan and DS 500, were shown to be highly 
efficient in reducing scrapie titers in mice infected with the 139A strain of scrapie (Ehlers and 
Diringer, 1984; Kimberlin and Walker, 1986). All intravenous or intraperitoneal combinations 
of injecting DS 500 or scrapie reduced the effective titer about 100- to 200 fold. The effect of 
DS 500 is long-lasting. Application of DS 500 up to 10 weeks before to infection increases 
the incubation period in mice. However, DS 500 itself is highly toxic and causes up to 50% 
mortality at a dose of 2 mg per mouse. Like HPA-23, DS 500 is thought to prevent PrPSc 
replication in spleen and lymph nodes and its mode of action is likely to be independent of its 
activity as a B-cell mitogen. The high-molecular-weight and negative charge may represent 
important factors in the anti-scrapie effect of DS 500. SP54 (Pentosan Polysulfate, Fig. 7A) 
has an anti-scrapie effect comparable to DS 500, but is less toxic. It has been shown that SP54 
significally increases scrapie incubation period in hamsters infected with 263K scrapie strain 
and in mice infected with the 139A, Me7 and 22A strains of scrapie (Ehlers and Diringer, 
1984; Farquhar et al., 1999; Ladogana et al., 1992). SP54 is even effective if only a single 
low-dose is injected after infection. A single injection of 250 µg of SP54 increased the mean 
incubation period of the ME7 strain by up to 66% and 1 mg of SP54 protected mice 
completely from the 22A scrapie strain. SP54 is thought be effective during the very early 
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events of pathogenesis by interfering with the uptake of PrPSc by nerve endings and/or carrier 
cells. The low-dose effect and the lower in vivo toxicity compared to other polyanions make 
SP54 a promising candidate in the field of anti-scrapie polyanions. 
  
Table IV. Antiscrapie drugs likely to interact directly with PrP 
 
Drug    Tested scrapie
strain 
 Successfully treated 
animals 
Suggested mode of action Comments References
HPA-23 139A, ME7, 22A 
and 263K 
Mouse and hamster Prevents early agent 
replication in the LRS, 
competes with GAG 
(glycosaminoglycan) 
binding site 
Effective in a lot of scrapie 
strains, rapid metabolism and 
excretion, 
toxic 
Kimberlin and 
Walker (1983; 
Kimberlin and 
Walker (1986 
DS 500 139A Mouse  Prevents agent replication 
in the LRS due to its high 
molecular weight and 
negative charge, competes 
with GAG 
(glycosaminoglycan) 
binding site 
Long-lasting anti-scrapie effect 
but toxic at therapeutic doses 
Ehlers and 
Diringer (1984); 
Kimberlin and 
Walker (1986) 
Pentosan 
Polysulfate 
139A, ME7, 22A 
and 263K 
Mouse and hamster Interferes with PrPSc 
uptake from nerve 
endings, competes with 
GAG 
(glycosaminoglycan) 
binding site 
Very promising drug, effective at 
extreme low dose 
Ehlers and 
Diringer (1984); 
Farquhar  et al. 
(1999); Ladogana 
et al. (1992) 
Amphotericin B C506M3 and 
263K 
Mouse and hamster Direct prevention of PrP 
conversion or interference 
with PrPSc uptake 
Acute nephrotoxicity and low 
solubility, widely used for the 
treatment of fungals  
Pocchiari  et al. 
(1987); Xi  et al. 
(1992) 
MS-8209   C506M3 and
263K 
Mouse and hamster Same as for AmB Lower toxicity than AmB Adjou et al. 
(1995); Demaimay 
et al. (1997) 
Adjou et al. (1999) 
Congo Red 263K and 139A Hamster Binding to PrPc with 
polyanion-like behavior, 
or binding to PrPSc 
(overstabilisation) 
Dyes amyloid Caspi et al. 
(1998); Caughey 
et al. (1993); 
Ingrosso et al. 
(1995) 
  
Anthrycycline 263K Hamster Binding to PrPSc, 
preventing amyloid 
deposition 
Used for the treatment of 
malignancies 
Tagliavini et al. 
(1997) 
Porphyrins and 
Phtalocyans 
263K 
   
Mouse expressing
hamster PrP 
 Binding to PrPSc Inhibits cell free PrPc/Sc 
conversion 
Caughey et al. 
(1998); Priola et 
al. (2000) 
Cp-60/Cp-62 ScN2a cells None Mimicking dominant 
negative inhibition of 
prion replication 
Identified by using a 
computational database search 
Perrier et al. 
(2000) 
IPrP13 (-sheet 
breaker) 
139A Mouse Direct change of PrP 
secondary structure 
Synthetic peptide Soto et al. (2000) 
Clusterin 
[apolipoprotein J 
(apo J)] 
----- None, prevents
aggregation of 
PrP106-126 
 Binding to PrPc/Sc Binds to extraneuronal PrPBSE McHattie and
Edington (1999) 
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All anti-scrapie polyanions published so far might act by competing directly with the binding 
of cellular glycoaminoglycans (GAGs) to PrPc (see chapter II. A) and/or PrPSc (Brimacombe 
et al., 1999; Caughey et al., 1994). Indeed, GAGs are involved in the metabolism of PrPc (see 
chapter II.A) and thus in the biogenesis of PrPSc. It was shown by surface plasmon resonance, 
that pentosan polysulfate shows the strongest binding to recombinant PrP followed by heparin 
and dermatan sulfate. This correlates to the ability of the molecules to delay scrapie disease 
and reduce PrPSc accumulation in scrapie-infected cell lines (Caughey and Raymond, 1993).  
 
2. Congo Red 
Congo red (Fig. 7C, Table IV) is a dye that can be used as a diagnosic stain for amyloids. It is 
well known that Congo red can inhibit PrPres accumulation in Sc+-MNB cells and PrPSc 
replication in 263K and 139H treated hamsters (Caspi et al., 1998; Caughey et al., 1994; 
Caughey et al., 1993; Ingrosso et al., 1995). The mechanism of the Congo red anti-scrapie 
effect probably involves direct binding to PrPc, which again is thought to block the binding of 
cellular GAGs to PrPc, as described for polyanions (Caughey et al., 1994). The proposed 
direct binding of Congo red to PrPSc is thought to stabilize PrP Sc, the abnormal isoform of the 
prion protein, and prevents its partial denaturation, which could be necessary for agent 
replication (Caspi et al., 1998). 
 
3. Polyene Antibiotics 
Amphotericin B (AmB) and MS-8209 (Fig. 7D) are polyene macrolide antibiotics, that have a 
ring structure containing a hydrophobic and a hydrophilic region on either side of the 
molecule. They are used for the treatment of systemic fungal infections like candidiasis, 
histoplasmosis and aspergillosis (Medoff et al., 1983). The effects of AmB and its derivative 
MS-8209 were studied in several models of rodents including 263K-infected hamsters. Both 
were very efficient in delaying scrapie disease and PrPSc accumulation. MS-8209 shows at 
least a five times lower toxicity and a higher solubility and is able to double the incubation 
time of scrapie in hamsters. In contrast to polyanions, polyene antibiotics are effective even 
after intracerebral infection (Adjou et al., 1995; Demaimay et al., 1994; McKenzie et al., 
1994; Pocchiari et al., 1987; Xi et al., 1992).  
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Fig. 7: Antiscrapie drugs of four different classes. (A) Pentosan polysulfate as a powerful 
drug belonging to the polyanion family. (B) IDX a derivative of doxorubicin. (C) Congo red 
belonging to the diazo dyes. (D) Amphotericin B and MS-8209 belonging to the family of 
polyene macrolide antibiotics. 
 
 
Presently AmB and its derivatives are the only category of antiscrapie drugs that are 
prolonging the incubation period when given at late stages of infection (Demaimay et al., 
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1997). However, the effect of polyene antibiotics vary between scrapie strains (Adjou et al., 
1996). Note that the only reported treatment of clinical CJD with AmB in humans was 
unsuccessful (Masullo et al., 1992). Several possible mechanisms are involved in the 
antiscrapie effect of polyene antibiotics. AmB and MS-8209 have been proposed to directly 
affect the PrPsen to PrPres conversion step and thus prevent PrPres accumulation (Adjou et 
al., 1999; Adjou et al., 1997; Demaimay et al., 1997). Nevertheless a more indirect mode of 
action seems to be possible, whereby AmB and its derivatives disturb the uptake of PrPres by 
cells most likely by interfering with membrane cholesterol-rich domains (rafts) (Bolard, 1986; 
Taraboulos et al., 1995).  
 
4. Other Therapeutics  
Anthracycline 4´-iodo-4´deoxy-doxorubicin (IDX) (Fig. 7B; Table IV) is a derivative of the 
drug doxorubicin, which is successfully used in the treatment of several malignancies 
(Barbieri et al., 1987). IDX binds to amyloid fibrils and induces amyloid resorption in 
patients suffering from plasma cell dyscrasias with immunoglobulin light-chain amyloidosis 
(Gianni et al., 1995; Merlini et al., 1995). IDX was shown to delay the clinical signs of 
scrapie disease in 263K-infected hamsters when co-incubated with the 263K material prior to 
intracerebral inoculation. At a molecular level IDX is thought to bind the abnormal form of 
PrP, thereby decreasing the number of template molecules available for the PrPc conversion 
process (Tagliavini et al., 1997). 
Porphyrins and phtalocyans (Table IV) prevented PrPres accumulation in scrapie-infected 
mouse neuroblastoma cell cultures (Caughey et al., 1998) and prolonged the incubation 
period in hamster PrP expressing mice infected with 263K scrapie (Priola et al., 2000). The 
molecules also inhibited a cell-free conversion of hamster PrPsen to PrPres, showing that the 
effect seems to be due to direct PrP-binding. Nevertheless, because PrPres preparations are 
not completely pure, interactions with other molecules might be possible. Some other 
interactions with cells involved in scrapie pathogenesis can also not be excluded (Manuelidis, 
2000).  
Based on the proposal of a protein X binding domain (Kaneko et al., 1997b) synthetic drugs 
were identified that are able to inhibit PrPSc formation in ScN2a cells (Perrier et al., 2000). 
Two compounds, Cp-60 and Cp-62 (Table IV) act in a dose-dependent manner and show low 
toxicity. They are suggested to mimic the dominant negative inhibition of PrP replication 
originally reported for a PrP mutant (Kaneko et al., 1997a).  
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A 13-residue -sheet breaker peptide (iPrP13) (Table IV) was shown to partly reverse PrPSc to 
a PrPc like state. Mice inoculated with iPrP12-pretreated infectious material showed delayed 
appearance of clinical symptoms (Soto et al., 2000). The peptide is thought to directly change 
the conformation of PrPSc from a -sheeted to a more -helical secondary structure and 
therefore reduce infectivity.  
An effect of clusterin (Table IV) on the in vitro aggregation of the prion neuropeptide 106-
126 was tested. Clusterin co-localizes with extraneuronal PrPBSE in terminal BSE and the 
aggregation of the neuropeptide 106-126 was inhibited by clusterin in a dose-dependent 
manner (McHattie and Edington, 1999). The neurotoxicty of peptide 106-126 is subject of 
discussion, since a recent report described aggregation but no neurotoxicity for this peptide 
(Kunz et al., 1999).  
Dapsone (Manuelidis et al., 1998) and flurpirtine (Perovic et al., 1995) have also been 
described as TSE therapeutics. In contrast to the previously described drugs, however, a direct 
interaction with PrP is unlikely (Table V). 
 
Table V. Antiscrapie drugs not thought to interact directly with PrP 
 
Drug Tested on 
scrapie strain 
Success in animal 
treatment 
Suggested mode of action References 
Dapsone SY Mouse Altering of macrophage 
processing of infectious 
agent and modulation of 
inflammatory factors 
Manuelidis et al, 
(1998) 
Flurpirtine 
(Katadolon) 
---- None, cures 
neuronal cells 
treated with 
PrP106-126 
Lowers toxic effect of 
PrP106-126 by 
normalization of GSH 
levels 
Perovic et al. 
(1995) 
 
 
E. Nucleic Acids  
So far, no nucleic acid directly linked to scrapie infectivity has been identified. The existence 
of scrapie-specific homogeneous nucleic acid of more than 80 nucleotides has been excluded 
by analysis of highly purified scrapie preparations involving improved return refocusing gel 
electrophoresis (Kellings et al., 1992). However, the presence of a nucleic acid associated 
with infectivity cannot be ruled out, as the BSE agent can be transmitted to mice in the 
absence of detectable abnormal PrP (Lasmézas et al., 1997).  
The in vitro interaction of nucleic acid with PrP has been described for both DNA and RNA. 
Using fluorescence labelled DNA, it was shown that the bindingstrength of peptide PrP106-
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126 to DNA was of a similar order of magnitude as the binding of retroviral protein p10 with 
model nucleic acids (Nandi, 1997). It was also shown that PrP106-126 polymerizes in the 
presence of DNA in solution, whereas the peptide alone fail to polymerize (Nandi, 1998). 
RNA aptamers that bind specifically to recombinant hamster PrP (Weiss et al., 1995) but not 
to recombinant PrP90-231 (Weiss et al., 1996) were isolated by in vitro selection (Weiss et 
al., 1997). RNA aptamers of three different motifs were isolated, and all revealed a G quartet 
scaffold, which was proved to be essential for PrPc binding. An RNA aptamer of only 29 
nucleotides, representing the G quartet scaffold, was sufficient for PrPc recognition. The 
interaction of the G quartet scaffold with PrPc was directed exclusively against the amino 
terminus (aa23-52) of PrP. However, it could not be excluded that the aptamer recognizes 
PrPSc, but failed to recognize PrP27-30, lacking aa23-89 from the amino terminus. 
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Abstract 
Recently, we identified the 37-kDa laminin receptor precursor (LRP) as an interactor for the 
prion protein (PrP). Here, we show the presence of the 37-kDa LRP and its mature 67-kDa 
form termed high-affinity laminin receptor (LR) in plasma membrane fractions of N2a cells, 
whereas only the 37-kDa LRP was detected in baby hamster kidney (BHK) cells. PrP co-
localizes with LRP/LR on the surface of N2a cells and Semliki Forest virus (SFV) RNA 
transfected BHK cells. Cell-binding assays reveal the LRP/LR-dependent binding of cellular 
PrP by neuronal and non-neuronal cells. Hyperexpression of LRP on the surface of BHK cells 
results in the binding of exogenous PrP. Cell binding is similar in PrP+/+ and PrPo/o primary 
neurons, demonstrating that PrP does not act as a co-receptor of LRP/LR. LRP/LR-dependent 
internalization of PrP is blocked at 4°C. Secretion of an LRP mutant lacking the 
transmembrane domain (aa86 to aa101) from BHK cells abolishes PrP binding and 
internalization. Our results show that LRP/LR acts as the receptor for cellular PrP on the 
surface of mammalian cells.  
 
 
Introduction 
The prion protein is an ubiquitous host protein expressed by all known mammals (Oesch et 
al., 1991; Oesch et al., 1985; Schätzl et al., 1995) predominantly in the brain (Chesebro et al., 
1985). While its exact function is still unknown, a role has been proposed in synaptic 
transmission by neuronal cells (Collinge et al., 1994; Fournier et al., 1995; Kitamoto et al., 
1992), in sleep behaviour (Tobler et al., 1996) and in cell survival (Kuwahara et al., 1999) 
(for review see (Weissmann, 1996)). The Purkinje cell degeneration (Sakaguchi et al., 1996), 
however, was not due to the lack of PrP, but to overexpression of doppel (Dpl) (Moore et al., 
1999). PrP binds copper in vivo (Brown et al., 1997) and reveals signal transduction activity 
by activating tyrosine kinase Fyn (Mouillet-Richard, 2000). PrP is essential for the 
development of transmissible spongiform encephalopathies (TSEs) (Bueler et al., 1993) also 
known as prion diseases, which represent fatal neurodegenerative diseases such as scrapie in 
sheep, BSE in cattle and Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker 
syndrome (GSS) and fatal familial insomnia (FFI) in humans (for review see (Lasmézas and 
Weiss, 2000; Prusiner et al., 1998; Weissmann and Aguzzi, 1997)).  
It is thought that an abnormal form of PrP, termed PrPres for its partial resistance to 
proteolytic digestion, which accumulates in the brain of infected individuals, is a major 
component of the infectious agent of TSEs (Prusiner, 1982). The process leading to the 
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harmful form of the protein results in a conformational change of -helices or unstructured 
regions of PrPc to -sheet structures in PrPres (Caughey et al., 1991). It is still unknown if the 
neuronal death observed in TSEs is due to a loss of function of PrPc or to the toxicity of 
PrPres. In this context, the identification of the cellular receptor for PrP would be a key step 
towards both, the understanding of disease pathogenesis and the development of therapeutics.  
Within the life cycle of the prion protein, PrPc is transported to the cell surface where it 
remains GPI anchored. PrPc is internalized via clathrin coated pits (Shyng et al., 1994) or 
caveolae like domains (Vey et al., 1996). The conversion of PrPc into PrPres may take place 
at the cell surface, in endosomes, lysosomes or endolysosomes. This process is thought to be 
influenced by an unknown protein termed protein X (Telling et al., 1995), which could 
represent a molecular chaperone such as Hsp60 identified as an interactor for PrPc 
(Edenhofer et al., 1996). The presence of a specific so far unidentified cell-surface receptor 
for PrP has been deduced from complementary hydropathy (Martins et al., 1997). 
Simultaneously, we identified the 37-kDa laminin receptor precursor (LRP) – which 
represents the precursor of 67-kDa laminin receptor (LR) - as an interactor for the prion 
protein in a yeast two-hybrid screen (Rieger et al., 1997) and hypothesized that LRP could act 
as a receptor or co-receptor for PrP (for review (Gauczynski et al., 2001; Rieger et al., 1999)). 
In the present study, we confirm the presence of the 37-kDa LRP and its mature 67-kDa 
isoform at the plasma membrane of N2a cells. We found that PrP co-localizes with LRP/LR 
at the surface of N2a and with LRP on BHK cells, the latter hyperexpressing LRP and PrP by 
recombinant (rec.) Semliki Forest virus vectors (for review on the SFV-system see 
(Liljestrom and Garoff, 1991; Tubulekas et al., 1997)). The relationship between 37-kDa LRP 
and 67-kDa LR is unknown so far (for review see (Gauczynski et al., 2001)). As we observed 
in this study both forms of the receptor in plasma membrane fractions of N2a cells, we 
suppose that both forms may act as the receptor for cellular PrP. We investigated the role of 
LRP/LR as a receptor for cellular PrP by the development of various cell-
binding/internalization assays for PrP. We further studied by PrP hyperexpression on baby 
hamster kidney (BHK) and Hela cells the possible role of endogeneous PrP acting as a co-
receptor for LRP/LR on the cell surface. Employing an LRP deletion mutant lacking the 
transmembrane domain of LRP, termed LRPdelTMD, we also investigated the necessity of 
LRP for PrP binding and internalization. We conclude from these data that 37-kDa LRP/67-
kDa LR acts as the main cell-surface receptor for PrP. 
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Results 
Co-localization of 37-kDa LRP/67-kDa LR with PrP on the surface of neuroblastoma 
cells 
Immunofluorescence (IF) analysis of non-permeabilized murine neuroblastoma cells 
(N2a[MHM2]) employing LRP- (Figure 1A) and PrP- (Figure 1B) specific antibodies 
demonstrated that PrP and LRP/LR co-localize on the surface of these cells (Figure 1C). The 
integrin LR VLA6 failed to co-localize with PrP (Figure 1D-F) and LRP/LR on the cell 
surface (Figure 1G-I). Fluorescence-activated cell (FAC) scans of non-permeabilized N2a 
cells employing an LRP specific antibody confirmed the cell-surface location of LRP/LR 
(Figure 1J). The -galactoside lectin galectin-3 (gal-3) (Yang et al., 1996), which was used as 
a control throughout the experiments because of a previously reported cross-reactivity with 
LRP (Buto et al., 1998), is not expressed on the surface of N2a cells (Figure 1L). Western 
blot analysis of cytoplasm free plasma membrane fractions of N2a cells using a monoclonal 
antibody against LRP/LR revealed that the 37-kDa form (LRP) and to a lesser extent its 
mature 67-kDa form (LR), are located on the plasma membrane of N2a cells (Figure 1K). IF 
and FACscans of non-permeabilized primary cultures of mouse cortical neurons (data not 
shown) and HeLa cells (Figure 4B) also demonstrated the cell-surface location of LRP/LR on 
these cells, used for PrP binding experiments. 
 
Location and orientation of LRP and human PrP on BHK cells transfected by 
recombinant Semliki Forest virus RNA 
In order to investigate more precisely the localization and orientation of LRP on the surface 
of mammalian cells, the Semliki Forest virus (SFV) system was used to express rec. 
LRP::FLAG in BHK cells. Immunofluorescence analysis (Figure 2A, left inset) and 
FACscans (Figure 2D) reveal a low level of endogenous LRP expression. Gal-3 was not 
expressed on the surface of BHK cells (Figure 2F). Detection of LRP::FLAG at the surface of 
SFV LRP-FLAG RNA transfected BHK cells with a FLAG antibody (Figure 2A) 
demonstrates that LRP acts as a type 2 receptor with its C-terminus oriented to the 
extracellular space. Flow cytometry confirmed the cell-surface location of LRP::FLAG 
(Figure 2E). Endogeneous LRP (Figure 2G, lane 1), hyperexpressed LRP::FLAG (Figure 2G, 
lanes 2 and 4) and human PrP (Figure 2G, lane 6) are located at the plasma membrane of 
BHK cells. Expression of LRP::FLAG in this cell system did not result in the 67-kDa form of 
the LR. These data lead to the model for LRP depicted in Figure 2C showing the laminin-
binding domain (Castronovo et al., 1991) coinciding with the direct PrP-binding site located 
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between amino acids (aa)161 and 179 (Hundt et al., 2001). An LRP mutant (LRPdelTMD) 
lacking the proposed transmembrane domain (Castronovo et al., 1991) secreted to the 
extracellular space of BHK cells (Figure 5D) demonstrating that this region indeed represents 
the transmembrane domain of LRP. Transfection of SFV human PrP RNA into BHK cells led 
to the translocation of non-tagged human PrP to the surface of BHK cells (Figure 2B). We 
then aimed to verify whether the cellular location of LRP and PrP would allow them to 
interact with each other. Co-expression of LRP::FLAG and human PrP in BHK cells proved 
that LRP (Figure 2H) and PrP (Figure 2I) co-localize to a large extent on the cell surface 
(Figure 2J).  
 
LRP/LR-dependent binding of human PrP to mammalian cells  
To investigate a possible role of LRP/LR for the PrP binding and internalization, we 
established cell-binding assays with prion proteins. We confirmed that the PrPc moiety of rec. 
GST::huPrP, employed in most of our assays, displays a conformation similar to native PrPc 
by CD spectroscopy (Figure 3E) as shown previously for  glutathione S-transferase (GST)-
fused hamster PrP23-231 (Volkel et al., 1998). The binding of GST::huPrP23-230 to N2a 
cells (Figure 3A) can be totally abolished by pre-incubating the cells with the LRP antibody 
W3 (Figure 3A, inset). Exogeneous PrP bound to the cell surface (Figure 3C) and co-
localized partly with LRP/LR (Figure 3B and D). The binding curve deduced from western 
blot quantification of the GST::huPrP binding to N2a cells (Figure 3 F) reveals that at a 
GST::PrPc concentration of 4 µg/ml (used in the co-localization assay) the receptor molecules 
were not saturated (visible as green dots on the cell surface in Figure 3 D). This is a possible 
explanation for the incomplete co-localization, which is compatible with the kD of 1 x 10-7 
mol/l deduced from this binding curve. At this GST::PrPc amount there might also be more 
receptor molecules on the cell surface than could bind 4 µg of PrP. The association of rec. PrP 
with N2a cells was competed in a dose-dependent manner with the LRP antibody W3 (Figure 
3G; Table I). Recently, a homology of the N-terminus of LRP with members of the Hsp70 
family was observed (Ardini et al., 1998) suggesting that LRP/p40 might be involved in 
protein folding. Antibodies directed against the molecular chaperones Hsp60, 70 or 90 
(Figure 3H; Table I), however,  did not influence the PrP-binding reaction. GST::huPrP23-
230, saturated with a GST antibody prior to exposure, bound also to human NT2 cells (data 
not shown). Authentic PrPc from hamster brain membrane preparations bound LRP/LR-
dependent to MNB cells (Figure 3I). All experiments performed to verify the strict LRP/LR 
and PrP specificity of the binding reaction are summarized in Table I. Pre-immune serum, 
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antibodies directed against GST, GFAP, laminin or gal-3 revealed no effect. Antibodies 
against other LRs such as the lutheran protein (El Nemer et al., 1998) and the integrin laminin 
receptor VLA6 (Magnifico et al., 1996) did not inhibit the binding of PrP. In addition, we 
observed that the lutheran protein failed to interact with LRP in the yeast two hybrid system 
(data not shown). Saturation of the rec. protein with the PrP antibody JB007 led to a complete 
inhibition of the binding. A monoclonal antibody directed against aa 285-295 of LRP/LR 
failed to compete for the binding of GST::huPrP, whereas the monoclonal LRP/LR antibody 
directed against aa 167-243 reduced the binding of PrP to neuronal cells (Figure 3G and 
Table I). 
 
Hyperexpression of LRP on the cell surface of BHK cells by the SFV system enhanced 
binding of recombinant PrP  
Next we aimed to verify whether a quantitative relationship exists between PrP binding and 
the amount of LRP available on the cell surface. Untransfected BHK cells with a low level of 
endogenous LRP (Figure 3J, lower panel and Figure 2A, left inset) in the absence of any 
detectable LR bind only barely detectable amounts of rec. PrP (Figure 3J, upper panel and 
Figure 3L, triangles). In contrast, hyperexpression of LRP::FLAG at the surface of BHK cells 
(Figure 3J, lanes 1-5, lower panel and Figure 2A) led to an enhanced dose-dependent binding 
of GST::huPrP (Figure 3J, lanes 1-5, upper panel and Figure 3L, squares). Binding of non-, 
mono- and diglycosylated human PrP (without any tag) produced in the SFV-system was 
significantly increased when LRP::FLAG was hyperexpressed at the cell surface (Figure 3K, 
lanes 1-5 versus 6-10 and Figure 3M, squares versus triangles). Next, we wanted to verify 
whether additional PrP on the cell surface influences the binding of externally added rec. PrP. 
The co-expression of LRP::FLAG (Figure 3J, lanes 6-10, lower panel) and human PrP 
(Figure 3J, lanes 6-10, upper panel) on the cell surface reduced the dose-dependent 
GST::huPrP binding (Figure 3J, lanes 6-10, upper panel and Figure 3L, diamonds) when 
compared with cells transfected with LRP::FLAG only (Figure 3L, squares). This finding 
suggests that PrP does not act as a co-receptor for LRP for the binding of externally added 
PrP on the surface of mammalian cells. 
 
Binding behaviour of PrP to HeLa cells hyperexpressing PrP at the cell surface 
The function of PrPc is unknown. However, due to its topography, it has been hypothesized 
that it could function as a receptor (Weissmann, 1996). We wanted to know whether PrP acts 
as a co-receptor for LRP/LR. To this purpose, we determined whether transiently transfected 
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HeLa cells ( 10-20 % of total cells) with a low level of endogeneous PrP (Figure 4E, non-
transfected cells) and a high level of LRP/LR on the cell surface (Figure 4B) hyperexpressing 
human PrP on their surface (fine red frame, Figure 4A) showed an enhanced binding of 
externally added rec. PrP compared with non-transfected HeLa cells. The binding of rec. PrP 
to cells hyperexpressing PrP was not increased compared with normal cells (Figure 4D-F, 
compare cells stained in red with the others). Both the binding of PrP to transfected and to 
non-transfected cells could be efficiently inhibited with the LRP specific antibody (data not 
shown). 
 
Similar binding of PrP to neurons isolated from PrPo/o mice and PrP wild-type mice 
In order to confirm that PrP at the cell surface does not participate in the binding of rec. PrP, 
we performed binding assays on primary cultures of neurons from PrPo/o mice versus wild-
type mice. The binding of GST::huPrP was similar for both types of neurons (Figure 4G and 
I) and was completely abolished by pre-incubating PrP+/+ or PrPo/o cells with the LRP 
antibody W3 (Figure 4H, J). 
 
LRP/LR-dependent binding and internalization of recombinant PrP by  N2a cells 
The internalization of PrP was shown on N2a cells incubated with GST::huPrP and 
trypsinized (Figure 5A, lane 3); it was blocked by the LRP antibody (Figure 5A, lane 5), 
whereas the gal-3 antibody had no effect (Figure 5A, lane 4). Lowering the incubation 
temperature to 4°C resulted in a complete inhibition of the PrP internalization process (Figure 
5B, lane 3) confirming that the process is active and receptor-mediated. These results 
demonstrate the LRP/LR-dependent internalization of the human prion protein. 
 
Secretion of an LRP mutant lacking the transmembrane domain totally abolished PrP 
binding and internalization 
In order to prove the necessity of LRP for the binding and internalization process, we 
compared the GST::huPrP binding/internalization by BHK cells expressing full-length LRP 
with cells expressing an LRP mutant lacking the proposed transmembrane domain (aa 86 to 
101) (Castronovo et al., 1991) termed LRPdelTMD. This mutant was detected in the 
supernatant of the cells and in the crude lysates revealing its presence at high amounts in the 
secretory pathway and its secretion to the extracellular space (Figure 5D, lanes 7-9, middle 
and lower panel, respectively), whereas full-length LRP::FLAG was detected in the crude 
lysate only (Figure 5D, lanes 4-6, middle panel). Binding and internalization of GST::huPrP 
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was observed in cells expressing wild-type LRP (Figure 5D, upper panel, lanes 5 and 6) but 
not in those expressing LRPdelTMD (Figure 5D, upper panel, lanes 8 and 9). Untransfected 
BHK cells having an extremely low level of endogeneous LRP bound no or only minimal 
amounts of externally added GST::huPrP (Figure 5D, lane 2). Binding and internalization of 
non-tagged highly glycosylated human PrP by LRP::FLAG hyperexpressing cells (Figure 5D, 
lanes 10 and 11) confirmed the observations made with GST-tagged human PrP. Levels of 
endogeneous LRP, as well as LRP::FLAG and LRPdelTMD::FLAG were only marginally 
reduced after trypsin treatment due to the fact that significant amounts of these proteins are 
located in the secretory pathway. Densitometric measurements revealed that N2a (Figure 5A 
and B) and BHK cells (Figure 5D) internalize between 25 and 50% of the bound PrP. 
 
 
Discussion 
The interaction of PrPc with 37-kDa LRP suggested that LRP and its mature 67-kDa LR 
might act as a receptor or co-receptor for cellular PrP (Rieger et al., 1997). In order to 
investigate this hypothesis we initiated a series of cell-binding/internalization assays 
employing neuronal and non-neuronal cells, recombinant as well as authentic prion proteins 
and a series of recombinant wild-type and mutated LRP molecules. 
 
Localization of LRP/LR 
A prerequiste for LRP/LR-dependent binding/internalization of PrP is the cell-surface 
location of LRP/LR. LRP has been found on 40S ribosomes and was dubbed p40 (Auth and 
Brawerman, 1992), in the nucleus (Sato et al., 1996) and on the cell surface. 37-kDa LRP is 
located in plasma membrane fractions of mosquito cells acting as a receptor for the 
Venezuelan equine encephalitis virus (Ludwig et al., 1996), in cell wall fractions of Candida 
albicans (Lopez-Ribot et al., 1994) and on the cell surface of mammalian cells such as 
Madin-Darby canine kidney cells (Salas et al., 1992). We showed by IF, flow cytometry and 
analysis of plasma membrane fractions that the 37-kDa LRP is located on the surface of 
neuroblastoma cells and non-transfected or LRP::FLAG hyperexpressing BHK cells. The 67-
kDa form of the LR locates also to the cell surface (for review see (Gauczynski et al., 2001)) 
where it acts as a receptor for the Sindbis virus (Wang et al., 1992). We showed the presence 
of 67-kDa LR in plasma membrane fractions of N2a cells and concluded that the 37-kDa 
LRP/67-kDa LR might act as a receptor for PrP at the plasma membrane. The 37-kDa 
LRP/67-kDa LR polymorphism is unsolved so far. The association of cell-surface molecules 
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such as HSPGs with 37-kDa LRP might explain the appearance of the 67-kDa form of the 
receptor (Hundt et al., 2001). LRP::FLAG hyperexpressing BHK cells revealed the cell-
surface localization of LRP with its C-terminus oriented to the extracellular space enabling 
prion proteins to interact with PrP-binding domains on LRP. In summary, we showed (i) the 
membrane location of LRP/LR and (ii) the co-localization of PrP with LRP/LR on the surface 
of neuroblastoma cells and LRP/PrP hyperexpressing BHK cells. 
 
LRP/LR-dependent binding of PrP to cells 
For PrP binding and internalization experiments, we used externally added recombinant 
human PrP or authentic hamster prion protein, and a series of mammalian cells including 
murine neuroblastoma cells (N2a, MNB), primary cultures of neurons, human 
teratocarcinoma (NT2) and BHK cells. We proved LRP/LR-dependent binding of 
GST::huPrP and authentic hamster PrP to these cells. The kD for the binding of rec. PrP to 
N2a cells was of 1x10-7 mol/l, which is in good agreement with the kDs of other cell-surface 
receptors such as the N-formyl peptide receptor (Christophe et al., 2001) or the proteinaceous 
receptor on the surface of antigen presenting cells (Sondermann et al., 2000). 
The strict LRP/LR specificity of the PrP binding to NT2 and N2a cells was demonstrated in 
competition assays with a series of different antibodies (Table I). Whereas the LRP antibody 
W3 raised against the entire protein (Rieger et al., 1997) competed totally for the binding of 
GST::huPrP to neuronal and non-neuronal cells, mAb LRP285-295 did not compete for the 
binding since aa 285-295 stretches outside the PrP binding domain (Hundt et al., 2001). mAb 
LRP167-243 encompassing parts of the direct binding domain (Hundt et al., 2001) was able 
to reduce the binding of PrP. Antibodies against the lutheran protein representing an erythroid 
receptor for laminin (El Nemer et al., 1998),  failed to compete for PrP cell binding. This 
receptor did not  interact with PrP in the yeast two-hybrid system (data not shown). Anti-
integrin receptor VLA6 antibodies (Magnifico et al., 1996) and anti--galactoside lectin gal-3 
antibodies also failed to compete for the PrP-binding reaction. VLA6 does not co-localize 
with PrP and LRP/LR on the cell surface. The use of  LRP hyperexpressing BHK cells 
demonstrated the quantitative relationship between the number of LRP receptor molecules 
and the PrP-binding process. 
 
LRP/LR-dependent internalization of PrP 
N2a cells internalized 25-50% of the human PrP bound to the cell surface in an LRP/LR-
dependent manner. The PrP internalization process represents an active receptor-mediated 
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event, confirmed by lowering the incubation temperature of N2a cells to 4°C resulting in a 
total blockage of PrP internalization without affecting PrP binding.  
Expression of an LRP mutant lacking the putative transmembrane domain (LRPdelTMD) 
(Castronovo et al., 1991) in BHK cells resulted in secretion of LRPdelTMD to the 
extracellular space confirming the hitherto indirect evidence that the transmembrane region 
stretches from aa 86 to 101. In contrast to full-length LRP hyperexpressing BHK cells, 
LRPdelTMD hyperexpressing cells did not bind or internalize PrP due to the secretion of the 
mutant to the extracellular space. Untransfected BHK cells similarly failed to bind and 
internalize PrP due to insufficient amounts of LRP on the cell surface, confirming that LRP is 
essential for PrP binding and internalization. 
 
Endogeneous PrP does not act as a co-receptor for LRP/LR 
The co-localization of LRP/LR and PrP at the surface of mammalian cells raises the 
possibility that PrP could act as a co-receptor for LRP/LR. Binding of rec. PrP to HeLa or 
BHK cells expressing additional PrP on the cell surface was not increased. On PrP plus LRP 
hyperexpressing BHK cells, PrP had even the adverse effect of hampering the increased 
binding due to LRP hyperexpression, probably by recruiting a proportion of the latter receptor 
for its own metabolism. Unaltered binding of rec. PrP to primary cortical neurons isolated 
from PrP knock-out mice confirmed that the absence of PrP on the cell surface had no 
influence on the LRP/LR-dependent PrP binding, demonstrating that endogeneous PrP does 
not act as a co-receptor for LRP/LR. 
 
Role of LRP/LR in the metabolism of PrP and implications for the pathogenesis of TSEs 
Our study has several implications in terms of both the metabolism of PrPc and the 
pathogenesis of TSEs. Our co-localization and internalization data suggest that LRP/LR is 
essential  for the normal cell cycle of PrP by mediating the internalization of PrPc after its 
exposure at the cell surface. Internalization of PrP might occur via caveolae-like domains 
(Vey et al., 1996) or via clathrin-coated pits (Shyng et al., 1994). The receptor-mediated 
endocytosis of the protein (by LRP/LR), would direct the complex into clathrin-coated pits 
(for reviews see (Pley and Parham, 1993; Schmid, 1997)) rather than caveolae-like domains 
(for review (Maxfield and Mayor, 1997)). The role of LRP/LR as a receptor for the 
extracellular-matrix proteins laminin and elastin also suggests that its interaction with PrP 
may induce a signal involved in cell survival. In this respect, it has been shown that primary 
neurons devoid of PrP are more prone to neuronal death than their PrP expressing 
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counterparts (Kuwahara et al., 1999). One possibility is that the interaction of an LRP/LR 
receptor on one cell with a PrP molecule on another cell would contribute to cell-to-cell 
communication essential for cell survival. Recently, a signal transduction activity of PrP by 
activating tyrosine kinase Fyn was described (Mouillet-Richard, 2000). The plasma 
membrane-associated LRP/LR (Figure 1 and 2) might mediate the signal transduction of the 
extracellular GPI-anchored PrP with the intracellular plasma membrane-associated Fyn 
kinase involving cell-surface HSPGs (Hundt et al., 2001). 
The fact that PrPc binds to and is internalized by LRP/LR raises the possibility that PrPres is 
also bound/internalized by LRP/LR. The expression of LRP/LR in human small intestinal 
mucosa (Shmakov et al., 2000) suggests that it may represent the portal of entry for PrPres 
after oral contamination. Our recent finding that LRP levels are increased in only those 
organs of rodents that accumulate PrPres, indicates that PrPres intervenes in the metabolism 
of LRP (Rieger et al., 1997). Whether the internalization of PrPres relies on the presence of 
LRP/LR, PrPc or both may be answered by cell biological studies. The generation of 
transgenic mice devoid of LRP/LR might also help to determine whether LRP/LR acts as the 
receptor for the infectious agent. 
Also of relevance for pathogenesis, a saturation of the binding sites of LRP/LR  may occur as 
a consequence of PrP accumulation in TSEs rendering the receptor unavailable to its ligand 
laminin and contributing to neurodegenerative processes. The absence of laminin-binding to 
its receptor sensitizes neurons to death, as demonstrated in mice affected with the weaver 
syndrome (Murtomaki et al., 1995).  Keeping in mind that laminin plays a central role in cell 
growth, differentiation and migration and that any interference with these functions may be 
deleterious for the organism, our findings demonstrating that PrP associates with and is 
internalized by LRP/LR into the cell open new avenues of research for anti-TSE therapeutics, 
either to block the entry of the infectious particle, to modify the metabolism of PrP or to 
interfere with the neurodegenerative process. 
 
 
Materials and methods 
Semliki Forest virus system 
pSFV1-LRP::FLAG, pSFV1-LRPdelTMD::FLAG, pSFV1-huPrP1-253 were constructed as 
described in the Supplementary data (see pages 84-90). pSFV-1 (Liljestrom and Garoff, 
1991), pSFV3-lacZ (Life Technologies) and the ORF from human PrP (Krasemann et al., 
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1996) were used. Transfections of BHK-21 C13 cells with rec. SFV-RNAs (transfection 
efficiencies = 90-100 %) are described (see Supplementary data).  
 
HeLa cells expressing huPrP 
Human epitheloid carcinoma of cervix HeLa cells (ATCC CCL2) were transfected with 
pCR3-uni™-huPrP1-253 containing human Prn-p cDNA (Jaegly et al., 1998) for huPrP 
expression as described (see Supplementary data). 
 
Tissue culture of N2a, N2a [MHM2], MNB, NT2, HeLa, BHK, Sf9 cells, primary mouse 
cortical neurons, PrPo/o neuronal cultures 
N2a, N2a [MHM2], MNB, NT2, HeLa, BHK, Sf9 cells, primary mouse cortical cultures and 
PrP0/0 neuronal cultures (C. Weissmann, Zürich) were cultivated and prepared as described 
(see Supplementary data).  
 
Generation of recombinant and authentic proteins 
pAcSecG2T-huPrP was generated and rec. baculoviruses produced as described (see 
Supplementary data). Rec. GST, GST::huPrP23-230, dialyzed against 20 mM HEPES, pH 7.4 
were expressed in the baculovirus system as described for GST::haPrP proteins (Weiss et al., 
1995; Weiss et al., 1996). Authentic PrPc was prepared from hamster brain membrane 
fractions (Meyer et al., 1986). Human PrP was expressed in the SFV-system (see 
Supplementary data). 
 
Far-UV Circular dichroism analysis 
CD spectra of GST::huPrP23-230 were recorded as described (see Supplementary data). 
 
PrP binding/internalization assays followed by immunofluorescence analysis, confocal 
microscopy or western blotting 
For competition studies the cells were either pre-incubated with the individual antibody 
before the addition of rec. protein or the rec. protein was pre-incubated with the individual 
antibody before addition to the cells (inoculum saturation). After 18 h of incubation, cells 
were processed (with or without trypsin treatment) for IF-staining, confocal microscopy or 
western blotting as described in the see Supplementary data.  
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FACS analysis (flow cytometry) 
Single-cell suspensions were prepared, cells treated and data acquisition obtained as described 
(see Supplementary data). 
 
Isolation of plasma membranes 
Plasma membrane preparations were done according to (Vleurick et al., 1999). 
 
Calculation of binding curves for recombinant PrP to cells and determination of the kD 
for the interaction of PrP with LRP/LR 
Calculations (NIH-Image)/kD determination (Prism 3) were performed as described (see 
Supplementary data). 
 
Antibodies 
The antibodies used are described in the Supplementary data. For saturation of pAb LRP W3 
with rec. PrP, immobilized GST::LRP was incubated with pAb LRP W3 and the supernatant 
assayed by IF on N2a/BHK cells. 
 
Supplementary data 
Supplementary data for this chapter are shown on pages 84 to 90. 
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Table I. Summary of the displacement capacity of antibodies for the binding of human PrP  
to neuronal cells. 
 
Inoculum saturationa Pre-incubation of cellsa Dilution Binding 
Inhibition 
 
pAb anti-PrP (JB007)   +++ 
Pre-immune serum 
(PrP immunization) 
  - 
pAb/mAb anti-GST   - 
 pAb anti-LRP 1/50 
1/100 
1/500 
1/1000 
1/10000 
+++ 
++ 
+ 
- 
- 
 pre-immune serum 
(LRP immunization) 
1/50 - 
 mAb anti-LRP 167-243 1/5 
1/50 
++ 
+ 
 mAb anti-LRP 285-295 1/5 
1/50 
- 
- 
 pAb anti-GFAP 1/50 - 
 pAb anti-laminin  1/50 - 
 mAb anti-VLA6 1/50 - 
 mAb anti-lutheran protein 1/50 - 
 pAb anti-galectin-3 Ab 1/50 - 
 mAb anti-Hsp60 1/50 - 
 mAb anti-Hsp70 1/50 - 
 mAb anti-Hsp90 1/50 - 
aN2a and NT2 cells have been incubated with GST::huPrP23-231 after pre-incubation of the protein with the 
indicated antibodies (inoculum saturation) or after pre-incubation of the cells with the indicated antibodies. 
Antibody displacement capacities were analysed by Immunofluorescence. Concentrations of all undiluted 
antibodies used range between 1.5 and 1.7 mg/ml. 
+++, ++, + : Inhibition of binding;  
- :  No inhibition of binding. 
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Fig. 1. Plasmamembrane-associated LRP/LR and PrP co-localize on the surface of 
neuroblastoma cells. Non-permeabilized N2a [MHM2] cells were incubated with the pAb 
LRP W3 sec. Ab fluorescein isothiocyanate (FITC) (A), pAb LRP W3 saturated with rec. 
GST::LRP sec. Ab carbocyanine Cy2, 4-6-diamidine-2-phenylindole (DAPI) (A, left inset) 
or the mAb LRP (aa 285-295 of LRP, sec. Ab Cy2) (A, right inset) and the mAb PrP 3F4 
sec. Ab indocarbocyanine (Cy3) (B), or the pAb PrP M-20 (B, inset). Merge of (A) and (B) 
DAPI staining (C) (magnification x630). N2a [MHM2] cells were incubated with the mAb 
VLA6 CD49f (sec. Ab Cy2) (D) and the pAb M-20  (sec. Ab Cy3) (E). Merge of (D) and (E) 
DAPI staining (F). N2a [MHM2] cells were incubated with the pAb LRP W3  (sec. Ab Cy2) 
(G) and the mAb VLA6 CD49f (sec. Ab Cy3) (H). Merge of (G) and (H) DAPI staining (I).  
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(J) Non-permeabilized N2a cells were analysed by FACscans. Filled profile, isotype control. 
non-filled profile, pAb LRP W3. Fluorescence intensity (abscissa) is plotted against relative 
cell numbers (ordinate). (K) Purified plasma membranes from N2a cells were analysed by 
western blotting employing a mAb LRP (directed against aa 167-243) (lane 1). Molecular 
weight markers are indicated. (L) Non-permeabilized N2a cells were analysed by FACscans. 
Filled profile, isotype control, non-filled profile, anti-gal-3 antibody. Fluorescence intensity 
(abscissa) is plotted against relative cell numbers (ordinate). 
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Fig. 2. Orientation, localization of LRP::FLAG and PrP and co-localization of both proteins 
in BHK cells transfected with rec. SFV RNAs. (A) Immunolocalization of LRP::FLAG to the 
cell membrane of non-permeabilized BHK cells transfected with rec. SFV LRP-FLAG RNA. 
Subcellular location was determined by IF using the mAb FLAG M2 (sec. Ab FITC). (Insets) 
Untransfected BHK cells incubated with the pAb LRP W3 (left), mAb FLAG M2 (right). (B) 
Immunolocalization of human PrPc to the cell membrane of non-permeabilized BHK cells 
transfected with rec. SFV huPrP1-253 RNA. Subcellular location was determined by IF using 
the mAb PrP 3B5 (sec. Ab Texas Red). (Inset) Untransfected BHK cells (Ab 3B5). (C) 
Orientation of LRP on the cell surface. Orientation and localization of LRP on the cell surface 
is confirmed in (A). *The direct PrP binding domain suggested by (Rieger et al., 1997) and 
mapped in detail by (Hundt et al., 2001) is identical with the laminin-binding domain 
(Castronovo et al., 1991). **The transmembrane domain (TMD) was first suggested by 
(Castronovo et al., 1991). Secretion of an LRP mutant lacking the transmembrane domain 
(LRPdelTMD) to the extracellular space of BHK cells (Figure 5D) confirmed that the TMD 
indeed stretches from aa 86 to 101 of LRP. FACscans of non-permeabilized non transfected 
(D) and SFV LRP-FLAG RNA transfected BHK cells (E). Filled profile, isotype control; 
non-filled profile, pAb LRP W3. (F) FACscans of non-permeabilized non-transfected BHK 
cells. Filled profile, isotype control; non-filled profile, pAb gal-3 . Fluorescence intensity 
(abscissa) plotted against relative cell numbers (ordinate). (G) Western blot analysis of 
plasma membrane fractions from non-transfected and rec. SFV transfected BHK cells. 
Purified plasma membranes from non-transfected cells (lanes 1, 3 and 5) and cells transfected 
with SFV LRP-FLAG RNA (lanes 2, 4) or SFV huPrP1-253 RNA (lane 6) were analysed by 
western blotting using mAb LRP (aa 167-243) (lanes 1 and 2), mAb FLAG M2 (lanes 3 and 
4) or mAb 3B5 (lanes 5 and 6). (H-J) IF-analysis of non-permeabilized BHK cells co-
transfected with rec. SFV RNAs encoding for LRP::FLAG and human PrP. Immunostaining 
was performed using (H) the pAb LRP W3 non-sarurated and (H, inset) saturated with rec. 
GST::LRP (sec. Ab Cy2, DAPI staining) and (I) mAb 3B5 (sec. Ab Cy3). (J) Merge of (H) 
and (I) DAPI staining (magnification A, B, H-J, x630).  
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Fig. 3. LRP/LR-dependent binding of PrP by neuronal and BHK cells transfected with rec. 
SFV RNAs. (A) N2a cells (pre-incubated with pre-immune serum) were incubated with 
GST::huPrP23-230 (6 µg/ml). Binding of the rec. protein was assessed by IF using mAb GST 
( sec. Ab Cy3). (Inset) Preincubation of cells with pAb LRP W3 (dilution 1:50). (B-D) Co-
localization of exogeneous GST::PrP23-230 with endogeneous LRP/LR on non-
permeabilized N2a cells. Cells were incubated with GST::huPrP23-230 (4 µg/ml). 
Endogeneous LRP was detected by IF using the pAb LRP W3 (sec. Ab Cy2, B), exogeneous 
GST::huPrP was detected by mAb 3F4 (sec. Ab Cy3, C). Merge (D) of (B) and (C) 
(magnification A-D x 630). (E) Analysis of GST::huPrP23-230 by SDS-PAGE and FAR-UV 
CD spectroscopy. One microgram of GST::huPrP23-230 (lane 1) was analysed on a 12 
%SDS-PA-gel stained with silver. FAR-UV CD spectrum (right panel) of GST::huPrP23-230 
in 10 mM sodium phosphate buffer, pH 7.4. (F) Western blot analysis of the binding assay 
illustrated in (A-D). Binding of GST::huPrP to N2a cells. 500 ng/ml (lane 3), 1 µg/ml (lane 
4), 2.5 µg/ml (lane 5), 5 µg/ml (lane 6) and 7.5 µg/ml (lane 7) of GST::huPrP23-230, 7.5 
µg/ml GST (lane 2) and no protein (lane 1) were incubated with N2a cells. Total cell extracts 
were loaded. Protein detection by mAb 3F4 . The binding curve (right panel) of 
GST::huPrP23-230  to N2a cells was obtained  by densitometric quantification (square pixels) 
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of the western blot signals for GST::huPrP23-230 plotted against the dose of rec. PrP (µg/ml). 
kD = 1x10-7 mol/l (calculation described in Supplementary data). (G) pAb LRP W3 and mAb 
LRP (aa 167-243) displacement of the GST::huPrP binding to N2a cells. Cells were incubated 
in the absence of protein (lane 1), with 7.5 µg/ml GST (lane 2 and 7), 3 µg/ml GST::huPrP23-
230 (lanes 3 and 8), 3 µg/ml GST::huPrP23-230 after pre-incubation with pAb LRP W3 at 
1:100 (lane 4), 1:10 (lane 5), 1:5 (lane 6), mAB LRP (aa 167-243) at 1:50 (lane 9) and pAb 
LRP W3 at 1:50 (lane 10). Proteins were detected by mAb 3 F4 (lanes 1-6 and lanes 8-10) or 
the pAb GST (lane 7). (H) GST::huPrP displacement on N2a cells with antibodies directed 
against molecular chaperones. Cells were incubated with 3 µg/ml of GST::huPrP23-230 
without antibodies (lane 1) and with pAb LRP W3 (lane 2), antibodies directed against Hsp60 
(lane 3), Hsp70 (lane 4) and Hsp90 (lane 5). Antibody dilution: 1:50. Blots were developed 
with the mAb 3F4. (I) LRP-dependent binding of authentic PrP isolated from hamster brains 
on MNB cells. MNB cells were incubated with 2 µg/ml of purified PrPc from hamster brain. 
Immunostaining was performed with the mAb 3F4 (sec. Ab Texas Red). (Inset) MNB cells 
saturated with the pAb LRP W3 (dilution 1:50) prior to PrP treatment (magnification x630). 
(J-M) Increased PrP binding by rec. SFV RNA transfected BHK cells overexpressing LRP at 
the cell surface. BHK cells (J) were either transfected with SFV LRP-FLAG RNA (lanes 1-
5), SFV LRP-FLAG RNA plus SFV huPrP1-253 RNA (lanes 6-10) or non transfected (lanes 
11 -15). Amounts of 0 µg/ml (lanes 1, 6 and 11), 1 µg/ml (lanes 2, 7 and 12), 2 µg/ml (lanes 
3, 8 and 13), 4 µg/ml (lanes 4, 9 and 14) and 8 µg/ml (lanes 5, 10 and 15) of GST::huPrP23-
230 were added to the cells. Total cell extracts were analysed by western blotting employing 
the mAb 3F4 (J, upper panels) or the pAb LRP W3 (J, lower panels). Please note that 
endogeneously expressed huPrP appeared as non-, mono- and diglycosylated isoforms (J). 
BHK cells (K) were transfected with SFV LRP-FLAG RNA (lanes 1-5) or non transfected 
(lanes 6-10). Amounts of 0 µg/ml (lanes 1 and 6), 1 µg/ml (lanes 2 and 7), 2 µg/ml (lanes 3 
and 8), 4 µg/ml (lanes 4 and 9) and 8 µg/ml of huPrP23-230 (SFV system) (lanes 5 and 10) 
were added to the cells. Total cell extracts were analysed by western blotting with the mAb 
3F4 (K, upper panels) and the pAb LRP W3 (K, lower panels). Please note that externally 
added rec. non-tagged human PrP used for binding studies appeared as non-, mono- and 
diglycosylated isoforms (panel K). Binding curves were obtained by quantitating the western 
blot signals for GST::huPrP in J (L) and for huPrP in K (M) by densitometry (square pixels). 
For binding studies the cells were incubated for 18 h with GST::huPrP before staining with 
the indicated individual antibody was performed. *GST::huPrP and huPrP concentrations 
represent the concentration of added recombinant protein in the cell media. Values (F, right 
panel, L and M) were calculated by optical scanning methods (see Supplementary data).  
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Fig. 4. Endogenous PrP does not act as a co-receptor of LRP/LR for the binding of 
exogeneous PrP. (A-F) Unaltered GST::huPrP23-230-binding by HeLa cells overexpressing 
human PrP at the cell surface. (A) Confocal z series of HeLa cells transiently transfected with 
cDNA encoding for human PrP1-253. Transfected HeLa cells were analysed employing the 
mAb 3F4 (sec. Ab Texas Red). Confocal scanning was performed from the cell surface (top 
panel left) towards the interior of the cell (bottom panel, right) (magnification x630). Non-
permeabilized HeLa cells were analysed by FACscans. Filled profile, isotype control (B and 
C), non-filled profile, pAb LRP W3 (B), pAb gal-3 (C). Fluorescence intensity (abscissa) is 
plotted against relative cell numbers (ordinate). (D-F) Binding of GST::huPrP23-230 by HeLa 
cells transfected with pCR3-uni™-huPrP1-253. (D) Cells were analysed by IF with pAb GST 
(sec. Ab FITC), (E) Immunostaining with mAb 3F4 (sec. Ab Texas Red), (F) Triple labelling 
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with PrP and GST antibodies, DAPI staining. pCR3-uni™-huPrP1-253 transfected cells are 
red-colored (magnification x400). (G-J) LRP-dependent binding of GST::huPrP23-230 by 
primary culture of neurons isolated from PrP wild-type and PrPo/o mice. Primary cultures of 
neurons from wild-type mice (G and H) or PrPo/o mice (I and J) were incubated with 
GST::huPrP23-230 (4 µg/ml) after preincubation with either pre-immune serum (G and I) or 
pAb LRP W3 (dilution 1:50) (H and J). Immunostaining was performed with mAb 3F4, DAPI 
staining and neuron staining with MAP-2 antibody (sec. Ab FITC) (magnification x400). 
 
 
 
 
 
Fig. 5.  LRP/LR-dependent binding and internalization of GST::huPrP by N2a cells. An LRP 
mutant lacking the transmembrane domain (LRPdelTMD) totally abolishes PrP binding and 
internalization on BHK cells. (A) Internalization of GST::huPrP by N2a cells. N2a cells not 
pre-incubated with antibodies (lane 1-3), pre-incubated with pAb gal-3 (dilution 1:5; lane 4), 
pAb LRP W3 (dilution 1:5; lane 5) were incubated with 8 µg/ml of GST::huPrP (lanes 2-5). 
Non-treated cells (lanes 1 and 2) and trypsin-treated cells (lanes 3-5) were analysed by 
western blotting employing mAb 3F4. (B) Temperature-dependent internalization of PrP by 
N2a cells. Cells were incubated with 8 µg/ml of GST::huPrP (lanes 2, 3, 5 and 6) at 4°C 
(lanes 1-3) and 37°C (lanes 4-6). Non-treated cells (lanes 1, 2, 4 and 5) and trypsin-treated 
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cells (lanes 3 and 6) were analysed by western blotting employing mAb 3F4. (C) Total cell 
extracts from trypsin-treated N2a cells (lane 2) or non-treated cells (lane 1) were analysed by 
western blotting employing pAb N-CAM directed against the neuron-specific cell adhesion 
molecule (N-CAM). (D) Binding and internalization of GST::huPrP by BHK cells 
hyperexpressing full-length LRP::FLAG or an LRP mutant lacking the transmembrane 
domain (aa 86 to 101) termed LRPdelTMD::FLAG. BHK cells either non-transfected (lanes 
1-3), hyperexpressing LRP::FLAG (lanes 4-6, 10 and 11) or LRPdelTMD::FLAG (lanes 7-9) 
by the SFV system were incubated with either 5 µg/ml of GST::huPrP (lanes 1-9) or 5 µg/ml 
huPrP (generated in the SFV-system, lanes 10 and 11). Total cell extracts from non trypsin-
treated (lanes 1, 2, 4, 5, 7, 8, and 10) and trypsin-treated cells (lanes 3, 6, 9 and 11) were 
analysed by western blotting employing the mAb 3F4 (upper panels), pAb LRP W3 
(middle/lower panels, lanes 1-3, 10 and 11) or the mAb FLAG M2 (middle/lower panel, lanes 
4-9). CL, crude lysate; SN, supernatant.  
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Deslys, J.-P., Dormont, D., Lasmézas, C. I. and Weiss, S. 2001. 
The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion 
protein.  EMBO Journal, 20, 5863-5875 
 
Materials and methods 
Recombinant pSFV plasmid constructions and SFV-mRNA generation 
The LRP (aa1-aa295) encoding cDNA was PCR-amplified from pCEP4 introducing BamHI 
(5') and XmaI (3‘) restriction sites at the 5' and 3' ends. The 943 bp fragment encompassing 
Kozak sequence/AUG (5') and a FLAG-tag (3') was cloned into the pSFV1 (Liljestrom and 
Garoff, 1991) resulting in pSFV1-LRP::FLAG. pSFV1-LRPdelTMD::FLAG  was generated 
by the QuikChangeTM site-directed mutagenesis method (Stratagene) employing pSFV1-
LRP::FLAG DNA as template. The human prion ORF (Krasemann et al., 1996) was 
subcloned into pBK-CMV (Stratagene, LA Jolla, USA) and subsequently pBS+ (Stratagene, 
La Jolla, USA) to create compatible BamHI sites. These BamHI fragments were subcloned 
into pSFV1 resulting in pSFV1-huPrP1-253. All constructs were confirmed by dideoxy 
sequencing. DNAs pSFV3-lacZ (Life Technologies), pSFV1-huPrP1-253, pSFV1-
LRP::FLAG and pSFV1-LRPdelTMD::FLAG were linearized with SpeI following 
purification by phenol-chloroform extraction. Transcriptions were carried out in a total 
volume of 50 µl containing 1,5 µg linearized plasmid DNA, 10x SP6 transcription buffer (0,4 
M Tris-HCl, pH 8,0 at 20°C; 60 mM MgCl2; 100 mM dithiothreitol; 20 mM spermidine), 1 
mM of each ATP, CTP and UTP, 500 µM of GTP, 1 mM of m7G(5')ppp(5')G, 50 units of 
RNasin and 50 units of SP6 RNA polymerase and incubated for 2 h at 37 °C. The correct 
length of  the transcripts was verified by agarose gel electrophoresis. RNA was stored at -
20°C.  
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BHK cell culture, transfection and co-transfection studies with the Semliki Forest virus 
(SFV) system 
Baby hamster kidney cells (BHK-21 C13; ATCC CCL 10) were cultured in Dulbecco's 
modified Eagle's medium supplemented with 10 % heat-inactivated FCS, 2 mM L-glutamine, 
100 µg/ml penicillin and 100 µg/ml streptomycin at 37 °C with 5 % CO2. Transfection and 
co-transfection (1:1) were carried out with individual SFV-RNAs by electroporation using a 
BioRad Gene Pulser. 1/10 volume of the electroporated cells (8x105) was diluted in complete 
growth medium and plated on 35 mm cell culture dishes for cell binding assays or wells 
containing a sterile glass coverslip for immunofluorescence microscopy. Cells were incubated 
for 24 h. Transfection efficiencies as determined by transfecting SFV3-lacZ control RNA 
followed by X-gal staining were 90-100% for BHK cells. 
 
Construction of pCR3-uni™-huPrP1-253 and transfection of Hela cells 
PCR primers PrPint2an and PrP813ac were used to amplify a 826 bp fragment encompassing 
the entire human PrP open reading frame from genomic human DNA. Subcloning of this 
fragment into pCR3-uni™ (Invitrogen) encompassing the CMV promoter resulted in pCR3-
uni™-huPrP1-253, confirmed by didesoxy sequencing (Jaegly et al., 1998). The human 
epitheloid carcinoma of cervix Hela (ATCC: CCL2) cells were cultured in RPMI 1640 
supplemented with 10% heat-FCS, 100 µg/ml of penicillin/streptomycine and 1% L-
glutamine. Confluent cells were transiently transfected overnight in OPTIMEM™ (BRL) 
medium on 8 well Labtek® Chambers using 2 µg of DNA in Lipofectin® Reagent mixture 
(Life/technologies). Cells were harvested 3 days after transfection in growing medium and 
then fixed in 4% PFA. Transfection efficiencies were 10-20%. 
 
Tissue culture of N2a, N2a [MHM2], MNB, NT2 and Sf9 cells 
N2a, N2a [MHM2] and MNB mouse neuroblastoma cells, human NT2 cells were maintained 
in DMEM medium containing 10 % FCS, 1 % glutamine, 100 µg/ml penicillin and 100 µg/ml 
streptomycine. Spodoptera frugiperda (Sf9) insect cells were maintained in Sf900II serum-
free medium.  
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Primary mouse cortical cultures 
Primary mouse cortical cells were established from 15 day old mouse embryos. Cortices were 
dissected in PBS Ca2+/Mg2+ free supplemented by 5% glucose, carefully freed of meninges 
and incubated in trypsin/EDTA solution for 10 min at 37 °C. The trypsin was inactivated by 
incubation in DMEM containing 4.5 g/l glucose, Glutamax-I and 1% FCS. Cells were then 
dissociated mechanically. The suspension was pelleted by centrifugation and resuspended in 
DMEM containing B27 and 3% FCS. Eight-well Labtetk® culture slides coated with 10 
µg/ml of poly D lysine were seeded at 3x105 cells per well in 0.3 ml of DMEM B27 
supplemented by 3% FCS and 100 µg/ml penicillin, 100 µg/ml streptomycin. Cultures were 
kept in a water saturated incubator with an atmosphere of 95% air 5% CO2 for 2 days. 
Medium was then changed for serum free containing DMEM supplemented with B27 
components. After 2 days, cells, which were immunocytochemically defined as 95 % pure in 
neurons (according to MAP2 immunolabelling) and containing less than 5% glial cells were 
exposed to recombinant PrP. PrP knock-out mice used to establish PrP0/0 neuronal cultures 
were kindly provided by C. Weissmann (University of Zürich, Switzerland). 
 
Construction of baculovirus expression vectors, protein synthesis in the Baculovirus, 
E.coli and SFV system 
cDNA encoding huPrP23-230 (H. A. Kretzschmar, Munich) was generated by PCR and 
cloned into the transfer vector pAcSecG2T via BamHI (5´) and EcoRI (3´) resulting in 
pAcSG2T-huPrP23-230. Recombinant viruses were generated by co-transfection of the 
transfer vectors with linearized viral DNA (Baculogold; Pharmingen). cDNA encoding for 
haPrP-peptide 23-89 was cloned via BamHI (5') and EcoRI (3') into pAcSG2T resulting in 
pAcSG2T::PrP23-89. Recombinant GST, GST::huPrP23-230, GST::haPrP23-89 and 
GST::haPrP90-231 were expressed in baculovirus infected Sf9 cells and purified to 
homogeneity as described for hamster GST::PrP fusions previously (Weiss et al., 1995; Weiss 
et al., 1996). All recombinant proteins were dialyzed against 20 mM Hepes, pH 7.4. 
Authentic PrPc was prepared from hamster brain membrane fractions as previously described 
(Meyer et al., 1986). Highly glycosylated wild-type human PrP was expressed in BHK cells 
transfected with pSFV1-huPrP1-253 RNA. 48 h post transfection the cells were harvested, 
washed once with PBS and then lysed in PBS supplemented with 0.1% TritonX-100 by 
repeated freezing and thawing. The crude lysate was obtained by centrifugation at 14 000 rpm 
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4°C for 15 min and dialyzed against 20 mM Hepes, pH 7.4. Purified Galectin-3 produced in 
E.coli was a generous gift from Prof. Hans-Joachim Gabius, Munich. 
 
Far-UV Circular dichroism analysis 
GST::huPrP23-230 was dialyzed against 20 mM Tris.HCl pH 9.0, 5 mM dithiothreitol, 1 mM 
EDTA followed by dialysis against 10 mM sodium phosphate buffer, pH 7.4. CD spectra 
were recorded on a Jasco model J-710 spectropolarimeter. Measurements were carried out in 
a 1 mm path-length cylindrical cuvette at room temperature at 190 -260 nm. Typically 10 
spectra were recorded at a scan speed of 20 nm/min with a step resolution of 0.1 nm.  
 
PrP-Binding Assays followed by immunofluorescence analysis and confocal microscopy 
For competition studies the cells were either pre-incubated for two hours with the individual 
antibody diluted to various concentrations in culture medium or incubated with recombinant 
protein which was pre-incubated with the antibody (inoculum saturation). In case of pre-
incubation medium was replaced and cells were incubated overnight with the indicated 
amounts of GST::huPrP. Cells were then washed three times with PBS and prepared for IF. 
Cells were seeded half confluently on coverslips, grown overnight for attachment, washed 
three times with PBS and fixed with 4% paraformaldehyde. Non-permeabilized cells were 
fixed with 2 % paraformaldehyde. After rinsing 3 times with PBS, cells were permeabilized 
for cytoplasmic staining with 0.2 % Triton X-100 (10 min/4 °C). The preparation was 
saturated with a 10 % FCS solution (in PBS) for 1 h at room temperature, washed and 
incubated with the primary antibodies diluted in PBS with 10 % FCS for 1 h at room 
temperature. Staining of the individual protein was performed with the indicated mono- or 
polyclonal antibodies. After washing 3 times with PBS the preparations were diluted in 
saturation buffer and incubated in the dark for 45-60 min with the individual secondary 
antibodies (goat anti mouse or goat anti rabbit) conjugated with FITC, Texas Red, Cy2 
(green) and Cy3 (red). For nuclear staining 1 µg/ml DAPI for 10 min at RT was used. Please 
note that both the primary and secondary antibodies were added after fixing the cells. The 
coverslip was mounted with aqueous mounting medium (Fluoromount®) and the slides were 
examined using a axioviert fluorescence microscope (Zeiss) with appropiate filters or a Zeiss 
confocal microscope. Immunofluorescence images were processed using Metamorph 
software®. 
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FACS analysis (flow cytometry) 
Single-cell suspensions were prepared in PBS, 2% fetal calf serum, 20 mM EDTA, 0.01% 
sodium azide (FACS buffer). For flow cytometry, cells were incubated with the first antibody 
at concentrations of ~1 µg/106 cells for 15 minutes at room temperature. Cells were washed 
in FACS buffer before incubation with FITC-conjugated anti-rabbit IgG for 15 minutes at 
room temperature. After washing in FACS buffer, data acquisition and analysis were 
performed with an EPICS XL-MCL (Coulter) flow cytometer. Dead cells were gated out by 
forward and side scatter properties. Polyclonal anti-gal-3 and polyclonal anti-LRP antibody 
(W3) were used as primary antibodies, rabbit IgG (Sigma) was used for isotype controls.  
 
PrP-Binding assay in cell culture followed by Western Blotting 
3x105 N2a cells and 8x105 BHK cells (either non-transfected or transfected with recombinant 
SFV RNAs as described above) were each seeded on 6-well plates and incubated at 37 °C. 
For competition studies cells were pre-incubated for two hours with the indicated antibody. 
Medium was replaced after pre-incubation. Cells were then incubated in medium containing 
different amounts of the individual protein for 18 h at 37°C or 4°C (when indicated). Cells 
were then washed several times with PBS and scraped off in PBS. After centrifugation the 
pellets were resuspended in lysis buffer (25 mM Tris/HCl pH 7.4, 150 mM NaCl, 1 mM 
CaCl2, 3 mM MgCl2, 1 % NP-40). After addition of Laemmli buffer samples were separated 
by SDS-PAGE and blotted on PVDF membrane. Western blotting was performed with the 
indicated primary antibody and peroxidase-coupled secondary antibodies. 
In order to analyze secreted proteins from the medium, the supernatants of transfected or non-
transfected BHK cells were centrifuged at 1100 rpm for 10 min and the supernatants were 
analyzed by Western blotting. 
 
Isolation of plasma membranes 
Plasma membrane preparations from 108 N2a and BHK cells, the latter either non-transfected 
or transfected with SFV-LRP-FLAG RNA, were prepared as described (Vleurick et al., 1999). 
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Calculation of binding curves for recombinant PrP to cells and determination of the kD 
for the interaction of PrP with LRP/LR 
Western Blots have been optically scanned employing a flat bed scanner. The optical density 
of the individual bands has been measured employing the NIH-Image software program. The 
resulting values represent square pixels. Background values have been subtracted from the 
values measured. Standard curves have been determined to prove that values range within the 
linear area. The dissociation constant (KD) for the interaction of PrP with LRP/LR on the cell 
surface has been calculated from the binding curve in Figure 3F by using the Prism 3 software 
program. The data were analyzed by non-linear regression using a hyperbolic curve fitting 
option. 
 
Trypsin cell treatment for PrP internalization studies 
Cells were incubated with recombinant proteins as described above. After 18 h at 37°C, cells 
were washed several times with PBS and incubated with trypsin (250 µg/ml) at 37°C for 10 
min. The reaction was terminated by addition of the cell specific growth medium. Cells were 
collected by centrifugation at 1100 rpm for 10 min, washed twice with PBS, lysed and 
analyzed by Western blotting. 
 
Antibody saturation 
In order to prove specificity of the polyclonal anti-LRP-Ab (W3), W3 was rotated over night 
with rec. GST::LRP immobilized to glutathione sepharose beads at 4 °C. The supernatant 
failed to recognize LRP by Western Blotting and was employed in IF-analyses on 
N2a{MHM2) and transfected BHK cells.  
 
Antibodies 
Polyclonal Ab anti-LRP W3 (Rieger et al., 1997), mAb directed against aa167-243 and 
aa285-295 of LRP, respectively, (J.P. Houchins, Minneapolis), the mAB 3B5 (G. Hunsmann), 
pAb GST (Santa Cruz Biotech. Inc.) and mAb GST (Sigma), mAb 3F4 (Senetek, USA), mAb 
SAF70 against aa 140 to 180 of PrP (Service de Pharmacologie et Immunologie, CEA, 
Saclay, France), pAb JB007 (Service de Neurovirologie, CEA, France), pAb against PrP (M-
20) (Santa Cruz Biotech. Inc.), pAb anti-laminin (Roche Diagnostics), mAb anti-lutheran 
protein (J.-P. Cartron, INTS, France), pAb anti-GFAP (Roche Diagnostics), pAb MAP-2 
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(Santa Cruz Biotech. Inc.), mAb anti-VLA-6 CD49-f (Immunotech), Ab anti-N-CAM (Santa 
Cruz Biotech. Inc.), Abs anti-Hsp60/70/90 (Sigma, Munich), mAb anti-FLAG M2 (Sigma), 
pAb anti-FLAG (Santa Cruz Biotech. Inc.), pAb anti-galectin-3 (H.-J. Gabius, Munich), 
secondary FITC, Cy2 (carbocyanine), Cy3 (indocarbocyanine) and Texas Red conjugated 
antibodies (used at 1:100 dilutions) (Jackson Laboratories and Southern Biotechnology, 
respectively) were used.  
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Abstract 
Cell-binding and internalization studies on neuronal and non-neuronal cells have 
demonstrated that the 37-kDa/67-kDa laminin receptor (LRP/LR) acts as the receptor for the 
cellular prion protein (PrP). Here we identify direct and heparan sulfate proteoglycan 
(HSPG)-dependent interaction sites mediating the binding of the cellular PrP to its receptor, 
which we demonstrated in vitro on recombinant proteins. Mapping analyses in the yeast two-
hybrid system and cell-binding assays identified PrPLRPbd1 [amino acids (aa) 144-179] as a 
direct and PrPLRPbd2 (aa53 to 93) as an indirect HSPG-dependent laminin receptor precursor 
(LRP)-binding site on PrP. The yeast two-hybrid system localized the direct PrP-binding 
domain on LRP between aa 161 and 179. Expression of an LRP mutant lacking the direct 
PrP-binding domain in wild-type and mutant HSPG-deficient Chinese hamster ovary cells by 
the Semliki Forest virus system demonstrates a second HSPG-dependent PrP-binding site on 
LRP. Considering the absence of LRP homodimerization and the direct and indirect LRP-PrP 
interaction sites, we propose a comprehensive model for the LRP-PrP-HSPG complex. 
 
 
Introduction 
We recently identified the 37-kDa laminin receptor precursor (LRP) as an interactor for the 
prion protein (PrP) (Rieger et al., 1997; for reviews see Rieger et al., 1999; Gauczynski et al., 
2001a). Employing a series of neuronal and non-neuronal cells, we proved that the 37-kDa 
LRP/67-kDa high-affinity laminin receptor (LR) acts as the receptor for the cellular PrP 
(Gauczynski et al., 2001b). In the present manuscript we used the yeast two-hybrid system 
and cell-binding studies on neuronal as well as non-neuronal cells involving the Semliki-
Forest-Virus (SFV) system (for review see Liljestrom and Garoff, 1991; Tubulekas et al., 
1997) to identify domains on the PrP and the LRP involved in the PrP-LRP interaction on the 
cell surface. We identified two binding domains for LRP on PrP termed PrPLRPbd1 and 
PrPLRPbd2. The first one binds directly to LRP, whereas the second one depends on the 
presence of heparan sulfate proteoglycans (HSPGs) on the cell surface. The yeast two-hybrid 
system and cell-binding assays on wild-type and mutant HSPG-deficient Chinese hamster 
ovary (CHO) cells also identified two binding domains for PrP on LRP . 
The relationship between 37-kDa LRP and 67-kDa LR is not yet fully understood and has 
been explained with homodimerization of 37-kDa LRP (Landowski et al., 1995) or an 
additional factor, such as a polypeptide (Castronovo et al., 1991), which might bind to 37-
 Chapter IV  93  
kDa LRP to form the 67-kDa form of the receptor. The 67-kDa heterodimer might be 
stabilized by hydrophobic interactions mediated by fatty acids such as palmitate, oleate and 
stearate bound to 37-kDa LRP and to a galectin-3 (gal-3) cross reacting polypeptide (Buto et 
al., 1998; Landowski et al., 1995). However, we recently proved that the -galactoside lectin 
gal-3 is not present on the surface of neuronal or non-neuronal cells used for PrP-
binding/internalization studies (Gauczynski et al., 2001b) and anti-gal-3 antibodies failed to 
compete for the 37-kDa LRP/67-kDa LR-mediated binding and internalization of the cellular 
PrP (Gauczynski et al., 2001b) suggesting that gal-3 is not a partner of 37-kDa LRP in this 
context. In this study we investigated by a yeast two-hybrid system analysis whether gal-3 
interacts with 37-kDa LRP and/or the cellular PrP. In addition, we investigated whether 37-
kDa LRP interacts with itself in the yeast two-hybrid and analyzed the monomer/dimer status 
of the receptor by size-exclusion chromatography. Both PrP (Brimacombe et al., 1999; 
Caughey et al., 1994; Chen et al., 1995b; Gabizon et al., 1993) and the 37-kDa/67-kDa LR 
(Guo et al., 1992; Kazmin et al., 2000) bind to heparan sulfates. HSPGs are required for the 
binding of the fibroblast growth factor (FGF) to its FGFR receptor (Spivak et al., 1994; 
Venkataraman et al., 1999; Yayon et al., 1991) and act as initial attachment receptors for 
bacteria (Chen et al., 1995b) and viruses including alphaviruses (Byrnes and Griffin, 1998), 
human immuno-deficiency virus (HIV) type 1 (Mondor et al., 1998) and vaccinia virus 
(Chung et al., 1998). Heparan sulfates are components of amyloid plaques in prion diseases 
(Gabizon et al., 1993). We investigated the role of HSPGs as possible co-factors for 37-kDa 
LRP mediating PrP binding. We also constructed recombinant (rec.) SFV-vectors leading to 
the expression of an LRP mutant termed LRPdelBD::FLAG lacking the direct-binding 
domain for PrP in wild-type and mutant HSPG-deficient CHO cells. We compared the PrP-
binding capacity to these cells with wild-type and mutant CHO cells hyperexpressing wild-
type LRP::FLAG. In light of our findings that 37-kDa LRP fails to form homodimers, and 
that HSPGs mediate the binding of PrP to 37-kDa LRP, the relationship between 37-kDa LRP 
and 67-kDa LR might be explained by the association of LRP with HSPGs as outlined in a 
proposed model for the LRP-PrP-HSPG complex on the cell surface. 
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Results 
Identification of a direct LRP interaction domain on PrP by the yeast two-hybrid system 
To determine the domains of PrP interacting directly with LRP, we employed a yeast two-
hybrid analysis with truncated PrP molecules in the bait position and LRP44-295 in the prey 
position. Only truncated PrP retaining the regions amino acids (aa) 144-179 (Figure 1A, rows 
6 and 7) interacted with LRP. This region contains domains corresponding to the first  helix 
(aa 144-154), the second -strand (aa 161-164) and the first amino acid of the second  helix 
(aa179-193) of the human prion protein (Zahn et al., 2000). Regions from aa 23 to 143  of the 
human PrP are not sufficient for binding to LRP (Figure 1A, rows 1-5). Regions  from aa 180 
to 230 of human PrP (row 8) are not required for the direct interaction between PrP and LRP. 
We termed this LRP interaction domain on PrP PrPLRPbd1. 
 
Retrenchment of the direct PrP-binding domain on LRP by the yeast two-hybrid system 
Recently, we mapped a direct PrP-binding domain on LRP between aa 157 and 180 (Rieger et 
al., 1997) employing N-terminally truncated LRP molecules. In order to retrench this binding 
domain precisely we co-expressed the C-terminally truncated LRP molecules LRP44-101 and 
LRP44-160, respectively, together with full-length PrP in the yeast two-hybrid system. Both 
truncations failed to interact with PrP (Figure 1B) confirming that this direct PrP-binding site 
coincides with the laminin-binding domain (aa161-180). Expression of an LRP mutant 
lacking this direct PrP-binding domain (LRPdelBD161-180) in CHO cells (Figure 4K) 
showed that LRPdelBD161-180::FLAG was still able to bind to PrP, indicating the presence 
of a second binding site for PrP on LRP, which locates either between aa 101-160 or 181 and 
295 of LRP. 
 
PrP144-179 interacts directly with LRP161-179 in the yeast two-hybrid system 
In order to prove a direct interaction between the PrP and the 37-kDa/67-kDa LRP/LR via 
PrP144-179 and LRP161-179, we co-expressed both protein domains in bait and prey 
position, respectively, resulting in a strong interaction (Figure. 1 C, row 1). In contrast, 
huPrP144-179 failed to interact with LRP180-295 (row 2) or LRP44-160 (row 3). 

-galactoside gal-3 does not interact with PrP or LRP in the yeast two-hybrid system 
The association of gal-3 with the LRP has been suggested (Buto et al., 1998; Landowski et 
al., 1995). However, gal-3 antibodies do not influence the LRP-dependent binding/ 
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internalization of PrP on the cell surface, suggesting that this molecule does not act as a co-
receptor for LRP (Gauczynski et al., 2001b). For confirmation that gal-3 does not interact 
with PrP, we expressed gal-3 in bait and PrP in prey position of the yeast two-hybrid system 
resulting in no interaction between the two proteins (Figure 2A, row 2). Gal-3 also failed to 
interact with LRP in the yeast two-hybrid system (Figure 2A, row 3). 
 
37-kDa LRP fails to interact with itself in the yeast two-hybrid system and appears 
monomeric by size-exclusion chromatography 
The polymorphism of the LRP is still unclear. In order to test whether homodimerization of 
LRP could account for this 37-kDa/67-kDa polymorphism and to understand better the 
configuration of the LRP-PrP-binding complex, we cloned the cDNA encoding for LRP in the 
bait and prey position of the yeast two-hybrid system. LRP fails to interact with itself (Figure 
2B, row 2), suggesting that LRP is unable to directly form homodimers. For confirmation we 
purified LRP::FLAG from SFV-RNA-LRP::FLAG transfected BHK cells by anti-FLAG 
antibody chromatography to homogeneity and analyzed the native protein by SDS-PAGE and 
size exclusion chromatography. The protein migrated as a 37-kDa protein on an SDS-
polyacrylamide gel (Figure 2 C, lane 1) and eluted as a 40-kDa protein from a native size-
exclusion column (Figure 2, D), confirming that 37-kDa LRP is monomeric under native 
conditions. Thus the 67-kDa form of the LRP may result from the association of the LRP with 
other molecules such as HSPGs. 
 
Identification of the PrP interaction domains PrPLRPbd1 and PrPLRPbd2 by binding 
assays with prion peptides to NT2 and N2a cells 
The yeast two-hybrid system identified the domain aa 144-179 of PrP as a direct binding site 
for LRP termed PrPLRPbd1. To identify other domains of PrP, which might bind indirectly to 
LRP, we exposed NT2 and N2a cells to glutathione S-transferase (GST)-fused PrP peptides 
covering the entire PrP sequence. Besides peptide 129-175 encompassing the direct binding 
domain PrPLRPbd1, GST::PrP53-93 bound to the cells in an LRP-dependent fashion. The 
binding of GST::PrP53-93 (Figure 3A) and GST::PrP129-175 (Figure 3C) is shown on NT2 
cells in comparison with GST::PrP90-109 (Figure 3B). This binding can be inhibited by 
addition of the LRP antibody W3 (insets in Figure 3A, C). The binding properties of the 
whole array of peptides are also shown on N2a cells (Figure 3D-J). Only GST::PrP53-93 
(Figure 3E) and GST::huPrP129-175 (Figure 3H) bound to the cells dependent on LRP-LR 
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(LRP antibody competition is shown in the bottom insets of Figure 3). The integrin laminin 
receptor VLA6 does not co-localize with PrP or LRP-LR on the surface of neuroblastoma 
cells (Gauczynski et al., 2001b). The addition of an anti-VLA6 antibody, failed also to 
compete for the binding of GST::PrP53-93 or GST::PrP129-175 to N2a cells (Figure 3 E and 
H, top insets), confirming that VLA6  does not act as a receptor for PrP. We termed the 
indirect binding domain PrPLRPbd2. As the two binding domains are located N- and C- 
terminally of the proteinase K cleavage site of PrPres, we tested longer peptides in our 
binding assay corresponding to the two fragments that result from proteolytic cleavage of PrP, 
i.e. PrP23-89 and PrP90-230. Both peptides bound to both cell types in an LRP-dependent 
manner (Table I). Combining these data with the results from the yeast two-hybrid system 
(Figure 1) we conclude that two binding sites on PrP for LRP termed PrPLRPbd1 (aa144 to 
179) and PrPLRPbd2 (aa53-93) do exist. Results of the PrP peptide binding studies to N2a and 
NT2 cells including antibody competitions are summarized in Table I. 
 
 
Table I: Summary of the binding behaviour of individual GST-fused PrP peptides to NT2 and 
N2a cells including LRP-LR and VLA6 antibody competition 
Peptide 
(aa)  
Binding to  
N2a cells 
LRP-LR 
antibody 
competition 
Binding to 
NT2 cells 
LRP-LR 
antibody 
competition 
PrP53 -93 +++ +++* +++ +++ 
PrP90-109 - - - - 
PrP110-128 - - - - 
PrP129-175 +++ +++* +++ +++ 
PrP180-210 - - - - 
PrP218-230 - - - - 
PrP23-89 +++ +++ +++ +++ 
PrP90-230 +++ +++ +++ +++ 
*No competition with an VLA6 antibody 
+++, strong binding/competition 
   -,  no binding/competition 
 
 
Binding of PrP to LRP via PrPLRPbd2 is dependent on HSPGs 
The cell-binding assay led to the identification of an additional binding domain for LRP on 
PrP which was not identified in the yeast two-hybrid system, indicating that a third molecule 
is necessary to mediate the binding of LRP to PrPLRPbd2. It has been reported that 60% of the 
binding of rec. chicken PrP to CHO cells depends on the presence of endogenous heparan 
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sulfates (Shyng et al., 1994). Mutant CHO cells (S745) are severely deficient in HSPGs 
because of an altered xylose transferase activity, the first enzyme required for 
glycosylaminoglycan (GAG) synthesis (Esko et al., 1985) and therefore represent an 
appropriate model system to investigate whether HSPGs might represent the third interactor 
in the binding of PrPLRPbd2 to LRP. First, we proved that the binding of rec. GST::huPrP23-
230 to wild-type CHO cells (Figure 4A) and to the mutant CHO cells (Figure 4B) was LRP-
LR-dependent (Figure 4C and D). We then saturated selectively PrPLRPbd1 by incubating 
GST::huPrP23-230 with a monoclonal PrP antibody directed against the domain 140-180 of 
PrP. Obstructing PrPLRPbd1 inhibited the binding of the rec. PrP to HSPG-deficient (Figure 
4F) but not to wild-type CHO cells (Figure 4E), demonstrating that binding of PrP to LRP via 
PrPLRPbd2 needs the presence of HSPGs. The peptide GST::PrP53-93 corresponding to 
PrPLRPbd2, which bound to normal cells (Figure 4G), did not bind to HSPG-deficient cells 
(Figure 4H). However, the binding was restored in a dose-dependent manner after addition of 
soluble HSPGs (Figure 4I and J), confirming that the interaction of PrP to LRP via PrPLRPbd2 
is HSPG-dependent. 
 
Identification an HSPG-dependent second binding site for PrP on LRP 
The two binding sites on PrP, one of which is direct and the other indirect, suggested that two 
‚acceptor‘ sites might also exist on LRP. To test this hypothesis we adapted our SFV 
expression system to CHO cells. We then expressed LRP::FLAG and a mutant LRP lacking 
the direct PrP-binding domain (aa 161-180), termed LRPdelBD::FLAG, in wild-type CHO 
cells and the mutant CHO-S745 cell line lacking HSPGs ( Figure 4K, lower panels). In wild-
type CHO cells (Figure 4K, lanes 1-6) the binding of GST::huPrP was enhanced, when 
LRP::FLAG was hyperexpressed (Figure 4K, lane 2 versus lane 6). Hyperexpression of 
LRPdelBD::FLAG did not reduce the amount of the bound GST::huPrP (Figure 4K, lane 4), 
indicating that the binding was HSPG mediated. In mutant CHO-S745 cells lacking HSPGs 
(Figure 4K, lanes 7-13) the amount of bound GST::huPrP was also enhanced in LRP::FLAG 
hyperexpressing cells compared with non-transfected  cells (Figure 4K, lane 8 and 13). CHO-
S-745 cells expressing LRPdelBD::FLAG, however, showed a reduced binding of 
GST::huPrP (Figure 4K, lane 10), similar to non-transfected cells (Figure 4K, lane 13) 
suggesting that the second indirect PrP-binding site was not functioning in the absence of 
HSPGs. In order to confirm that HSPGs are responsible for the binding of PrP to the second 
binding domain on LRP, we added HSPGs to cells overexpressing LRPdelBD::FLAG 
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resulting in a total restoration of the PrP-binding (Figure 4K, lane 11). HSPGs failed to 
increase the binding of GST::huPrP to CHO wild-type (Figure 4L, lanes 2 and 3) and CHO-S-
745 cells (Figure 4L, lanes 5 and 6) due to the presence of the direct binding domains on PrP 
and LRP. We conclude from these data that two binding sites for PrP on LRP exist: a direct 
one, which is located from aa161-179 and a second indirect one which resides either between 
aa101-160 or between aa 180-295 of LRP. 
 
Interaction of PrP and LRP in vitro 
The direct binding domains on LRP (aa161-179) and PrP (aa144-179) should allow the two 
proteins to interact with each other in vitro. GST-fused LRP (Rieger et al., 1997) and 
immobilized FLAG::huPrP (Figure 4 M, lanes 1 and 2) were able to interact with each other 
in vitro as shown in the pull down assay depicted in Figure 4 M. As already observed on 
wild-type CHO and CHO-S-745 cells, HSPGs did not influence the interaction due to the 
presence of the direct interaction domains (Figure 4M, lanes 2 and 3). However, HSPGs did 
affect the LRP-PrP53-93 interaction (HSPG-dependent binding domain on PrP) and the 
LRPdelBD-PrP interaction (lacking the direct binding domain on LRP) in CHO-S-745 cells 
(Figure 4G-J and K, respectively). 
 
 
Discussion 
Cell-binding and internalization studies proved that the 37-kDa LRP/67-kDa LR acts as the 
receptor for the cellular PrPc, on the cell surface (Gauczynski et al., 2001b). In order to 
investigate the interaction domains on PrP and LRP-LR mediating the binding of these two 
proteins a series of interaction studies employing the yeast two-hybrid system as well as PrP-
binding assays with neuronal and non-neuronal cells including the SFV-system have been 
performed. 
 
Mapping of the LRP interaction sites on PrP 
First, we aimed to determine which part of the PrP interacts with LRP. We performed a yeast 
two-hybrid analysis with a series of PrP deletion variants and employed a series of PrP 
peptides covering the entire PrP in various cell-binding assays. 
In the yeast two-hybrid system, we identified the PrP domain aa144-179 as a direct LRP- 
binding domain, termed PrPLRPbd1. This binding domain was confirmed in cell-binding 
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assays in N2a and NT2 cells with PrP peptides encompassing the entire PrP sequence. As 
already observed with full-length PrP (Gauczynski et al., 2001b), the staining pattern with the 
PrP peptides to N2a and NT2 cells is also punctuate due to either receptor clustering or PrP-
PrP peptide aggregation, or both. Receptor clustering was observed with a variety of other 
cell-surface receptors such as the FGF receptor (Utton et al., 2001), the muscle nicotinic 
acetylcholine receptor (AChR) (Hoch et al., 2001)  or the tumor necrosis factor receptor 
(TNFR55) (De Wilde et al., 2001). In addition to the yeast two-hybrid assay, which identified 
the direct PrP-LRP-LR interaction domain PrPLRPbd1, the cell-binding assay identified a 
second binding domain between aa53 and aa93 of PrP, termed PrPLRPbd2. This domain was 
not functional in the yeast two-hybrid system, indicating that an additional factor lacking in 
the yeast cell nucleus is required for mediating the interaction between LRP and PrP through 
PrPLRPbd2. Employing a mutant HSPG-deficient CHO cell line, in the binding assay revealed 
that PrPLRPbd2 binds to LRP via HSPGs. This finding was confirmed by using the PrP 
peptide 53-93 corresponding to PrPLRPbd2. PrP53-93 failed to bind to the mutant CHO cells 
but the binding was restored in a dose-dependent manner by the addition of soluble HSPGs. 
Our mapping data, which resulted in the identification of two LRP-binding sites on PrP, are 
consistent with the results obtained with PrP knock-out mice expressing PrPs with N-
proximal deletions, suggesting that PrP could bind to its natural ligand, termed Lprp which 
could represent a PrP receptor, in a region C-terminal to aa 134 of the PrP (Shmerling et al., 
1998). In line with this study, PrPLRPbd1 would correspond to the Lprp-binding domain. The 
same authors hypothesized the existence of a second domain located more N-terminally 
initiating a signal transduction necessary to maintain normal cellular functions. Recently, a 
signal transduction activity of the PrP by activation of the tyrosine kinase Fyn was described 
(Mouillet-Richard et al., 2000). As PrP resides as a GPI-anchored protein outside the cell, 
whereas the tyrosine kinase Fyn locates to the inner plasma membrane inside the cell, 
transmembrane orientated LRP-LR might be a reasonable candidate mediating the 
intracellular signal transduction between PrPc and Fyn. The cytosolic domain of N-syndecans 
(syndecan-3),  one of a family of four  transmembrane cell surface HSPGs, has recently been 
shown to bind to complexes containing c-Src and Fyn kinases (Kinnunen et al., 1998). This 
activity is related to neurite outgrowth (Kinnunen et al., 1998).  Hence, it is also conceivable 
that HSPGs might be necessary for the so far hypothetical LRP-LR-mediated signal 
transduction between PrPc and Fyn. A possible intercellular role of the PrP-LRP-LR 
interaction involving HSPGs which might result in signalling or cell attachment (for review 
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see (Gauczynski et al., 2001a) will be further investigated in detailed cell-cell interaction 
assays. 
Recently,  studies on the transmission of human prions to transgenic mice suggested that a so 
far unidentified protein X may participate in the formation of the PrPres. Substitution of 
residues 167, 171 and 218 prevented PrPres formation suggesting that protein X may interact 
with those residues of the prion protein (Kaneko et al., 1997b). As aa 167 and 171 reside 
within the direct PrP-LRP interaction domain termed PrPLRPbd1 it cannot be excluded that 
LRP-LR might function as protein X. Application of LRP-LR in PrP oligo/multimerization 
processes may enlighten a possible role of the 37-kDa/67-kDa laminin receptor in PrPres 
formation. 
 
Mapping of the PrP interaction sites on LRP 
A yeast two-hybrid analysis with C-terminal LRP truncations extended a previous analysis 
(Rieger et al., 1997) and retrenched that the direct PrP-binding domain to aa161-179 of LRP. 
As the binding domain PrPLRPbd2 on PrP is HSPG-dependent, we hypothesized that a second 
indirect binding domain for PrP may also exist on LRP. To test this hypothesis, we analyzed 
PrP-binding to wild-type CHO cells, to mutant HSPG-deficient CHO cells and to both cell 
types hyperexpressing either the full length LRP::FLAG or an LRP mutant lacking the direct 
PrP-binding domain (aa161-180), termed LRPdelBD::FLAG. HSPGs failed to increase the 
binding of GST::huPrP to CHO wild-type and CHO-S745 cells due to the presence of the 
direct binding domains on PrP and LRP. CHO and CHO-S745 cells transfected with 
recombinant SFV RNAs further revealed the role of HSPGs in the binding of PrP to LRP. 
Hyperexpression of LRP::FLAG or LRPdelBD::FLAG in wild-type CHO cells resulted in 
approximately the same increase of GST::huPrP-binding when compared with non-
transfected cells. This indicates that binding of PrP to LRP::FLAG can occur via a second 
PrP-interaction domain present in LRPdelBD::FLAG. In HSPG-deficient CHO cells, 
however, PrP-binding to cells hyperexpressing LRPdelBD::FLAG was similar to non-
transfected cells, indicating that the second interaction domain on LRP was not functioning. 
In contrast, LRP::FLAG hyperexpressing HSPG-deficient CHO cells showed an increased 
binding of GST::huPrP due to the presence of the direct HSPG-independent PrP-binding 
domain (aa161-179). The addition of HSPGs to LRPdelBD::FLAG hyperexpressing HSPG-
deficient CHO cells restored GST::huPrP-binding to levels achieved with LRP::FLAG 
hyperexpressing cells. The data demonstrate the existence of a second HSPG-dependent PrP-
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binding domain on LRP, residing either between aa101 and 160 or aa181 and 285 of LRP. 
The identification of a HSPG-binding domain on LRP-LR which resides between aa 205 and 
229 of LRP-LR (Kazmin et al., 2000) suggests that this domain may represent the HSPG-
dependent-binding site for PrP. A monoclonal antibody directed against aa 167-243 of LRP 
reduces PrP-binding to neuronal cells (Gauczynski et al., 2001b) suggesting that the indirect 
binding domain may reside between aa180 and 285 rather than aa101 to 160 of LRP. 
 
Interaction of PrP and LRP in vitro 
Rec. purified PrP and LRP interact with each other in vitro due to the presence of the direct 
PrP-LRP interaction domains. The influence of HSPGs on the indirect PrP-LRP interaction 
domains, however, was only detectable on the HSPG-deficient CHO-S745 cells employing 
PrP53-93 (representing the indirect binding domain on PrP) and LRPdelBD (lacking the 
direct binding domain on LRP). 
 
The relationship between 37-kDa LRP and 67-kDa LR  
Attempts to isolate the gene for the 67-kDa LR revealed a cDNA fragment encoding the 37-
kDa LRP (Grosso et al., 1991; Rao et al., 1983; Yow et al., 1988). Pulse-Chase experiments 
with 37kDa LRP specific antibodies demonstrated that 37-kDa LRP is the precursor of 67-
kDa LR (Castronovo et al., 1991; Rao et al., 1989). The 37-kDa molecule encoded by the 
full-lengh gene identified for the LR is virtually identical to the ribosomal protein p40. The 
37LRP/p40 evolved from a ribosomal protein essential for protein synthesis lacking any 
laminin-binding abilities, to a laminin-binding cell surface receptor (for review see (Ardini et 
al., 1998). The molecular structure of the 37-kDa LRP/67-kDa LR and the mechanism by 
which the 37-kDa LRP forms the mature 67-kDa LR remains unclear. Our data from a yeast 
two-hybrid analysis show that LRP fails to interact with itself, an argument against the 
hypothesis of a direct homodimerization. In addition, homogeneous rec. LRP::FLAG appears 
to be monomeric as analyzed by size-exclusion chromatography. Although we only used 0.1 
% Triton-X-100 in the purification procedure, we cannot exclude that this small amount of 
non-ionic detergent may disrupt a native dimeric state of the receptor. A recent study 
suggested that acylation of LRP would allow it to associate with a heterologous molecule 
(Buto et al., 1998). In the light of our results, the relationship between the 37-kDa LRP and 
67-kDa LR might be explained by the association of an LRP molecule with heparan sulfates. 
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Role of heparan sulfates in the PrP-LRP interaction process 
The binding of chicken PrP to the surface of mammalian cells has been shown to depend 
partly on the availability of heparan sulfates expressed by these cells (Shyng et al., 1995). PrP 
interacts with heparan sulfates (Brimacombe et al., 1999; Caughey et al., 1994; Chen et al., 
1995a; Gabizon et al., 1993). Recent studies demonstrated that the binding of copper to PrP 
which occurs within the octarepeat region (Brown et al., 1997) (corresponding to PrPLRPbd2) 
can be competed by the addition of HSPGs (Brimacombe et al., 1999), confirming that this 
region of PrP binds to HSPGs. Finally, LRP-LR has also been shown to be a heparin/heparan 
sulfate-binding molecule (Guo et al., 1992; Kazmin et al., 2000). The predicted -helical 
structure (aa205-aa229) of LRP-LR is proposed to have heparin binding characteristics 
(Kazmin et al., 2000). The requirement of heparin-like molecules for the formation of a 
ligand-receptor complex is not unprecedented and is well illustrated by the example of the 
binding of the FGF to its receptor, FGFR (Yayon et al., 1991; Spivak et al., 1994; 
Venkataraman et al., 1999). All these data match very well with our findings, providing a 
comprehensive model of the PrP-LRP-LR interaction (Figure 5). A heparan sulfate arm of a 
cell-surface HSPG molecule might be located between PrPLRPbd2 and the indirect binding 
domain of LRP to create a sandwich interaction site, whereas PrP would interact with LRP-
LR (aa161-179) directly via PrPLRPbd1. We cannot exclude that HSPGs intervene in a more 
indirect manner, by changing the conformation of LRP-LR as to render it amenable to its 
interaction with the PrPLRPbd2 region of PrP. 
Components blocking the direct and indirect PrP-LRP interaction domains on PrP and LRP 
may represent a novel class of molecules suitable for a therapeutic intervention in prion 
diseases. 
 
 
Materials and methods 
Construction of pSFV1-LRPdelBD::FLAG- preparation of SFV mRNAs in vitro 
The LRP mutant pSFV1-LRPdelBD::FLAG (deletion of the direct PrP-binding domain 
located between aa161 and aa180) was generated by the QuikChangeTM site-directed 
mutagenesis method (Stratagene) using the pSFV1-LRP::FLAG plasmid DNA (Gauczynski et 
al., 2001b) as template for PCR and confirmed by dideoxy sequencing. The rec. plasmid 
DNAs pSFV3-lacZ (Life Technologies), pSFV1-LRP::FLAG and pSFV1-LRPdelBD::FLAG 
were linearized, purified and transcribed as described (Gauczynski et al., 2001b). The correct 
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length of the transcripts was verified by agarose gel electrophoresis. RNA was stored at -
20°C.  
 
Mammalian cell culture, transfection and co-transfection studies with the SFV system 
Mutant CHO cells (S745) deficient in xylose transferase (Esko et al., 1985) as well as wild-
type CHO (K1) were cultivated in NUT.MIX.F-12(HAM) supplemented with GLUTAMAX-I 
(GIBCO-BRL), 10 % fetal calf serum (FCS), 100 µg/ml penicillin and 100 µg/ml 
streptomycin at 37 °C with 5 % CO2. Transfection and co-transfection were carried out as 
described (Gauczynski et al., 2001b). Transfection efficiencies as determined by transfecting 
SFV3-lacZ control RNA followed by X-gal staining were  80% for CHO-K1 or CHO-S745 
cells. 
 
Purification of LRP::FLAG from the SFV system 
Transfection of BHK cells with the rec. SFV LRP::FLAG RNA was performed as described 
(Gauczynski et al., 2001b). The total volume of the electroporated cells was plated on 10-cm 
dishes containing 15 ml of complete growth medium followed by incubation for at least 48 h 
at 37 °C. Fourty-eight hours post transfection, cells were harvested, washed once with 
phosphate-buffered saline (PBS) and then lysed in PBS supplemented with 0.1% Triton-X100 
by repeated freezing and thawing. The crude lysate was obtained by centrifugation at 14 000 
r.p.m, 4°C for 15 min and purified by the batch method using an anti-FLAG M2 affinity gel 
(Sigma). The FLAG-tagged protein was bound over night by rotating at 4°C, washed four 
times with Tris-buffered saline (TBS), eluted over night by competition with 1 ml TBS 
containing 100 µg/ml FLAG peptides and dialyzed against 20 mM Hepes, pH 7.4. The purity 
and the concentration of the protein was checked by SDS-PAGE followed by silver staining 
of the gel. 
 
Recombinant  proteins generated in the Baculovirus and Escherichia coli system 
Rec. GST, GST::huPrP23-230, GST::haPrP23-89 and GST::haPrP90-231 were expressed in 
Baculovirus infected Sf9 cells and purified to homogeneity as described for hamster 
GST::PrP fusions previously (Weiss et al., 1995; Weiss et al., 1996). GST-fused PrP-peptides 
(haPrP23-52, haPrP53-93, haPrP90-109, haPrP129-175, haPrP180-210, haPrP218-231) were 
expressed in Escherichia coli and purified to homogeneity as described for GST fusions 
(Weiss et al., 1995). cDNA encoding for huPrP110-128 was cloned via EcoRI (5') and 
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BamHI (3') into pGEX-2T, GST::huPrP110-128 was expressed in E. coli and purified to 
homogeneity as described (Weiss et al., 1995). All rec. proteins were dialyzed against 20 mM 
Hepes, pH 7.4.  
 
PrP-binding assays followed by immunofluorescence analysis 
N2a, and human NT2 cells were maintained in DMEM medium containing 10 % FCS, 1 % 
glutamine, 100 µg/ml penicillin and 100 µg/ml streptomycin. Mutant CHO cells (S745) as 
well as wild-type CHO-K1 were cultivated as described above. For competition studies the 
cells were either pre-incubated for 2 h with the individual antibody diluted in culture medium 
or co-incubated with rec. protein and antibody (inoculum saturation). In case of pre-
incubation, medium was replaced and cells were incubated overnight with 4 µg/ml of rec. 
GST-fusion proteins per ml of culture medium. Cells were then washed three times with PBS 
and prepared for immunofluorescence microscopy, which was performed as described 
(Gauczynski et al., 2001b). 
 
PrP-Binding assay in cell culture followed by western blotting 
CHO/CHO-S745 cells 8x105 (either non-transfected or transfected with rec. SFV RNAs) 
were seeded on 6-well plates and incubated at 37 °C. Twenty-four hours post-transfection, 
cells were incubated in medium containing 5 µg/ml of rec. GST-huPrP23-230 18 h at 37°C. 
Together with the rec. protein, cells were co-incubated with 40 µg/ml of HSPGs (when 
indicated). Cells were then washed several times with PBS and scraped off in PBS. After 
centrifugation the pellets were resuspended in lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1 mM CaCl2, 3 mM MgCl2, 1 % NP-40). After addition of Laemmli buffer, samples 
were separated by SDS-PAGE and blotted on PVDF membrane. Western blotting was 
performed with the monoclonal anti-PrP antibody 3B5 or the pAb LRP W3 and peroxidase-
coupled secondary antibodies. 
 
Mapping of LRP and PrP-binding sites in the yeast two-hybrid system 
Constructions of plasmids pSH2-1 and pJG4-5 were described previously (Rieger et al., 
1997). For mapping the LRP-PrP interaction site on PrP, the following C-terminal truncated 
constructs of PrP were generated: pSH2-1-GST::huPrP23-93, pSH2-1-GST::huPrP23-118, 
pSH2-1-GST::huPrP23-127, pSH2-1-GST::huPrP23-131, pSH2-1-GST::huPrP23-143, pSH2-
1-GST::huPrP23-154, pSH2-1-GST::huPrP23-181, and pSH2-1-GST::huPrP180-230. The 
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PrP-fragments were amplified by PCR using oligodesoxyribonucleotides coding for different 
PrP sequences flanked by a BamHI (5‘) and a SalI (3‘) restriction site. The fragments were 
cloned via BamHI and SalI into the vector pSH2-1-GST. All PrP constructs were confirmed 
by sequencing. The different bait plasmids, the prey plasmid pJG4-5-LRP44-295 and the 
reporter plasmid pSH18-34 (lacZ) were co-transformed into EGY48 cells and transformants 
were tested in -galactosidase assays. Construction of the plasmid pSH2-1-GST::huPrP23-
230 was described previously (Rieger et al., 1997). For mapping the PrP interaction site on 
LRP, the C-terminal truncated constructs of LRP pJG4-5-LRP44-101 and pJG4-5-LRP44-160 
were designed. The LRP fragments were amplified by PCR using oligodesoxyribonucleotides 
coding for different LRP sequences flanked by EcoRI (5‘) and SalI (3‘). The fragments were 
cloned via EcoRI and XhoI restriction sites into the vector pJG4-5. The resulting constructs 
were confirmed by didesoxysequencing. The different bait plasmids, the prey plasmids and 
the reporter plasmid pSH18-34 (lacZ) were cotransformed into EGY48 cells and 
transformants were tested in -galactosidase assays. 
 
LRP-LRP and gal-3-PrP interaction studies in the yeast two-hybrid system 
The constructs pSH2-1-GST, pJG4-5-GST, pSH2-1-GST::huPrP and pJG4-5-LRP44-295 
were described previously (Rieger et al., 1997). The LRP44-295 encoding cDNA was PCR 
amplified from pJG4-5-LRP44-295. The PCR-product flanked by EcoRI (5‘) and SalI (3‘) 
restriction sites, respectively, was cloned into the vector pSH2-1 via both restriction sites 
resulting in pSH2-1-LRP44-295 which was confirmed by dideoxy sequencing. Yeast 
transformations and dotting were carried out as described above. Total RNA was isolated 
from 293 cells by RNeasy kit (Quiagen). Gal-3 cDNA was amplified by RT-PCR and 
subcloned into pSH2-1 via EcoRI (5‘) and SalI (3‘) restriction sites resulting in pSH2-1-Gal-
3, which was confirmed by dideoxy sequencing. The huPrP23-230 encoding cDNA was 
excised from pSH2-1-GST::huPrP23-230 and subcloned into pJG4-5 via EcoRI and SalI. The 
resulting plasmid pJG4-5-GST::huPrP23-230 was confirmed by didesoxy sequencing. Yeast 
transformations and dotting was carried out as described above. 
 
Analysis of native LRP::FLAG by size-exclusion chromatography 
The Superose 12 PC 3.2/30 column (Amersham Pharmacia) was calibrated with the LMW 
calibration kit in 20 mM HEPES pH 7,4. Purified LRP-FLAG (2.5 µg) of expressed in the 
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SFV system were loaded in a total volume of 25µl. Chromatography was performed at a flow 
rate of 30µl/min. The eluted LRP was detected with a UV-M II monitor at 280 nm. 
 
In vitro interaction of PrP and LRP 
Rec. FLAG::huPrP23-230 was expressed in the Baculovirus system (C. Hundt et al, 
manuscript in preparation) according to rec. FLAG::haPrP23-231 (Rieger et al., 1997) and 
immobilized on anti-FLAG M1 beads. Twenty microlitres of beads (1:1 slurry; 500 ng of 
FLAG::huPrP), were incubated in TBS supplemented with 2 mM MgCl2 with 500 ng of rec. 
GST and 1 µg of GST-LRP (Rieger et al., 1997), respectively (molar ratio: 1:1) in the absence 
and presence of 1.5 µg HSPGs (Sigma). Homogeneity of GST-LRP, GST and 
FLAG::huPrP23-231 was proven on silver-stained SDS-PA gels. After 1h at room 
temperature, the supernatant was removed, beads washed four times with TBS, boiled in 
SDS-sample buffer and analysed by western blotting developed with mAb GST. 
 
Antibodies 
pAb LRP W3 (Rieger et al., 1997) was purified by protein A-Sepharose chromatography. 
mAb GST (Santa Cruz Biotechnology), mAb VLA6 (Immunotech.), mAb 3B5 (G. 
Hunsmann), mAb SAF70 (aa 140-180 of PrP) and pAb JB007 (CEA, France), secondary 
fluorescein isothiocyanate (FITC), Cy3 (indocarbocyanine) and Texas Red-conjugated 
antibodies (used at 1:100 dilutions; Jackson Laboratories/Southern Biotechnology) were used.  
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Fig. 1. Identification of direct PrP-LRP interaction domains. (A) Identification of the direct 
PrP-LRP interaction domain on PrP. HuPrP23-93 (row 1), huPrP23-118 (row 2), huPrP23-
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127 (row 3), huPrP23-131 (row 4), huPrP23-143 (row 5), huPrP23-154 (row 6), huPrP23-181 
(row 7) and huPrP180-230 (row 8) were co-expressed in fusion with GST in the bait position 
together with LRP in prey position of the yeast two-hybrid system. (B) Retrenchment of the 
direct PrP-LRP interaction domain on LRP (Rieger et al., 1997). LRP44-101 (row 1), LRP44-
160 (row2), LRP44-295 (row 3) were co-expressed in prey position together with huPrP23-
230 fused to GST in bait position of the yeast two-hybrid system. *Interactions between 
LRP157-295 and LRP 180-295 (in prey position) versus huPrP23-230 fused to GST (in bait 
position) have been investigated previously (Rieger et al., 1997). (C) PrP144-179 interacts 
directly with LRP161-179 in the yeast two-hybrid system. PrP144-179 fused to GST in bait 
position was co-expressed with LRP161-179 (row 1), LRP180-295 (row 2) and LRP44-160 
(row 3) in prey position of the yeast two-hybrid system. (A-C) All interactions were 
monitored by the -galactosidase reporter system. 
 
 
 
 
 
Fig.2.  LRP fails to interact with itself in the yeast two-hybrid system and appears monomeric 
by native size-exclusion chromatography. Gal-3 fails to interact with PrP and LRP. (A) 
huPrP23-230 and LRP fail to interact with the -galactoside lectin gal-3 in the yeast two-
hybrid system. huPrP23-230 fused to GST in bait position was co-expressed with LRP44-295 
in prey position (row 1), gal-3 in bait position was co-expressed with GST::huPrP23-230 (row 
2), and LRP44-295 (row 3) in prey position. (B) LRP fails to interact with itself in the yeast 
two-hybrid system. GST (row 1), LRP44-295 (row 2) and GST::huPrP23-230 (row 3) were 
expressed in bait and GST (row 1), and LRP44-295 (row 2 and 3) in the prey position of the 
yeast two-hybrid system. Detection (A and B) by the -galactosidase reporter system. (C) 
Analysis of rec. LRP::FLAG on SDS-PAGE. One microgram of rec. LRP::FLAG purified 
under native conditions from the SFV system was analyzed on a 12.5 % SDS-PA-gel stained 
 Chapter IV  109  
with silver (lane 1). Marker proteins are indicated. (D) Analysis of rec. native LRP::FLAG by 
size exclusion chromatography. Homogeneous LRP::FLAG (2.2 µg) were analyzed by size 
exclusion chromatography on a Superose12PC3.2/30 column (Amersham Pharmacia). Marker 
proteins are indicated. 
 
 
 
 
 
 
 
Fig. 3. Identification of PrP-interaction domains for LRP/LR by binding assays with rec. 
prion peptides on NT2 and N2a cells. (A-C) Binding to NT2 cells. NT2 cells were incubated 
with PrP peptides fused to GST in the absence (A-C) and presence (insets in A-C) of the 
preincubated pAb LRP W3 (dilution 1:50). The following  peptides (4 µg/ml) were used: 
GST::PrP53-93 (A), GST::PrP90-109 (B) and GST::PrP129-175 (C). Immunofluorescence 
analysis was performed by triple labelling involving actin staining (phalloidin, red), nuclear 
staining [4‘,6-diamidino-2-phenylindole (DAPI), blue] and GST staining (sec. Ab FITC, 
green) (magnification x630). (D-J) Binding to N2a cells. N2a cells were incubated with PrP 
peptides fused to GST in the absence (D-J) or presence of either pre-incubated pAb LRP 
(dilution 1:50) (bottom insets in D-J) or pre-incubated mAb VLA6 (dilution 1:50) (top inset 
in E and H). The following peptides (4 µg/ml) were used: GST::PrP23-52 (D), GST::PrP53-
93 (E), GST::PrP90-109 (F), GST::PrP110-128 (G), GST::PrP129-175 (H), GST::PrP180-
210 (I) and GST::PrP218-230 (J). Immunofluorescence was performed with mAb GST, sec. 
Ab Texas Red, DAPI staining; magnification x400). 
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Fig. 4. Influence of HSPGs on the LRP-LR-PrP-binding reaction analyzed by wild-type and 
mutant HSPG-deficient CHO cells; use of an LRP deletion mutant lacking the direct PrP-
binding domain on LRP; PrP-LRP in vitro interaction studies. (A-F) Binding of 
GST::huPrP23-230 to CHO cells and to HSPG-deficient CHO cells (S745) (Esko et al., 1985) 
in the absence and presence of antibodies. Binding of 4 µg/ml GST::huPrP23-230 to CHO 
wild-type cells in the absence of any antibody (A), in the presence of the pAb LRP W3 (1:50) 
(C), mAb SAF 70 (aa140-180 of PrP) (E). Binding of GST::huPrP23-230 to CHO-S745 cells  
in the absence of any antibody (B), in the presence of the pAb LRP W3 (D) and in the 
presence of the mAb SAF 70 (F). The mAb SAF70 was used at a 1:1000 dilution to saturate 
GST::huPrP23-230 while pAb LRP was pre-incubated with the cells at a 1:50 dilution prior to 
addition of the rec. PrP. Immunofluorescence analysis: pAb LRP (sec. Ab FITC ), mAb 3F4 
(sec. Ab Texas Red; DAPI staining; magnification 400x). (G-J) Binding of GST::PrP53-93 to 
CHO wild-type and CHO-S745 cells. Binding of 4 µg/ml GST::huPrP53-93 to CHO wild-
type (G) and CHO-S745 cells in the absence of HSPGs (H), and in the presence of 10 (I) and 
40 µg/ml (J) HSPGs, respectively. Immunofluorescence analysis: mAb GST (sec. Ab Texas 
Red; DAPI staining; magnification x400). (K) Binding of PrP by wild-type CHO and mutant 
HSPG-deficient CHO-S745 cells hyperexpressing LRP::FLAG or LRPdelBD::FLAG 
(lacking aa 161-180). CHO cells (lanes 1-6) either hyperexpressing LRP::FLAG (lanes 1 and 
2), LRPdelBD::FLAG (lanes 3 and 4) by the SFV system or non-tranfected (lanes 5 and 6) 
were incubated with 5 µg/ml GST::huPrP (lanes 2, 4 and 6). CHO-S745 cells (lanes 7-13) 
either hyperexpressing LRP::FLAG (lanes 7 and 8), LRPdelBD::FLAG (lanes 9-11) by the 
SFV system or non-transfected (lanes 12 and 13) were incubated with 5 µg/ml GST::huPrP 
(lanes 8, 10, 11 and 13). HSPGs (40 µg/ml) were added simultaneously with GST::huPrP to 
the CHO-S745 cells overexpressing LRPdelBD::FLAG (lane 11). Total cell extracts were 
analyzed by western blotting employing the mAb 3B5 (upper panels) or pAb LRP W3 (lower 
panels). (L) Binding of PrP by non-transfected wild-type CHO and mutant HSPG-deficient 
CHO-S745 cells. Non-transfected CHO wild-type cells (lanes 1-3) and non-transfected CHO-
S745 cells (lanes 4-6) were incubated with 5 µg/ml GST::huPrP (lanes 2, 3, 5 and 6). HSPGs 
(40 µg/ml) were added simultaneously with GST::huPrP to both cell types (lanes 3 and 6, 
respectively). Total cell extracts were analyzed as described in (K). Interaction of rec. 
FLAG::PrP and rec. GST::LRP in vitro (M). FLAG::huPrP23-230 (0.5 µg) immobilized on 
anti-FLAG Sepharose beads analyzed on a 12 % SDS-PA gel stained with silver (lane 1) and 
by western blotting employing the pAb JB007 (lane 2) were incubated with 1 µg of 
GST::LRP in the absence (lane 4) or in the presence of 1.5 µg/µl HSPGs (lane 3), 0.5 µg of 
GST in the absence (lane 6) or the presence of 1.5 µg/µl HSPGs (lane 5). Unloaded beads 
were incubated with 1 µg of GST::LRP in the presence of 1.5 µg/µl HSPGs (lane 7). Beads 
after washing were analyzed by western blotting on a 12% SDS PA-gel employing mAb GST 
(sec. antibody POD). 
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Fig. 5. Model for the function of LRP-LR as the receptor for PrP. The PrP molecule binds to 
LRP-LR via PrPLRPbd1 and PrPLRPbd2. PrPLRPbd2 (aa 53-93) is dependent on the presence of 
a heparan sulfate arm of a HSPG molecule whereas PrPLRPbd1 (aa 144-179) interacts directly 
with LRP-LR (as shown in the yeast two-hybrid system). The simultaneous presence of both 
PrPLRPbd1 and PrPLRPbd2 would stabilize considerably the binding of the entire PrP molecule 
to its receptor. Direct binding of LRP-LR to PrP occurs via the direct binding site located 
between aa 161-179 of LRP-LR (Figure 1). The indirect HSPG-dependent binding domain 
might locate between aa 101 and 160 or between aa 180-285 [presumably aa 205 and 229 of 
LRP (Kazmin et al., 2000)]. The association of LRP-LR with HSPGs might explain the 
relationship between 37-kDa LRP and 67-kDa LR. 
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Recombinant human prion protein mutants  
huPrP D178N/M129 (FFI) and huPrP+9OR (fCJD)  
reveal proteinase K resistance 
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Sabine Gauczynski, Susanne Krasemann, Walter Bodemer and Stefan Weiss. 
The recombinant human prion protein mutants huPrP D178N/M129 (FFI) and huPrP+9OR 
(fCJD) reveal proteinase K resistance. 
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Abstract 
The Semliki Forest virus (SFV) sytem was used to overexpress human wild-type and mutant 
prion proteins as well as FLAG-tagged human and bovine PrP in mammalian cells. The 
application of recombinant SFV vectors allowed a high-level production of highly 
glycosylated prion proteins with a molecular weight ranging from 25 to 30 kDa for 
recombinant wild-type human PrP and from 26 to 32 kDa for wild-type bovine PrP. Further, 
we report here about the generation of recombinant mutant prion proteins which are 
associated with inherited human prion diseases such as fatal familial insomnia (FFI) and 
Creutzfeldt-Jakob disease (CJD). Both mutated variants, the FFI-associated PrP carrying a 
mutation at amino acid (aa) position 178 and the CJD-linked form containing an insertion of 
nine additional octarepeats reveal proteinase K (PK) resistance, one of the most typical 
biochemical properties characteristic for the infectious scrapie isoform of the prion protein. In 
contrast, recombinant wild-type PrP was completely protease K sensitive when expressed in 
SFV-transfected BHK cells. The subcellular location of both PrP mutants at the cell surface 
and in intracellular compartments of transfected BHK cells was similar to that of wild-type 
PrP without any significant differences regarding the cellular distribution and expression 
level. In order to purify recombinant human and bovine PrP from cell lysates, a FLAG-tag 
was introduced either at the N-terminus behind the signal peptide or at the C-terminus close to 
the adhesion site of the GPI anchor. N-terminal insertion did not influence trafficking of the 
FLAG-tagged protein to the cell surface whereas insertion close to the GPI attachment site 
clearly affected the transport of PrP to the cell membrane probably resulting in the retention 
within the secretory pathway. All FLAG-tagged prion proteins were expressed high 
efficiently in BHK cells showing the typical glycosylation pattern allowing the rapid and 
simple purification via anti-FLAG antibody chromatography. 
 
 
Introduction 
The causative agent of transmissible spongiform encephalopathies (TSEs) is termed prion 
defined as a proteinaceous infectious particle (Prusiner, 1982). Prion diseases (for review see 
(Lasmézas and Weiss, 2000; Prusiner, 1998; Weissmann and Aguzzi, 1997)) belong to a new 
class of fatal neurodegenerative disorders affecting humans and animals. The key event in the 
development of disease are conformational changes of the cellular prion protein, PrPc. The 
misfolded, disease-associated form is termed PrPSc, a partially proteinase K resistant isoform 
with a high -sheet content compared to the proteinase K sensitive and predominantly -
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helical PrPc (Caughey et al., 1991). TSEs may occur spontaneously, inherited or transmitted. 
Human prion diseases include Kuru, Creutzfeldt-Jakob disease (CJD), fatal familial insomnia 
(FFI) and Gerstmann-Sträussler-Scheinker syndrome (GSS) (for review see (Lasmézas and 
Weiss, 2000; Prusiner, 1998; Weissmann and Aguzzi, 1997). Whereas 85% of all CJD cases 
occur sporadically in the absence of any mutations, FFI, GSS and the remaining 15% of CJD 
are dominantly inherited diseases caused by defined mutations within the Prn-p gene on 
chromosome 20 (Masters, 1981; Sparkes et al., 1986). Genetic linkage or association has 
been identified for several amino acid substitution in the C-terminus of the PrP as well as for 
octarepeat insertions within the N-terminal part of the molecule. Here, the spontaneous 
conversion of PrPc to PrPSc in the absence of exogenous prions has been supposed (Young, 
1999) but the exact mechanism by which these mutations provoke the conformational 
changes is still unknown. Destabilization of the PrPc structure or effects on the 
thermodynamic stability of PrP are suggested (Liemann and Glockshuber, 1999; Riek et al., 
1998; Swietnicki et al., 1998; Zhang et al., 2000). 
The physiological function of PrP still remains unclear. It has been proposed that PrP might 
play a role in synaptic processes (Collinge et al., 1994), in the regulation of circadian activity 
rhythms and sleep (Tobler et al., 1996) and in copper transport (Hornshaw et al., 1995). 
Further on, a function in the survival of purkinje cells (Sakaguchi et al., 1996) was suggested 
but very recently, it has been reported that the upregulation of the prion-like protein termed 
doppel causes Purkinje cell degeneration in Prnp0/0 mice instead of PrP depletion (Moore et 
al., 1999). More recently, a superoxide dismutase activity (Brown et al., 1999) and a role in 
signal transduction (Mouillet-Richard et al., 2000) of PrP has been suggested. Due to the 
absence of any phenotype for PrP described in various reports (Bueler et al., 1992; Lledo et 
al., 1996; Manson et al., 1994), the only confirmed role of PrPc seems to be its necessity for 
the development of TSEs (Bueler et al., 1993). Cellular PrP is synthesized in the rough 
endoplasmic reticulum (rER) and is transported via the Golgi and secretory granules to the 
surface of neuronal cells where it is anchored to the plasma membrane by its glycosyl 
phosphatidylinositol (GPI) moiety (Rogers et al., 1991). Three different PrP glycoforms 
differing in their glycosylation degree have been observed on the cell surface: diglycosylated 
(70%), monoglycosylated (25%) and unglycosylated PrP (5%) (Caughey et al., 1989; Monari 
et al., 1994; Petersen et al., 1996). Recently, we identified the 37 kDa Laminin Receptor 
Precursor (LRP) as an interactor for the prion protein (Rieger et al., 1997) (for reviews see 
(Gauczynski et al., 2001a; Rieger et al., 1999)). Cell-binding and internalization studies on 
neuronal and non-neuronal  cells have demonstrated that the 37-kDa/67-kDa  laminin receptor  
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acts as the cell-surface receptor for the cellular prion protein (Gauczynski et al., 2001b). 
Direct and heparan sulfate proteoglycan (HSPG)-dependent interaction sites mediating the 
binding of cellular PrP to its receptor have been identified (Hundt et al., 2001). Cell culture 
experiments demonstrated the 37-kDa/67-kDa LR dependent binding  and internalization of 
recombinant GST::human PrP generated in insect cells and glycosylated human PrP 
synthesized in BHK cells transfected with recombinant SFV-RNA (Gauczynski et al., 2001b).  
High-level expression and purification of recombinant, glycosylated prion proteins in 
mammalian cells is essential for a better understanding of the physiological function of PrPc 
and biochemical processes responsible for familial prion diseases. The synthesis and study of 
wild-type as well as mutant PrP in cell culture systems allows a better insight into the biology 
of these proteins due to the presence of important organelles, membranes and other cellular 
cofactors which are necessary for the correct processing, trafficking and localization of the 
protein. Therefore, we used the Semliki Forest virus (SFV) system to express high amounts of 
glycosylated wild-type and mutant disease-associated prion protein in cultured mammalian 
cells. The SFV system supplies a multitude of advantages for the expression of recombinant 
proteins in mammalian cells: (i) a large-scale production for up to 72 hours post-transfection, 
(ii) a broad host range,  (iii) modifications such as glycosylation in a correct and sufficient 
way and (iv) the easy and fast transfection procedure with in vitro-transcribed RNA. The 
Semliki Forest virus is an insect-borne alphavirus and belongs to the family of Togaviridae 
(Schlesinger, 1986). Its viral genome consists of capped and polyadenylated single-stranded 
RNA of positive polarity and encodes its own RNA polymerase. SFV expression vectors are 
based on a cDNA copy of the viral genome. Here, viral structural genes are deleted and 
replaced by the gene of interest. Due to the remaining viral replicase which leads to an 
efficient production of recombinant RNA within the cell, a high-level synthesis of the foreign 
protein proceeds (Liljestrom and Garoff, 1991).  
In the present work, we have generated recombinant disease-related mutant isoforms of 
human PrP in BHK cells transfected with rec. SFV RNAs. The FFI-associated mutant PrP 
D178N/M129 and the CJD-related PrP+9OR were efficiently and highly glycosylated 
expressed in cultured cells. We further examined biochemical features  such as glycosylation 
status and proteinase K resistance of recombinant mutated PrP in comparison to recombinant, 
wild-type PrP as well as their subcellular localization in transfected BHK cells. We observed 
that both mutants were PK resistant at 8 µg/ml PK sharing this biochemical hallmark with 
infectious PrPSc. Therefore,  the  SFV system  does not  only  result  in expression system for 
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high-level production of glycosylated prion proteins, but may also function as a cell culture 
model for inherited human prion diseases. 
To facilitate purification and to introduce an additional epitope for immunodetection, we 
introduced a FLAG-tag at different positions of the cellular human and bovine PrP. FLAG-tag 
insertions at the C-terminus of PrP located two amino acids N-terminally of the GPI-
anchorage site, allowed the purification of predominantly diglycosylated human and bovine 
PrP from cell lysates by anti-FLAG antibody affinity chromatography.  
 
 
Results 
Expression of glycosylated wild-type and mutant prion proteins in BHK cells 
transfected with recombinant Semliki Forest virus (SFV) RNAs 
In order to produce high amounts of recombinant prion proteins in mammalian cells, we used 
the Semliki Forest virus (SFV) expression system which is based on a cDNA copy of the viral 
replicon. Transfection efficiency of Baby hamster kidney (BHK) cells used throughout all our 
experiments was almost 100% (data not shown) warranting the high-level production of 
glycosylated prion proteins. BHK cells were transiently transfected with recombinant SFV 
RNAs encoding full-length human PrP encompassing aa 1 to 253, human PrP containing the 
FFI-associated mutation at codon 178 (D178N,129M), human PrP with the CJD-linked 
insertion of nine octarepeats and wild-type bovine PrP from aa 1 to 264. Western blot analysis 
of crude lysates demonstrates the expression of di-, mono- and low amounts of non-
glycosylated forms of PrP with a molecular weight ranging from 25 to 30 kDa for wild-type 
and FFI-associated human PrP,  from 31 to 37 kDa for huPrP+9OR and from 26 to 32 for 
bovine PrP (Figure 1, lane 1, 3, 5 and 7), respectively. Also high-molecular, i.e. hyper-
glycosylated forms of cellular and mutant PrP were synthesized and detected by the mAb 
anti-PrP 3B5 (Figure 1). To confirm the glycosylation state of recombinant prion proteins, 
cell lysates were treated with N-glycosidase F leading to a decrease in di- and 
monoglycosylated forms accompanied by an augmentation of the non-glycosylated PrP 
(Figure 1, lane 2, 4, 6 and 8).  
 
Proteinase K status of recombinant cellular PrP and disease-associated PrP variants 
The partial resistance to proteinase K is a major hallmark of PrPSc. In contrast, cellular PrP is 
completely pK sensitive. To investigate whether recombinant FFI- and CJD-associated PrP 
isoforms synthesized in SFV-transfected BHK cells share PrPSc-like properties, proteinase K 
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was added to total cell extracts at increasing concentrations of 2, 4 and 8 µg/ml followed by 
incubation at 37 °C for 30 minutes (Figure 2). Both mutant PrPs, the FFI-associated PrP as 
well as the CJD-related insertion mutant, were resistant towards PK amounts up to 8 µg/ml, 
yielding PK-resistant fragments with molecular weights ranging from 23 to 25 kDa (Figure 2, 
lanes 8 and 12). In contrast, wild-type PrP was completely digested after treatment with 
8µg/ml PK (Figure 2, lane 4).  
 
Cellular localization of recombinant prion proteins in transfected BHK cells  
To proof, whether recombinant prion proteins, either wild-type or mutant, are transported to 
the surface of transfected BHK cells, non-permeabilized cells were analysed by 
immunofluorescence (IF) microscopy. In cells expressing wild-type human or bovine PrP, the 
protein traffics to the cell surface where it appears partially in a punctuated manner (Figure 
3B and E). Virtually all cells synthesizing PrP+9OR (Figure 3C)  or PrP-FFI (Figure 3D)  
showed similar staining patterns and comparable expression levels on the cell surface 
suggesting that mutated PrP variants are correctly processed to the cell surface. To visualize 
PrP in the interior of transfected cells, cells were permeabilized prior to immunostaining. 
Expression of wild-type human and bovine PrP (Figure 3B and E, insets) as well of both 
mutated PrPs (Figure 3D and E, insets) revealed a wide-spread staining pattern including 
areas surrounding the nucleus and regions of the cytoplasm. Thus, regarding the subcellular 
localization, no differences between PrP mutants and the cellular forms were detectable. Cells 
transfected with SFV RNA encoding the viral replicase only showed no detectable PrP 
staining neither on the cell surface nor in the interior of permeabilized cells (Figure 3A and 
inset) suggesting that BHK cells express no or only marginally amounts of endogenous PrPc. 
 
Expression of glycosylated FLAG-tagged prion protein 
To facilitate purification of human and bovine prion proteins and to introduce an additional 
epitope for immunodetection, we inserted a FLAG-tag at the C-terminus near the GPI-anchor 
adhesion site resulting in the constructs huPrP227FLAG and boPrP239FLAG and at the N-
terminus behind the signal peptide resulting in huPrP22FLAG (Figure 4A). FLAG-tagged PrP 
isoforms were expressed highly glycosylated in transfected BHK cells (Figure 4B, lanes 1-3 
and 4C, lanes 1 and 2). To confirm the glycosylation state, samples were deglycosylated by 
treatment with N-glycosidase F resulting in augmentation of the non-glycosylated PrP forms 
(Figure 4B, lanes 4-6 and 4C, lanes 3 and 4).  
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Cellular localization of FLAG-tagged prion proteins in transfected BHK cells  
To proof, whether the FLAG tagged prion proteins are transported to the surface of 
transfected BHK cells, non-permeabilized cells were stained with anti-PrP antibody 3B5 and 
analysed by IF microscopy. As already shown in Figure 3, human and bovine wild-type PrP 
were efficiently transported to the cell surface of transfected BHK cells (Figure 3B and E; 
Figure 5B and E). Due to the overexpression of recombinant protein in rec. SFV RNA-
transfected cells, wild-type human and bovine PrP were also detectable inside permeabilized 
cells (Figure 5B and E, insets). Permeabilization of transfected cells prior to immunostaining 
reveals intracellular deposits of both, wild-type and FLAG-tagged, prion proteins (Figure 5, 
insets). Whereas huPrP22FLAG was detectable on the cell surface at comparable levels 
(Figure 5C), both prion proteins carrying the FLAG-tag insertion close to the GPI-attachment 
site were only weakly transported to the surface of transfected BHK cells (Figure 5D and F) 
suggesting that the FLAG-tag at this position hampers trafficking of PrP to the cell surface. 
Indeed, most of the protein remains within the interior of the cell as shown by IF analysis on 
permeabilized cells (Figure 5D and F, insets). BHK cells transfected with SFV RNA 
encoding for the viral replicase only showed neither surface nor intracellular staining (Figure 
3A and inset) confirming that no or only low amounts of cellular PrP are synthesized by BHK 
cells. 
 
Purification of glycosylated FLAG-tagged PrP 
Purification of FLAG-tagged prion proteins was performed by anti-FLAG antibody 
chromatography. FLAG-tagged proteins from cell lysates were immobilized to anti-FLAG 
M2-conjugated agarose beads (Figure 6A and B, lanes 2). Silver stained SDS gels revealed 
that mainly the diglycosylated PrP form was purified to homogeneity by this one-step 
purification process (Figure 6C). Both kinds of recombinant proteins were recognized by the 
PrP specific antibody 3B5 (Figure 6A and B, lanes 3). 
 
 
Discussion 
Synthesis of wild-type and mutant prion proteins in mammalian cells by the Semliki 
Forest virus system 
In order to unseal the mystery about the physiological function of the cellular prion protein, 
great efforts have been done to get a better understanding of the biology and structure of 
PrPc. Different expression systems have been applied to produce recombinant prion proteins 
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in prokaryotic, insect, yeast or mammalian cells. Expression of Syrian golden hamster prion 
protein in E. coli and in Baculovirus-infected insect cells using the glutathione S-transferase 
(GST) fusion system were described (Volkel et al., 1998; Weiss et al., 1996; Weiss et al., 
1995). Although these systems resulted in large-scale protein production, only unglycosylated 
or marginal glycosylated PrP has been obtained. Thus, we decided to establish the SFV-
system for high-level expression of different wild-type and mutant prion proteins in 
mammalian cells. As expected, rec. glycosylated PrP was synthesized in BHK cells 
transfected with recombinant SFV RNAs. The typical glycosylation pattern consisting of 
unglycosylated, mono- and diglycosylated PrP was observed when we investigated the total 
cell extracts by western blot analysis. The presence of N-linked oligosaccaride chains was 
confirmed by N-glycosidase F treatment which led to deglycosylation of PrP resulting in the 
generation of mainly the non-glycosylated PrP form.  
 
Processing and trafficking of wild-type and mutated human prion proteins 
Correctly processed PrP traffics to the cell surface where it is anchored to the plasma 
membrane by its GPI-moiety (Rogers et al., 1991). We investigated the subcellular location 
of recombinant wild-type and disease-associated mutant PrP by IF microscopy. Very recently, 
it has been observed that mutant PrP molecules which are linked to familial prion diseases 
partially retained in the endoplasmic reticulum (ER) (Ivanova et al., 2001). This led to the 
conclusion that several pathogenic mutations i.e. point and insertion mutations within the 
Prn-p gene exert influence on the trafficking of PrP and that protein quality control might 
play an important role in TSEs (Ivanova et al., 2001) (for summary see table 1). For several 
mutations an additional mode of membrane association resulting in the resistance against 
enzymatic cleavage of the GPI-anchor was reported (Lehmann and Harris, 1995; Lehmann 
and Harris, 1996a), a phenomen which is also typical for infectious PrPSc. Previous studies 
have already described that mutant prion proteins are inefficiently processed to the cell 
surface and accumulate in intracellular compartments such as ER, Golgi and 
endosomes/lysosomes (Capellari et al., 2000; Jin et al., 2000; Petersen et al., 1996; Singh et 
al., 1997; Zanusso et al., 1999) (for summary see table 1). In contrast, IF analysis of non-
permeabilized, transfected BHK cells expressing huPrP-FFI or huPrP+9OR revealed similar 
surface staining in comparison to cells expressing wild-type human PrP at their cell surface. 
In addition, the intracellular staining of wild-type as well as both mutant PrP isoforms 
revealed the same wide-spread pattern encompassing nearly the entire interior of the cell. This 
effect might  be based on  the SFV-system due to  the hyperexpression of recombinant protein 
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while competing out the host translation machinery. Therefore, it might be difficult to detect 
subcellular trapped PrP in cells overexpressing this protein. However, we cannot exclude that 
mutant PrP molecules are partially retained in cellular compartments such as the ER.  
 
Proteinase K resistance of mutated human prion proteins 
One major biochemical characteristic of PrPSc represents its resistance to proteinase K (PK). 
Some mutant isoforms of the mouse prion protein carrying mutations homologous to familial 
human prion diseases were produced in stably transfected CHO cells and displayed scrapie-
like biochemical properties such as proteinase K resistance (for summary see table 1) and  
detergent insolubility (Daude et al., 1997; Lehmann and Harris, 1996a; Lehmann and Harris, 
1996b). Furthermore, hamster insertion mutants encompassing additional octarepeats showed 
protease resistance when synthesized in cultured cells (table 1) (Priola and Chesebro, 1998). 
To investigate whether genetically-linked human PrP mutants expressed in transiently 
transfected BHK cells behave similar to PrPSc, total cell extracts were treated with PK at a 
final concentration of 2, 4 and 8 µg/ml for 30 min at 37°C. Under these conditions, we 
detected a protease-resistant fragment of FFI-associated and CJD-related human PrP with a 
molecular weight ranging from 23 to 25 kDa. Previous reports describing a partially PK 
resistance for disease-associated PrP used partly lower PK concentrations and/or shorter 
incubation times (for summary see table 1). The mouse PG14 PrP mutant encompassing nine 
additional octarepeats, was PK sensitive at a concentration of 2 µg/ml when synthesized in 
stably transfected BHK cells using the Sindbis replicon (Ivanova et al., 2001). In addition, the 
human PrP mutant D178N/M129 was totally degraded when digested with low amounts of 
PK for 1 hour or with 5 µg/ml PK for at least 5 minutes (table 1). It is difficult to compare the 
characteristics of mutant PrPs of different species, expression systems and cells used for 
generation and the diverse conditions of PK digestion. Employing the SFV system, we were 
able to synthesize glycosylated, cell-surface orientated and PK resistant (up to 8 µg/ml) 
human PrP mutants recommending its capability as a cellular model system for familial 
human prion diseases. Bioassays will prove whether these PK-resistant PrP molecules will 
harbor endogeneous infevtivity. 
 
Processing, trafficking and purification of FLAG-tagged human and bovine prion 
proteins 
In order to purify prion proteins rapid and simple from total cell extracts and to introduce an 
epitope  suitable  for  specific immunogenic  detection, a  FLAG-tag  was inserted  within  the 
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human PrP encoding sequence close to the GPI anchorage site at residue 227 or at the N-
terminus following the signal peptide sequence at residue 22. A homologous FLAG-tag 
insertion within the bovine PrP sequence termed boPrP239FLAG was also constructed. The 
locations of the FLAG-tag insertion consisting of the eight aa-sequence, Asp-Tyr-Lys-Asp-
Asp-Asp-Asp-Lys, influenced the processing of bovine and human PrPc in transfected BHK 
cells. HuPrP22FLAG was processed normally and expressed at high amounts similar to wild-
type PrP on the cell surface of transfected cells. In contrast, introduction of the FLAG-tag 
close to the GPI-attachment site hampered the transport of huPrP227FLAG and 
boPrP239FLAG to the cell surface. Only low amounts of both proteins attained the cell 
surface. One possible explanation for this phenomenon might be the hampering effect of the 
FLAG-tag insertion close to the GPI-attachment site leading to a disruption of the transit of 
huPrP227FLAG and boPrP239FLAG to the cell surface and a retention of these proteins 
within cellular compartments of the secretory pathway such as the endoplasmic reticulum. 
However, glycosylation of all FLAG-tagged prion protein variants was not impaired. 
Therefore, recombinant glycosylated huPrP227FLAG and boPrP239FLAG have been 
purified from crude lysates by anti-FLAG-antibody chromatography. Such an epitope-tagged 
prion protein which can be purified simple and fast direct from total cell extracts might 
represent an useful tool to elucidate the physiological function of PrPc and its role in the 
pathological mechanisms of TSEs. 
 
 
Materials and methods 
Cell culture 
Baby hamster kidney cells (BHK-21 C13; ATCC CCL 10) were cultured in Dulbecco's 
modified Eagle's medium supplemented with 10 % heat-inactivated FCS, 2 mM L-glutamine, 
100 µg/ml penicillin and 100 µg/ml streptomycin at 37 °C with 5 % CO2. 
 
Recombinant pSFV plasmid constructions  
pSFV-1 (Liljestrom and Garoff, 1991), pSFV3-lacZ (Life Technologies) and the ORFs from 
human PrP and bovine PrP were used. The plasmid DNAs pSFV1-boPrP1-264, pSFV1-
huPrP1-253 (Krasemann et al., 1996), pSFV1-huPrP-FFI (encoding aa 1-253 of the human 
PrP containing a FFI associated mutation at codon 178 Asp  Asn plus Met at position 129) 
and pSFV1-huPrP+9OR (encoding aa 1-253 of the human PrP including nine additional 
octapeptide repeats) (Krasemann et al., 1995) were used. pSFV1-huPrP22FLAG was 
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generated by the QuikChangeTM site-directed mutagenesis method (Stratagene) employing 
pSFV1-huPrP1-253 DNA as a template. Construction of pSFV1-huPrP227FLAG (insertion of 
the FLAG-tag encoding sequence between codons 227 and 228 of the human PrP sequence) 
was described elsewhere (Hundt et al., in preparation). Construction of pSFV1-
boPrP239FLAG. The insertion of a FLAG-tag encoding sequence between codon 239 and 
240 of the bovine PrP sequence was performed by PCR using the pSFV1-boPrP1-264 plasmid 
DNA as a template. A 125 bp fragment (insertion of the FLAG encoding sequence) which 
encodes the carboxy-terminus of boPrP, was amplified introducing a HinfI restriction site 
(endogenous site within codons 232 - 233) at the 5' end, the tag-encoding sequence between 
codon 239 and 240 as well as a SmaI site at the 3' end.  This PCR-fragment encoding the C-
terminal part of boPrP was digested with HinfI  and SmaI and ligated via the HinfI restriction 
site to a 707 bp fragment encoding the aminoterminal part of boPrP from pSFV1-boPrP1-264 
digested with HinfI and SmaI. The ligated DNA fragments were cloned into the expression 
plasmid pSFV1 via the SmaI restriction sites resulting in pSFV1-boPrP1-239FLAG240-264. 
All constructs were confirmed by dideoxy sequencing. 
 
SFV-mRNA generation by in vitro transcription 
DNAs pSFV3-lacZ (Life Technologies), pSFV1-huPrP1-253, pSFV1-huPrP-FFI and pSFV1-
huPrP+9OR, pSFV1-huPrP22FLAG, pSFV1-huPrP227FLAG, pSFV1-boPrP1-264 and 
pSFV1-boPrP239FLAG were linearized with SpeI following purification by phenol-
chloroform extraction. Transcriptions were carried out in a total volume of 50 µl containing 
1,5 µg linearized plasmid DNA, 10x SP6 transcription buffer (0,4 M Tris-HCl, pH 8,0 at 
20°C; 60 mM MgCl2; 100 mM dithiothreitol; 20 mM spermidine), 1 mM of each ATP, CTP 
and UTP, 500 µM of GTP, 1 mM of m7G(5')ppp(5')G, 50 units of RNasin and 50 units of 
SP6 RNA polymerase and incubated for 2 h at 37 °C. The correct length of  the transcripts 
was verified by agarose gel electrophoresis. RNA was stored at -20°C.  
 
Cell transfection  
For transfection, BHK cells were trypsinized, washed onces in PBS (w/o MgCl2 and CaCl2) 
and finally resuspended in PBS resulting in a cell number of 1x107 cells per ml.  800 µl of the 
cell suspension were mixed with the individual SFV-RNA and then transferred to a 0.4 cm 
cuvette. Transfections were carried out by electroporation at room temperature by two 
consecutive pulses at 0,8 kV/25 µF using a Gene Pulser (BioRad). Cells were diluted in 
complete growth medium and plated on 10 cm cell culture dishes. For IF microscopy 
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maximal 1/10 volume of the electroporated cells (8x105) was diluted in complete growth 
medium and transferred onto 35 mm wells containing a sterile glass coverslip. Cells were 
incubated for at least 24 h. Transfection efficiencies as determined by transfecting SFV3-lacZ 
control RNA followed by X-gal staining were almost 100% for BHK cells. 
 
Deglycosylation assay 
8x106 BHK cells were transfected with recombinant SFV RNA as described above and plated 
on 10 cm culture dishes. 24 h post transfection cells were washed once with PBS, scraped off 
in PBS, harvested by centrifugation and finally lysed in 250 µl N-glycosidase F buffer by 
repeated freezing and thawing. The crude lysates were obtained by centrifugation at 14000 
rpm 4°C for 15 min. A 20 µl aliquot of the supernatants were then treated with 2 units of N-
glycosidase F (Roche Diagnostics) at 37 °C over night and analysed by western blotting. 
 
Proteinase K digestion 
8x106 BHK cells were transfected with recombinant SFV RNA as described above and plated 
on 10 cm culture dishes. 24 h post transfection cells were washed once with PBS, scraped off 
in PBS and harvested by centrifugation. Cells were resuspended in lysis buffer (10 mM Tris 
pH 7,5, 100 mM NaCl, 10 mM EDTA, 0,5% Triton-X100, 0,5% DOC) and finally lysed on 
ice for 15 min. The crude lysates were obtained by centrifugation at 14000 rpm 4°C for 15 
min. proteinase K (Roche Diagnostics) was added to a 20 µl aliquot to get a final 
concentration of 2, 4 and 8 µg/ml. Reactions were carried out at 37 °C for 30 min, stopped 
with 0,5 mM pefabloc and analysed by western blotting.  
 
Western blot analysis 
After addition of Laemmli buffer, protein samples were separated on 12% SDS-
polyacrylamide gels by SDS-PAGE and transferred to PVDF membranes Immobilon P 
(Millipore Corp.) for 1,5 h at 55 V. The membranes were blocked with I-Block (Tropix) in 
Tris-buffered saline pH 7,5 supplemented with 0,05% Tween, probed with the monoclonal 
anti-PrP antibodies 3B5 or 3F4 and thereafter with an appropiate peroxidase-coupled 
secondary antibody. The immunoreactivity was visualized by enhanced chemiluminescence 
(NEN Life Science Products) on Kodak BioMax MR-1 films and by staining with 
diaminobenzidine-tetrahydrochloride (Sigma). 
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Immunofluorescence analysis 
To investigate the cellular localization of recombinant prion proteins in BHK cells, we used 
immunofluorescence microscopy. 24 hours post-transfectionally, cells were washed three 
times with PBS and fixed with 4% paraformaldehyde. Non-permeabilized cells were fixed 
with 2 % paraformaldehyde. After rinsing 3 times with PBS, cells were permeabilized for 
cytoplasmic staining with 0.2 % Triton X-100 (10 min/4 °C). The preparation was saturated 
with a 10 % FCS solution (in PBS) for 1 h at room temperature, washed and incubated with 
the primary antibody mAB 3B5 diluted in PBS with 10 % FCS for 1 h at room temperature. 
After washing three times with PBS the preparations were diluted in saturation buffer and 
incubated in the dark for 45-60 min with the secondary antibody (goat anti mouse) conjugated 
with indocarbocyanine (Cy3) (red). For nuclear staining 1 µg/ml 4-6-diamidine-2-
phenylindole (DAPI) for 10 min at RT was used. Please note that both the primary and 
secondary antibodies were added after fixing the cells. The coverslip was mounted with 
aqueous mounting medium (Fluoromount®) and the slides were examined using an axioviert 
fluorescence microscope (Zeiss) with appropiate filters. IF images were processed using 
Metamorph software®. 
 
Purification of FLAG-tagged prion proteins by anti-FLAG antibody chromatography 
Transfection of BHK cells with the rec. SFV-huPrP227FLAG or the rec. SFV-
boPrP239FLAG RNA was performed as described above. The total volume of the 
electroporated cells was plated on 10 cm dishes containing 15 ml of complete growth medium 
followed by incubation for at least 48 h at 37 °C. 48 h post transfection, cells were harvested, 
washed once with PBS and then lysed in PBS supplemented with 0.1% Triton-X100 by 
repeated freezing and thawing. The crude lysates were obtained by centrifugation at 14 000 
rpm  4°C for 15 min. The FLAG-tagged proteins from the supernatants were bound over night 
to anti-FLAG M2 affinity gel (Sigma) by rotating at 4°C. Beads with immobilized protein 
were then washed four times with TBS, eluted over night by competition with 1 ml TBS 
containing 100 µg/ml FLAG peptides (Sigma) and dialyzed against 20 mM HEPES, pH 7.4. 
The purity and the concentration of the proteins were checked by SDS polyacrylamide gel 
electrophoresis followed by silver staining of the gel. 
 
Antibodies 
For western blot anaylses monoclonal anti-PrP antibodies 3F4 (Chemicon) and 3B5 (G. 
Hunsmann) were used. For IF analyses mAb 3B5 and a secondary Cy3 (indocarbocyanine) 
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conjugated antibody (used at 1:200 dilutions) (Jackson Laboratories and Southern 
Biotechnology, respectively) was used.  
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Table I. Summary of cellular localization and proteinase K status of rec. PrP mutantsa-g 
 
PrP mutants Human 
Disease 
  
Expression system  Cellular localization Proteinase K status
MoPrP PG14  
(+9OR)a 
fCJD  
(model) 
BHK cells transfected 
with Sindbis viral 
replicona 
Low level cell-surface 
expressiona; retention in the 
endoplasmic reticuluma 
resistant  
(up to 1 µg/ml PK  
30 min 37°C)a 
MoPrP PG11 
(+6OR)b,c,d 
fCJD 
(model) 
Stably transfected  
CHO cells 
(pBC12/CMV)b,c,d 
Cell-surface expression with 
additional mode of membrane 
associationb,c 
resistant  
(3,3 µg/ml PK  
10 min 37°C)b,d 
MoPrP E199Kb,d fCJD 
(model) 
Stably transfected CHO 
cells (pBC12/CMV)b,d 
Cell-surface expression with 
additional mode of membrane 
associationb 
resistant  
(3,3 µg/ml PK  
10 min 37°C)b,d 
MoPrP 
D177N/M128a,b 
FFI 
(model) 
Stably transfected CHO 
cells (pBC12/CMV)a,b 
Low level cell-surface 
expressiona; additional mode of 
membrane associationb; retention 
in the endoplasmic reticuluma 
resistant  
(3,3 µg/ml PK  
10 min 37°C)b 
MoPrP P101La,b GSS 
(model) 
Stably transfected CHO 
cells (pBC12/CMV)a,b 
Low level cell-surface 
expressiona; additional mode of 
membrane associationb; retention 
in the endoplasmic reticuluma 
resistant  
(3,3 µg/ml PK  
0 min 37°C)b 
HaPrP+2/4/6ORe fCJD 
(model) 
Mouse fibroblast cells 
transf. with retroviral 
vectore 
Aberrant cell-surface expressione resistant  
(up to 0,8 µg/ml 
PK 10 min 37°C)e 
HaPrP+4/6ORe fCJD 
(model) 
Mouse neuroblastoma 
cells  transf. with 
retroviral vectore 
Normal cell-surface expressione resistant  
(up to 1 µg/ml PK  
10 min 37°C)e 
HuPrP 
D178N/V129f 
fCJD Human neuroblastoma 
cells transf. with 
episomal vectorf 
 
Impaired transport of 
unglycosylated PrP to the cell 
surfacef 
sensitive (at least  
0.5 µg/ml PK 1 h 
or 5 µg/ml PK  
5 min 37°C)f 
HuPrP E200Kh fCJD Human neuroblastoma 
cells transf. with 
episomal vectorh 
Underrepresentation of 
unglycosylated PrP at the cell 
surfaceh 
resistant 
(3,3 µg/ml PK  
10 min 37°C)h 
HuPrP 
D178N/M129f 
FFI Human neuroblastoma 
cells transf. with 
episomal vectorf 
 
Impaired transport of 
unglycosylated PrP to the cell 
surfacef 
sensitive (at least  
0.5 µg/ml PK 1 h 
or 5 µg/ml PK  
5 min 37°C)f 
HuPrP 
Q217R/V129g 
GSS Human neuroblastoma 
cells transf. with 
episomal vectorg 
Impaired transport to the cell 
surfaceg; accumulation of 
aggregated PrP in intracellular 
compartmentsg 
resistant  
(3,3 µg/ml PK  
5 min 37°C)g 
HuPrP+9OR fCJD BHK cells transfected 
with Semliki Forest 
virus RNA 
Expression at the cell surface and 
in intracellular compartments 
 
resistant* 
(8 µg/ml PK  
30 min 37°C) 
HuPrP 
D178N/M129 
FFI BHK cells transfected 
with Semliki Forest 
virus RNA 
Expression at the cell surface and 
in intracellular compartments 
 
resistant* 
(8 µg/ml PK  
30 min 37°C) 
fCJD: familial Creutzfeldt-Jakob disease; FFI: Fatal Familial Insomnia; GSS: Gerstmann-Sträussler-Scheinker 
syndrome 
MoPrP: mouse PrP; HaPrP: hamster PrP; HuPrP: human PrP; +OR: additional octarepeats;  
transf.: transfected; assoc.: association; PK: proteinase K 
a (Ivanova et al., 2001) b (Lehmann and Harris, 1996a) c (Lehmann and Harris, 1995) d (Lehmann and Harris, 
1996b) e (Priola and Chesebro, 1998) f (Petersen et al., 1996) g (Singh et al., 1997) h (Capellari et al., 2000)   
*data described in this manuscript 
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Fig. 1: Expression of wild-type as well as mutant human PrP and wild-type bovine PrP in 
transfected BHK cells and the effect of N-glycosidase F. Immunoblot analysis of prion 
proteins from total cell lysates of transfected BHK cells. Cells were transiently transfected 
with recombinant SFV RNAs encoding wild-type human PrP (lane 1), human PrP-FFI (lane 
3), human PrP+9OR (lane 5) and wild-type bovine PrP (lane 7). 24 h p.t. the expression was 
analysed with mAb anti-PrP 3B5. Glycosylation patterns: di-, mono- and non-glycosylated 
PrP isoforms. Analysis of prion proteins huPrP (lane 2), huPrP-FFI (lane 4), huPrP+9OR 
(lane 6) and boPrP (lane 8) after N-glycosidase F treatment.  
 
 
 
 
Fig. 2: Proteinase K status of prion protein mutants from total cell lysates of transfected BHK 
cells. Cells were transiently transfected with recombinant SFV RNAs encoding wild-type 
human PrP (lanes 1-4), human PrP-FFI (lanes 5-8) and human PrP+9OR (lanes 9-12). 24 h 
p.t. the expression was analysed by western blotting using mAb anti-PrP 3F4. Crude lysates 
were treated with increasing amounts of PK for 30 min at 37 °C: 0 µg/ml (lanes 1, 5 and 9), 2 
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µg/ml (lanes 2, 6 and 10), 4 µg/ml (lanes 3, 7 and 11) and 8 µg/ml (lanes 4, 8 and 12). PK 
resistant bands range fom 23 to 25 kDa as indicated (brackets). 
 
 
 
 
Fig. 3: Localization of huPrP, huPrP-FFI, huPrP-9OR and boPrP at the surface and in 
intracellular compartments of BHK cells transfected with rec. SFV RNAs. Subcellular 
location was determined by IF using the mAb anti-PrP 3B5 and a secondary Ab (goat anti-
mouse IgG) konjugated with indocarbocyanine (Cy3). Cell surface immunostaining of non-
permeabilized BHK cells transfected with (A) SFV-1 RNA (without any insert), (B) rec. 
SFV-huPrP1-253 RNA, (C) rec. SFV-huPrP-FFI RNA, (D) rec. SFV-huPrP+90R RNA and  
(E) rec. SFV-boPrP1-264 RNA. Insets A-E: Intracellular immunostaining of permeabilized, 
transfected BHK cells. (magnification A-E: x630).  
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Fig. 4: Expression of glycosylated FLAG-tagged human and bovine PrP in BHK cells 
transfected with rec. SFV RNAs (A) Constructs of human PrP containing a FLAG-tag 
insertion either between aa 227 and 228 close to the GPI-anchor adhesion site or behind the 
N-terminal signal peptide between aa 22 and 23 and a bovine PrP construct with the FLAG-
tag inserted between aa 239 and 240. (B) Expression and deglycosylation of wild-type and 
FLAG-tagged human PrP. (C) Expression and deglycosylation of wild-type and FLAG-
tagged bovine PrP. Total cell extracts from SFV-transfected BHK cells were incubated over 
night with N-glycosidase F at 37 °C and analysed by western blotting. For detection mAb 
anti-PrP 3B5 was used. FLAG-tagged prion proteins were glycosylated in the same manner as 
wild-type PrP (B, lane 2 and 3 and C, lane 2) . After treatment with N-glycosidase F the 
glycosylated forms are clearly reduced accompanied by an increase of the non-glycosylated 
forms (B, lane 4, 5 and 6; C, lane 3 and 4). The shift in the molecular weight of non-
glycosylated FLAG-tagged PrPs is due to the additional eight amino acids  of the FLAG-tag.  
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Fig. 5: Subcellular localization of wild-type and FLAG-tagged human and bovinePrP in BHK 
cells transfected with rec. Semliki Forest virus RNAs. Subcellular location was determined by 
IF employing the mAb anti-PrP 3B5 and a secondary Ab (goat anti-mouse IgG) konjugated 
with indocarbocyanine (Cy3). Immunostaining of non-permeabilized BHK cells transfected 
with (A) SFV-1 RNA (without any insert), (B) rec. SFV-huPrP1-253 RNA, (C) rec. SFV-
huPrP22FLAG RNA, (D) rec. SFV-huPrP227FLAG RNA, (E) rec. SFV-boPrP1-264 RNA 
and (F) rec. SFV-boPrP239FLAG RNA. Insets A-F: Intracellular immunostaining of 
permeabilized, transfected BHK cells, respectively. (magnification A-F: x630).  
 
 
 
 
Fig. 6: Anti-FLAG-antibody purification of FLAG-tagged prion proteins from BHK cells. (A 
and B) Total cell extracts from transfected BHK cells expressing huPrP227FLAG (A) or 
boPrP239FLAG (B) were analysed by western blotting employing mAb anti-PrP 3B5. In 
order to purify FLAG-tagged PrP, crude lysates (cl) (A and B, lanes 1) were immobilized to 
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anti-FLAG M2 affinity gel (i) (A, B, lanes 2) and eluted by competition with FLAG peptides 
(e) (A and B, lanes 3). The arrows indicate the heavy and the light chain of the mAb anti-
FLAG M2 (A and B, lanes 2). (C) The silver stained gel shows purified glycosylated 
huPrP227FLAG and boPrP239FLAG.  
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Abstract 
Recently, crystallization of the prion protein in a dimeric form was reported. Here we show 
that native soluble homogeneous FLAG tagged prion proteins from hamster, man and cattle 
expressed in the baculovirus system are predominantly dimeric. The PrP/PrP interaction was 
confirmed in SFV-RNA transfected BHK cells co-expressing FLAG and oligohistidine 
tagged human PrP. The yeast two-hybrid system identified the octarepeat region and the C-
terminal structured domain (aa90-aa230) of PrP as PrP/PrP interaction domains. Additional 
octarepeats identified in patients suffering from  fCJD reduced (wtPrP versus PrP+9OR) and 
completely abolished (PrP+9OR versus PrP+9OR) the PrP/PrP interaction in the yeast two-
hybrid system. In contrast, the Met/Val polymorphism (aa129), the GSS mutation Pro102Leu 
and the FFI mutation Asp178Asn did not affect PrP/PrP interactions. Proof of interactions 
between human or sheep and bovine PrP, and sheep and human PrP as well as failure of 
interactions between human or bovine PrP and hamster PrP suggest that interspecies PrP 
interaction studies in the yeast two-hybrid system may serve as a rapid pre-assay system to 
investigate species barriers in prion diseases. 
 
 
Introduction 
Prions are thought to be the infectious agents of transmissible spongiform encephalopathies 
(TSEs) (for review, see Ref. (Lasmézas and Weiss, 2000; Prusiner et al., 1998; Weissmann 
and Aguzzi, 1997)). Several binding partners for the cellular form of the prion protein have 
been identified (for review (Gauczynski et al., 2001a)) among them are molecular chaperones 
such as Hsp60 (Edenhofer et al., 1996), protein X (Kaneko et al., 1997b) and the 37 kDa/67 
kDa laminin receptor (Rieger et al., 1997), very recently identified as the receptor for the 
cellular prion protein (Gauczynski et al., 2001b). Direct interactions of the prion protein with 
itself have not been investigated so far. 
One of the proposed models explaining the replication of prions is the protein only hypothesis 
(Alper et al., 1967; Griffith, 1967; Prusiner, 1982) which states that a PrPSc monomer 
interacts with a PrPc monomer to form a PrPSc/PrPc heterodimer. PrPSc then converts PrPc 
to a PrPSc homodimer by changing its secondary/tertiary structure. Another model states that 
a nucleus or seed consisting of PrPSc molecules incorporates PrPc monomers starting a 
nucleation dependent polymerization or crystal seed reaction in which the PrPc monomers 
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become converted to PrPSc molecules (Lansbury and Caughey, 1995). Both models result in 
an oligo-/multimerization process finally leading to PrPSc aggregation.  
PrP dimers (for review see (Gauczynski et al., 2001a)) could play an essential role in this 
conversion process and have been characterized as an intermediate state during PrP-
multimerization as analyzed by fluorescence correlation spectroscopy (FCS) (Jansen et al., 
2001; Post et al., 1998). PrP dimers have been observed in N2a cells and in scrapie-infected 
hamster brains (Priola et al., 1995). Molecular modelling suggested the existance of PrP/PrP 
dimers (Warwicker and Gane, 1996), which might be involved in PrP interspecies 
transmission (Warwicker, 1997). The existence of a monomer-dimer equilibrium of partially 
purified PrPc from cattle has been shown (Meyer et al., 2000). Very recently, crystallization of 
dimeric PrP has been reported involving domain swapping of -helical structures (Knaus et 
al., 2001). Here we show by size exclusion chromatography that recombinant FLAG tagged 
PrP from hamster, human and cattle, purified to homogeneity from the baculovirus system, 
elute predominantly as dimers under native conditions. In the presence of DTT, the 
monomeric PrP form was marginally increased suggesting that disulfide bonds do not 
contribute to dimer formation. We confirmed the PrP/PrP interaction in BHK cells co-
expressing oligohistidine and FLAG tagged prion proteins using recombinant Semliki Forest 
virus RNAs. Employing the yeast two-hybrid system, in which the PrP/PrP interaction was 
further confirmed, we identified both the octarepeat region and the carboxyterminus of the 
prion protein (PrP90-230) as PrP/PrP interaction domains.  
Defined mutations within the Prn-p gene lead to familial Creutzfeldt Jakob Disease (fCJD), 
Gerstmann-Sträussler-Scheinker (GSS) Syndrom and fatal familial insomnia (FFI) (for review 
see (Lasmézas and Weiss, 2000)). A series of mutations affect the octarepeat region of the 
prion protein. fCJD-patients encompassing two (Goldfarb et al., 1993), four (Campbell et al., 
1996), five (Goldfarb et al., 1991), six (Owen et al., 1990), seven (Goldfarb et al., 1991), 
eight (Goldfarb et al., 1991) and nine additional octarepeats (Owen et al., 1992) have been 
described. All these patients are heterozygous regarding these mutations (Majtenyi et al., 
2000). The mutation 102 proline to leucine leads to GSS (Goldgaber et al., 1989). The 
polymorphism at position 129 of the human prion protein determines whether an organism 
suffers from FFI (position 178 Asp to Asn together with methionine at position 129), fCJD 
(position 178 Asp to Asn together with valine at position 129) or remains healthy (178 Asp 
and 129 Met or 129 Val) (Tateishi et al., 1995 and references therein). Each patient suffering 
from nvCJD investigated so far was homozygous for methionine at position 129 (Zeidler et 
al., 1997). We investigated whether relevant mutations and polymorphisms within the Prn-p 
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gene affect the PrP/PrP interaction behaviour. Mutated PrP proteins with alterations in the 
octarepeat region, the first PrP/PrP binding domain, encompassing two, five and nine 
additional octarepeats reduced the PrP/PrP interaction when tested against wild-type PrP, and 
completely abolished the PrP/PrP interaction when PrP+5OR or PrP+9OR were tested against 
themselves. Point mutations which are located in the second PrP/PrP interaction domain (90-
230), however, leading to amino acid substitutions at position 102 (proline to leucine), 129 
(methionine to valine) and 178 (aspartate to asparagine), respectively, did not influence the 
PrP/PrP interaction behaviour as assayed in the yeast two-hybrid system suggesting a 
pathogenic mechanism different from that induced by the additional octarepeats. Finally we 
investigated interspecies interactions of prion proteins of different species including man, 
cattle, sheep and hamsters in the yeast two-hybrid system, suggesting that this system might 
be a useful and rapid pre-assay system to investigate species barriers in prion diseases. 
 
 
Results 
Recombinant human, bovine and hamster PrP are dimeric under native conditions 
FLAG tagged human, bovine and hamster PrP were synthesized in Sf9 cells infected with 
recombinant baculoviruses and purified to homogeneity by anti-FLAG-antibody 
chromatography. The homogeneous PrP from hamster, cattle and man revealed a molecular 
weight of approx. 27 kDa under denaturing conditions on an SDS-PA-gel (Figure 1 A, D and 
G) and was recognized by PrP specific antibodies (Figure 1 B, E and H). Under native 
conditions, however, FLAG tagged hamster, bovine and human PrP revealed molecular 
weights of 53, 54 and 53 kDa, respectively, and to a minor extent molecular weights of 24, 25 
and 24 kDa, respectively, as determined by size exclusion chromatography (Figure 1 C, F and 
I), demonstrating that PrP from these three species are predominantly dimeric under native 
conditions. The measured values are close to the values derived from the individual amino 
acid sequences, which are 23,9; 24,5 and 23,7 kDa, respectively for hamster, bovine and 
human PrP. In the presence of DTT, the proportion of the monomeric form of human PrP was 
increased from 1.9 to 6.6 % wheras the proportion of the dimeric form decreased from 98.1 to 
93.4 %  (Figure 1 J), suggesting that intermolecular disulfide bonds do not or only marginally 
contribute to PrP dimer formation. The FLAG tagged heat shock protein Hsp60 synthesized 
in the baculovirus system (Figure 1 K, L) was monomeric under native conditions as 
measured by size exclusion chromatography (Figure 1 M) demonstrating that the FLAG tag is 
not responsible for the dimerization behaviour of FLAG tagged PrP.  
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PrP/PrP interaction in recombinant Semliki Forest virus (SFV)-RNA transfected BHK 
cells co-expressing oligohistidine and FLAG tagged PrP 
In order to confirm the PrP/PrP interaction in an eucaryotic system, we chosed BHK cells co-
expressing highly glycosylated oligohistidine and FLAG tagged human prion proteins after 
transfection with recombinant Semliki Forest virus RNAs. The protein/protein interaction was 
investigated by pull-down assays immobilizing oligohistidine tagged PrP on nickel columns 
followed by the detection of the interacting FLAG tagged protein with an anti-FLAG 
antibody. After co-expression of PrP227-oligohistidine-228 and PrP227-FLAG-228, the non-, 
mono-, and diglycosylated forms of FLAG tagged PrP were detectable (Figure 2, lane 3), 
demonstrating the interaction of both prion proteins in BHK cells. Expression of FLAG 
tagged PrP alone resulted in a weak background binding to the nickel-column due to the 
histidine-rich octa-repeat region of PrP (lane 4). As positive controls the PrP interacting 
proteins 37 kDa laminin receptor precursor (LRP) (Rieger et al., 1997; Gauczynski et al., 
2001b; Hundt et al., 2001) and Hsp60 (Edenhofer et al., 1996) (lane 1) both tagged with 
FLAG were used. Both proteins bound to oligohistidine tagged PrP (lane 1 and 2, 
respectively). The system confirms the PrP/PrP interaction in BHK cells. 
 
PrP/PrP interaction and identification of PrP/PrP interaction domains by yeast two-
hybrid analyses   
Co-expression of human PrP tagged to the highly soluble GST in bait and prey position of the 
yeast two-hybrid system (Gyuris et al., 1993) resulted in a strong interaction of both proteins 
(Figure 3, row 3) confirming the PrP/PrP interaction observed in recombinant SFV-RNA 
transfected BHK cells. GST failed to interact with itself and with GST::PrPc (Figure 3, rows 1 
and 2, respectively). Next, we investigated which regions of the prion protein are involved in 
the PrP/PrP interaction process. The highly flexible unstructured octarepeat region of PrP 
(Donne et al., 1997; Riek et al., 1997) (also known as the proline/glycine rich region), which 
has been shown to bind copper in vivo (Brown et al., 1997), consists of five (six in cattle) 
repeats of a stretch of eight amino acids (PHGGGWGQ). Co-expression of the human PrP 
octarepeat domain in both positions of the yeast two-hybrid system resulted in a strong 
interaction between the two truncated PrP proteins (Figure 3, row 5). The ultimate amino 
terminus of PrP (aa23-50), however, failed to interact with itself (Figure 3, row 6), 
demonstrating that this region of PrP is not involved in the PrP/PrP interaction. Deletion of 
the octarepeat domain resulted in a weaker interaction signal (Figure 3, row 4), suggesting the 
existance of a second PrP/PrP interaction domain. Co-expression of PrP90-230 in both bait 
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and prey position of the yeast two-hybrid system indeed resulted in a strong interaction signal 
(Figure 3, row 7). In summary, these data demonstrate that the octarepeat region and PrP90-
230 contribute to PrP/PrP interactions. 
 
Additional octarepeats located in the first PrP/PrP interaction domain impede PrP/PrP 
interaction 
Since the octarepeat region represents a PrP/PrP interaction domain, we investigated whether 
additional octarepeats identified in familial CJD patients might influence the PrP interaction 
behaviour. When human PrP encompassing two (Figure 4, row 7), five (row 8) and nine (row 
9) additional octarepeats were expressed in bait versus wild-type PrP in prey position of the 
yeast two-hybrid system, the PrP/PrP interaction was only slightly diminished. This situation 
mimics the heterozygous state in all patients investigated so far expressing the mutated PrP on 
one allele and the wild-type PrP from the other allele. However, when mutated human prion 
proteins encompassing two (Figure 4, row 4), five (row 5) and nine (row 6) additional 
octarepeats were co-expressed in both positions of the yeast two-hybrid system reflecting a so 
far hypothetical case of a patient homozygous for this Prn-p mutation, the PrP/PrP interaction 
was in the case of two additional octarepeats strongly reduced (row 4) and in case of five (row 
5) and nine (row 6) additional octarepeats completely abolished. 
 
The mutations  Pro102Leu (GSS) Asp178Asn (FFI) and the polymorphism Met129Val  
do not influence the PrP/PrP interaction 
We investigated the polymorphism Met-Val at position 129, the mutation Pro-Leu at position 
102 and the mutation Asp-Asn at position 178 (polymorphism aa129 methionine) of the 
human prion protein with respect to their influence on the PrP/PrP interaction behaviour. 
Neither this polymorphism nor the mutation at position 102 expressed in bait position versus 
wild type PrP in the prey position (Figure 5, lanes 6 and 4, respectively) or both expressed in 
both bait and prey position (Figure 5, lanes 7 and 5, respectively) reflecting the heterozygous 
and homozygous state, respectively, affected the PrP/PrP interation behaviour. In addition, the 
FFI related mutation 178 Asp to Asn (aa129 methionine) did not influence the PrP/PrP 
interaction behaviour when expressed in bait versus wild-type PrP in prey position 
(heterozygous case; Figure 5, lane 8). We conclude that both mutations together with the 
polymorphism which all reside within PrP90-230 have no influence on the PrP/PrP 
interaction behaviour. Thus PrP dimers can be formed in all familial CJD (including cases due 
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to additional octarepeats since they are exclusively heterozygous), GSS and FFI cases 
investigated. 
 
Interaction of prion proteins of different species in the yeast two-hybrid system 
In order to investigate whether prion proteins of different species interact with each other, we  
verified the interaction between prion proteins of different species in the yeast two-hybrid 
system. As already observed with human PrP (Figure 3), bovine PrP (Figure 6, row 5), ovine 
PrP (AQ) (Figure 6, row 8) and hamster PrP (Figure 6, row12) also interact with each other. 
Regarding interspecies interactions, human PrP interact with bovine PrP (Figure 6, row 6) and 
ovine PrP (AQ) (Figure 6, row 10), but not with hamster PrP (Figure 6, row 13). Bovine PrP 
shows an interaction with ovine PrP (Figure 6, row 9) but no interaction with hamster PrP 
(Figure 6, row 14). For specificity controls all PrP species failed to interact with GST (Figure 
6, row 2, 4, 7 and 11).  
 
 
Discussion 
According to the protein only hypothesis (Prusiner, 1982) and the nucleation dependent 
polymerization model (Lansbury and Caughey, 1995), PrPc converts into PrPSc by either a 
PrPSc monomer (Prusiner, 1982) or a PrPSc seed (Lansbury and Caughey, 1995). Recently, 
PrP dimers have been characterized as an intermediate state during the PrP-oligo- and 
multimerization process analyzed by fluorescence correlation spectroscopy (FCS) (Post et al., 
1998). PrP dimers consisting of -helical PrP monomers were only stable for less than a 
minute but PrP dimers consisting of mainly -sheeted monomers have been found to be stable 
for about 10 minutes (Post et al., 1998). Recently, a soluble and stable -helical intermediate 
of recombinant hamster PrP (90-231) was identified by size exclusion chromatography and 
chemical cross-linking (Jansen et al., 2001). PrP dimers have also been described in 
uninfected mouse neuroblastoma cells (Priola et al., 1995) with an approximate molecular 
weight of 60 kDa. Similar 60-kDa PrP molecules were identified in scrapie-infected hamster 
brains but not in uninfected brains (Priola et al., 1995). These authors suggested that the 60-
kDa dimeric PrP might contribute to the conversion of protease-sensitive to protease K 
resistant PrP. 
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Dimerization of recombinant prion proteins from human, cattle and hamster under 
native conditions 
A monomer-dimer equilibrium of partially purified PrPc from cattle has been described 
(Meyer et al., 2000). Very recently, crystallization of  the dimeric recombinant PrP has been 
reported involving domain swapping of the C-terminal helix 3 and rearrangement of the 
disulfide bond (Knaus et al., 2001). We show in this manuscript that recombinant full-length 
FLAG tagged PrP from human, cattle or hamster from insect cells infected with recombinant 
baculoviruses appear predominantly dimeric under native conditions. Our recombinant PrP 
was purified under native conditions from the medium of insect cells infected with 
recombinant baculoviruses. Addition of DTT increases the monomeric form of PrP slightly, 
suggesting that disulfide bridges do not or only marginally participate in PrP dimer formation. 
We can exclude that the FLAG tag used for purification induces dimerization of our 
recombinant protein, since FLAG tagged Hsp60 appeared to be solely monomeric. 
 
PrP/PrP interactions in BHK cells transfected with recombinant SFV-RNAs 
In order to prove the PrP/PrP interaction in highly developed eucaryotic cells, we transiently 
co-expressed FLAG tagged and oligohistidine tagged PrP in BHK cells using the Semliki 
Forest virus system. Employing pull down assays, we demonstrated the interaction of these 
highly glycosylated prion proteins in an evolutionary highly developed cell system. 
 
PrP/PrP interactions and identification of PrP/PrP interaction domains 
Direct PrP/PrP interactions have not been reported so far. We employed the yeast two-hybrid 
system as a powerful tool for the detection of protein/protein interactions (Gyuris et al., 
1993). The yeast two-hybrid system is also useful for the identification of interaction domains 
of  cytosolic (Lopez et al., 2001) and membrane-associated proteins (Bowman et al., 2000). 
Expression of PrP in bait and prey position of the yeast two-hybrid system resulted in a direct 
interaction of both proteins. Expression of PrP truncations and deletion mutants in the same 
system identified the octarepeat region as one PrP/PrP interaction domain with a copper 
binding capacity in vivo (Brown et al., 1997) and an intrinsic superoxide dismutase activity 
(Brown, 1999). This flexible unstructured region of PrP (Donne et al., 1997; Riek et al., 
1997) might be important for the physiological function of the prion protein and might be 
involved in the PrPc/PrPSc conversion process. The internalization process of the prion 
protein is governed by metal binding to octarepeats (Sumudhu et al., 2001). Very recently, the 
octarepeat region has been identified as an indirect interaction domain for the binding of the 
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prion protein to its 37 kDa/67 kDa laminin receptor mediated by cell surface heparan sulfate 
proteoglycans (HSPGs) (Hundt et al., 2001).  
Deletion of the octarepeat region resulted in a weaker PrP/PrP interaction in the yeast two-
hybrid system suggesting that a second PrP/PrP interaction domain within the 
carboxyterminal part of PrP may exist. Co-expression of PrP90-230 in both positions of the 
yeast two-hybrid system resulted in a direct interaction between both truncated PrP 
molecules, demonstrating that the carboxy-terminus of PrP (PrP90-230) represents a second 
PrP/PrP interaction domain. Since DTT affects PrP dimerization only marginally (Figure 1 J), 
we conclude that intermolecular disulfide bridges do not or only marginally contribute to PrP 
dimer formation. 
 
Influence of additional octarepeats in PrP/PrP interaction processes 
Additional octarepeats have been identified in patients suffering from familial CJD (Campbell 
et al., 1996; Goldfarb et al., 1993; Goldfarb et al., 1991; Owen et al., 1992; Owen et al., 
1990). PrP encompassing nine additional octarepeats associated with familial CJD failed to 
undergo Cu2+ -mediated endocytosis, suggesting that neurodegeneration may arise from the 
ablation of internalization due to mutation of the octarepeats (Sumudhu et al., 2001). Since 
these mutations affect the octarepeat region as one PrP/PrP interaction domain, we 
investigated whether these mutations may influence the PrP/PrP interaction behaviour. 
Expression of mutated PrP encompassing two, five and nine additional octarepeats in bait 
position versus wild-type PrP in prey position of the yeast two-hybrid system diminished 
slightly the PrP/PrP interaction process. This situation mimics heterozygous CJD patients 
with the mutated Prn-p gene on one allele and the wild-type Prn-p on the other (Majtenyi et 
al., 2000). Expression of mutated PrP with five and nine additional octarepeats in both 
positions of the yeast two-hybrid system resulted in total inhibiton of the PrP/PrP interaction 
reflecting a to our knowledge hypothetical homozygous CJD patients expressing this mutated 
PrP on both alleles of the Prn-p gene. Our results suggest that PrP/PrP interactions take place 
in all heterozygous CJD patients expressing additional octarepeats. 
Transgenic mice expressing a mutant PrP encompassing nine additional octarepeat copies 
exhibit a slowly progressive neurological disorder characterized clinically by ataxia and 
neuropathologically by cerebellar atrophy and granule cell loss, gliosis, and PrP deposition 
that is most prominent in the cerebellum and hippocampus (Chiesa et al., 1998). Moreover, 
these mice produce PrP that is more pK resistant than normal PrPc (though it seems not to 
represent bona fide PrPSc), which accumulates concomitant with massive apoptosis of 
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granule cells in the cerebellum (Chiesa et al., 2000). These features are more pronounced in 
homozygous (Tg(PG14+/+) than in heterozygous (Tg(PG14+/-) mice (Chiesa et al., 2000). 
These data together with the observation that additional octarepeats cause familial CJD in 
humans demonstrate that additional nine octarepeats indeed have a pathogenic effect. 
Undimerized PrPc may not be able to full-fill its normal physiological function and be 
abnormally processed. The recent finding that nine additional octarepeats in PrP prevent the 
protein from copper mediated endocytosis (Brown et al., 1997) provides one explanation for 
the neurodegeneration observed in patients encompassing this mutation.  Whether the wild-
type prion protein appears monomeric or dimeric at the cell surface remains to be 
investigated.  
Moreover, a free N-terminus might render the non-dimerized prion protein more prone to 
misfolding and probably to conversion into PrPSc. We hypothesize that the availability of the 
second carboxyterminal PrP/PrP interaction domain is then required for PrPSc to convert 
more free PrPc molecules resulting in prion propagation. This requirement is full-filled in 
heterozygous cases of familial CJD, were PrP/PrP interaction does still occur as shown in the 
yeast two-hybrid analysis (PrP+9OR versus wild-type PrP).  
Hence, we speculate that PrP/PrP interaction via the octarepeat binding domain may be 
important for the normal physiological function of PrP and for the stabilization of PrPc/PrPc 
dimers. In the heterozygous case PrPc/PrPc interaction is reduced but PrPc/PrPSc interaction 
does still occur most likely via the second PrP/PrP interaction domain (PrP90-230). We 
speculate, thus, that this binding domain might be important for PrPc/PrPSc conversion 
process, since PrP90-230 dimers have been identified within the PrP 
oligomerization/multimerization process analyzed by FCS (Post et al., 1998; Jansen et al., 
2001). 
 
Influence of TSE relevant mutations and polymorphisms on the PrP/PrP interaction 
behaviour 
Defined mutations within the human Prn-p gene such as the Leu102Pro mutation or the 
Asp178Asn mutation lead to GSS and FFI, respectively (for review see (Lasmézas and Weiss, 
2000)). The polymorphism at position 129 Met/Val influences the susceptibility of humans 
towards FFI, fCJD and nvCJD. Interestingly enough, all patients suffering from nvCJD 
investigated so far are homozygous for methionine at this position. All these mutations and 
the polymorphism either expressed in both positions or in bait versus wild-type PrP in prey 
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position of the yeast two-hybrid system did not affect the PrP/PrP interaction process. This 
findings are in good harmony with the assumption that only mutations such as E200K 
affecting helix 3 of the prion protein may interfere with PrP dimer formation via the 
structured region of PrP.  
In summary, PrP/PrP interactions occur via the octarepeat region and the carboxyterminal 
region stretching from aa90 to 230 in case of human PrP. From these findings we assume that 
interactions of the prion protein might occur in all patients suffering from GSS, FFI, fCJD and 
nvCJD and might be important for the PrPc/PrPSc conversion process. Here, PrP/PrP 
interaction inhibitors may act as powerful tools in therapy of TSEs. Also in case of familial 
CJD caused by additional octarepeats PrP/PrP interaction may still occur most likely via the 
PrP90-230 interaction domain. Blockage of this interaction may also result in an interference 
of the PrPSc replication process. In a homozygous case, in which PrP/PrP interaction might 
be completely blocked by five or nine additional octarepeats (here also the interaction via the 
second PrP binding domain PrP90-230 is impeded probably due to sterical reasons), the 
monomeric PrP might not be processed normally and may not fulfill its normal physiological 
functions leading to the syndromes observed in transgenic mice expressing a mutated PrP 
with nine additional octarepeats. Such a PrP seems to aggregate in a more pK resistant form 
but prion replication has not been proved (Chiesa et al., 2000; Chiesa et al., 1998).  
 
Heterodimerization of prion proteins of different species 
Investigating the interspecies interaction of prion proteins, we expressed prion proteins of 
different species in bait and prey position of the yeast two-hybrid system. Bovine PrP 
interacted with human PrP, but hamster PrP failed to interact with bovine and human PrP 
(Table I). These data are in fairly good harmony with interspecies transmissions of prions. 
Indeed there is now convincing evidence from interspecies transmission studies in animals 
(Bruce et al., 1997; Lasmézas et al., 1996; Lasmezas et al., 2001) and transgenic mice (Hill et 
al., 1997; Scott et al., 1999) that cattle BSE prions have transmitted to humans (Table I). 
Hamsters have not been successfully inoculated with bovine PrP (Bradley and Wilesmith, 
1993), and Creutzfeldt-Jakob disease was only serially transmitted to Syrian hamsters via 
guinea pigs (Manuelidis et al., 1978) (Table I). In the latter case, incubation times varied 
depending on the CJD strain used. Our yeast two-hybrid data further demonstrate an 
interaction between ovine PrP (AQ) and bovine or human PrP.  There are no transmission 
data between sheep and humans (Table I). However, the ovine scrapie agent has been 
transmitted to transgenic mice expressing bovine PrP (Scott et al., 2000). Cattle  infected with 
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the scrapie agent either intracerebrally (Cutlip et al., 1994) or intramuscularly, 
subcutaneously or orally (Clark et al., 1995) developed TSEs (Table I). Although 
epidemiological data suggest that the ovine scrapie agent is hardly transmittable to humans, a 
sheep-human transmission which we suggest from our yeast two-hybrid data cannot be 
excluded. Employing the in vitro conversion system (Caughey et al., 1995) interconversion 
studies have been performed which further confirm our interspecies interaction results 
obtained from the yeast two-hybrid system: both, bovine PrPBSE and ovine PrPSc (AQ) 
converted human PrPsen, although only to a minimal extend, into a proteinase K (pK) 
resistant form (Raymond et al., 2000) (Table I). Sheep PrPsen (AQ) was converted by PrPBSE 
into the pK resistant state (Raymond et al., 1997) (Table I), whereas hamster PrPsen was not 
converted by bovine PrPBSE (Raymond et al., 1997) (Table I). In summary, our results of 
interspecies PrP interactions in the yeast two-hybrid system are in good harmony with 
transmission data obtained from transgenic and non-transgenic animals  and with 
interconversion results obtained from the in vitro conversion assay. Therefore, we suggest 
that the yeast two-hybrid system acts as a fast pre-assay system to investigate species barriers 
in prion diseases. 
Additional experiments including powerful PrP/PrP dimerization inhibitors might further 
enlighten the role of PrP dimers in the replication mechanism of prions and the physiological 
function of PrP. 
 
Table I: Comparison of interspecies interactions in the yeast two-hybrid system with interconversion studies performed by the in vitro  
conversion systema and transmission studies  in transgenic and non-transgenic animals 
PrP species PrP species Interspecies inter-
actions by the yeast 
two-hybrid system 
Interconversions by in 
vitro conversion assaysa 
Interspecies transmissions 
in transgenic mice 
Interspecies transmissions  
in animals 
human    +  +cattle + +b c d 
sheep    +  +
     
   
    
cattle + +e f g 
sheep human + +b n.d. n.d.
hamster human - n.d. n.d. via guinea pigsh 
hamster cattle - -e n.d. -i 
+: interaction in the yeast two-hybrid system, interconversion by in vitro conversion assays, transmission in transgenic mice and non-transgenic animals 
-: no interaction in the yeast two-hybrid system, no interconversion, no transmission in animals 
n.d.: not determined 
a: according to (Caughey et al., 1995) 
b: (Raymond et al., 2000) 
c: (Hill et al., 1997); (Scott et al., 1999) 
d: link between nvCJD and BSE demonstrated in macaques inoculated with PrPBSE (Lasmézas et al., 1996;)  and mice inoculated with PrPBSE / PrPnvCJD (Bruce et al., 1997), (Lasmezas et al., 2001) 
e: (Raymond et al., 1997) 
f: (Scott et al., 2000) 
g: (Cutlip et al., 1994), (Clark et al., 1995) 
h: (Manuelidis et al., 1978) 
i: (Bradley and Wilesmith, 1993) 
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Materials and methods 
Recombinant proteins generated in the Baculovirus system 
FLAG::haPrP23-231 has been generated as described (Rieger et al., 1997). cDNAs encoding 
huPrP23-230, bovPrP25-242 obtained by H. Kretzschmar, Munich, and M. Shinagawa, 
Obihiro, Japan, respectively, were generated by PCR and cloned into the transfer vector 
pFLAG-BAC (Rieger et al., 1997) via BamHI (5´) and EcoRI (3´). The Hsp60 encoding 
cDNA was amplified  from the vector pEt3a introducing a BamHI (5’) and a PstI (3’) 
restriction site and cloned into the vector pFLAG-BAC (Rieger et al., 1997). Recombinant 
viruses were generated by co-transfection of the transfer vectors with linearized viral DNA 
according to the manufacturer's instructions (Baculogold; Pharmingen). Recombinant FLAG:: 
haPrP23-231, FLAG::huPrP23-230 and FLAG::bovPrP25-242 were expressed in baculovirus 
infected Sf9 cells and purified to homogeneity as described for FLAG tagged haPrP 
previously (Rieger et al., 1997). 
 
Recombinant pSFV plasmid constructions 
Construction of SFV1-LRP::FLAG was described (Gauczynski et al., 2001b). Construction of 
pSFV1-Hsp60::FLAG. The Hsp60 encoding cDNA was amplified by PCR from pEt3a 
introducing a BamHI and a XmaI restriction site at the 5' and 3' ends. The 1755 bp fragment 
which contains the Kozak sequence and AUG at the 5' end and a FLAG-tag encoding 
sequence at the 3' end was cloned into the SFV expression plasmid pSFV1 (Liljestrom and 
Garoff, 1991) via BamHI/XmaI restriction sites, resulting in pSFV1-Hsp60::FLAG. 
Construction of pSFV1-huPrP1-227FLAG228-253 and pSFV1-huPrP1-227HIS228-253. The 
insertion of a FLAG- or a HIS-tag encoding sequence between codon 227 and 228 of the 
human PrP sequence was done by PCR using the pSFV1-huPrP1-253 plasmid DNA as a 
template. A 135 bp fragment (insertion of the FLAG encoding sequence) and a 129 bp 
fragment (insertion of the HIS encoding sequence) which both encode the carboxy-terminus 
of huPrP, were amplified introducing a StuI restriction site (endogenous site within codon 223 
- 225) at the 5' end, the tag-encoding sequence between codon 227 and 228 as well as a 
BamHI site at the 3' end. Both fragments were digested with StuI and BamHI and ligated via 
the StuI restriction site to a 707 bp fragment encoding the aminoterminal part of huPrP from 
pSFV1-huPrP1-253 digested with BamHI and StuI. The ligated DNA fragments were cloned 
into the expression plasmid pSFV1 via the BamHI restriction sites resulting in pSFV1-
huPrP1-227FLAG228-253 and pSFV1-huPrP1-227HIS228-253. The correct constructions of 
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pSFV1-Hsp60::FLAG, pSFV1-huPrP1-227FLAG228-253 and pSFV1-huPrP1-227HIS228-
253 have been confirmed by dideoxysequencing. The plasmid DNA pSFV1-huPrP1-253 was 
described elsewhere (Krasemann et al., 1996). 
 
Preparation of SFV-mRNA in vitro 
The recombinant plasmid DNAs pSFV1-huPrP1-227FLAG228-253, pSFV1-huPrP1-
227HIS228-253, and pSFV1-LRP::FLAG were linearized with SpeI, the pSFV1-
Hsp60::FLAG plasmid DNA was cut with SapI (due to the internal SpeI restriction site within 
the encoding sequence). The linearized plasmid DNAs were purified by phenol-chloroform 
extraction followed by ethanol precipitation. Transcriptions were carried out in a total volume 
of 50 µl containing 1,5 µg linearized plasmid DNA, 10x SP6 transcription buffer (0,4 M Tris-
HCl, pH 8,0 at 20°C; 60 mM MgCl2; 100 mM dithiothreitol; 20 mM spermidine), 1 mM of 
each ATP, CTP and UTP, 500 µM of GTP, 1 mM of m7G(5')ppp(5')G, 50 units of RNasin 
and 50 units of SP6 RNA polymerase and incubated for 2 h at 37 °C. The correct length of  
transcripts was proven by agarose gel electrophoresis. RNA was stored at -20 °C.  
 
Mammalian cell culture, transfection and co-transfection studies with the Semliki Forest 
virus (SFV) system 
Baby hamster kidney cells (BHK-21 C13; ATCC CCL 10) were cultured in Dulbecco's 
modified Eagle's medium supplemented with 10 % heat-inactivated fetal calf serum (FCS), 2 
mM L-glutamine, 100 µg/ml penicillin and 100 µg/ml streptomycin at 37 °C with 5 % CO2. 
Transfection and cotransfection were carried out by electroporation, where RNA was added 
directly from the in vitro transcription reaction to the BHK cells. BHK cells with a confluency 
of ~80 % were rinsed with PBS (without MgCl2 and CaCl2), trypsinized, washed again and 
finally resuspended in PBS to a density of 107 cells/ml. The total amount of transcribed RNA 
was mixed with 0.8 ml cells and the mixture transfered to a 0.4 cm cuvette. Performing 
cotransfection both RNAs were added in proportion 1:1 to the cells. Electroporation was 
carried out at room temperature by two consecutive pulses at 850 V / 25 µF using a BioRad 
Gene Pulser. The time constant after each pulse should be 0.4 to 0.5. The total volume of the 
electroporated cells (8x106) was plated on 10 cm dishes containing 15 ml of complete growth 
medium. The cells were incubated at 37 °C with 5 % CO2 for 48 h.  
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Pull down assays 
BHK cells co-expressing huPrP-HIS and FLAG-tagged proteins such as huPrP-FLAG, 
LRP::FLAG, Hsp60::FLAG (SFV-system) were harvested 48 h post transfection, washed 
once with PBS and then lysed in PBS supplemented with 0.1% Triton-X-100 at 4°C. The 
crude lysates were obtained by centrifugation at 14000 rpm 4°C for 15 min and purified by 
the batch method using a Chelating Sepharose Fast Flow gel (Pharmacia/Biotech) charged 
with nickel. The histidine-tagged protein (huPrP-HIS) was bound over night by rotating at 
4°C, washed four times with PBS and eluted over night by competition with PBS containing 
500 mM imidazole at 4°C. In order to investigate the interaction between huPrP-HIS and the 
co-expressed FLAG-tagged proteins (mentioned above) the eluates were analyzed by Western 
Blotting using the monoclonal anti-FLAG antibody M2 (Sigma). 
  
Yeast two-hybrid analysis 
Constructions of plasmid pSH2-1-GST::huPrP23-230 was described previously (Rieger et al., 
1997). The cloning procedure of all other human PrP constructs into the vector pSH2-1 was 
analogous. The GST::huPrP23-230 encoding cDNA was excised from pSH2-1-
GST::huPrP23-230 and subcloned into pJG4-5 via EcoRI and SalI. All other constructs were 
cloned into the vector pJG4-5 in the same way. The construct pSH2-1-GST::huPrPGP 
lacking the octarepeat region aa 51-91 was generated via Kunkel mutagenesis(Kunkel, 1985). 
The constructs pSH2-1-GST::huPrPGP (aa52-93), pSH2-1-GST::huPrP23-50 and pSH2-1-
GST::huPrP90-230 were amplified by PCR using oligodesoxyribonucleotides coding for the 
different PrP-sequences flanked by a BamHI (5') and a SalI (3') restriction site. The fragments 
were cloned via BamHI and SalI restriction sites into the vector pSH2-1. The construct pSH2-
1-GST::huPrP23-230+9OR was subcloned from the vector pSFV1-huPrP+9OR (gift from Dr. 
S. Krasemann). The constructs pSH2-1-GST::huPrP23-230+2OR and pSH2-1-
GST::huPrP23-230+5OR were generated by BstXI restriction of the construct with additional 
9 octarepeats and ligation of the restriction products with different length. This results in the 
insertion of 2 and 5 additional octarepeats. The constructs pSH2-1-GST::huPrP23-230P102L 
and pSH2-1-GST::huPrPM129V were cloned via Kunkel mutagenesis. The construct pSH2-1-
GST::huPrPD178N (FFI) was subcloned from the plasmid pSFV1-huPrPD178N (FFI) 
(Krasemann et al., 1996)which was a generous gift from Dr. S Krasemann. The construct 
pSH2-1-GST::bovPrP25-242 was subcloned from the plasmid pSFV1-bovPrP via BamHI 
(Krasemann et al., 1996) and SalI. The construct pSH2-1-GST::haPrP23-231 was subcloned 
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from the plasmid pGEX-2T::haPrP23-231 (Weiss et al., 1995) via BamHI and SalI. The 
construct pSH2-1-GST::shPrP25-234 (A/Q) was subcloned from a ovine DNA (generous gift 
from W. Goldmann) via BamHI and SalI. All PrP constructs were confirmed by sequencing. 
The different bait plasmids, the prey plasmid pJG4-5-LRP and the reporter plasmid pSH18-34 
(lacZ) were co-transformed into EGY48 cells and transformants were tested in a -
galactosidase assays. 
 
Size Exclusion chromatography (SEC) 
Phast System (Amersham Pharmacia)The Superose 12 PC 3.2/30 column (Amersham 
Pharmacia) was calibrated with the LMW calibration kit using the buffer 20mM HEPES pH 
7.4. 2.5 µg (25 µl) each of the  homogeneous FLAG-tagged PrP from human, bovine and 
cattle expressed in the baculovirus-system were loaded. The proteins were eluted with the 
same buffer at a flow rate of 30µl/min and detected with a UV-M II monitor at 280nm. For 
denaturation FLAG::huPrP23-230 was incubated with 100mM DTT, 95°C for 15 minutes. 
 
Antibodies 
The monoclonal anti-PrP antibody 3B5 was kindly provided by G. Hunsmann, Göttingen, 
Germany, the polyclonal antibody JB007 was a kind gift of Corinne Ida Lasmézas, Fontenay-
aux-Roses, France. Anti-FLAG antibody M2 was purchased from Sigma. Secondary anti-
mouse IgG-POD conjugated was provided by Sigma.  
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Fig. 1. Analysis of recombinant FLAG::PrP from hamster, cattle and man and FLAG::Hsp60 
under native and denaturing conditions. 400 ng of purified FLAG::haPrP23-231 were 
analyzed by SDS-PAGE (12.5 % PA) followed by silver staining of the gel (A) and Western 
Blotting (B) employing the monoclonal 3B5 antibody. (C) 6 µg of non-denatured 
FLAG::haPrP23-231 were analyzed by size exclusion chromatography (SEC) on a Superose 
12 PC 3.2/30 column (Amersham Pharmacia). Marker proteins (LMW calibration kit) are 
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indicated. 600 ng of purified FLAG::bovPrP25-242 were analyzed by SDS-PAGE (12.5 %) 
followed by silver staining of the gel (D) and Western Blotting (E) employing the 3 B5 
antibody. (F) 4 µg of non-denatured FLAG::bovPrP25-242 were analyzed by SEC as 
described above. 400 ng of FLAG::huPrP23-230 were analyzed by SDS-PAGE (12.5 % PA) 
followed by silver staining of the gel (G) and Western Blotting employing the JB007 antibody 
(H). (I) 8 µg of non-denatured FLAG::huPrP23-230 were analyzed by SEC in the absence of 
DTT as described above. (J) 6 µg of FLAG::huPrP23-230 were analyzed by SEC after 
denaturing with DTT. 300 ng of purified FLAG::HSP60 were analyzed by SDS-PAGE (12.5 
%) followed by silver staining of the gel (K) and Western Blotting (L) employing an Hsp60 
specific antibody. (M) 4 µg of non-denatured FLAG::Hsp60 were analyzed by SEC as 
described above. 
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Fig. 2.  Analysis of PrP/PrP interactions in BHK cells co-transfected with recombinant 
Semliki Forest virus RNAs. Extracts of total protein from BHK cells either non-transfected 
(lane 5), transfected with SVF1-huPrP1-227FLAG228-253 (lane 4) or co-transfected with 
SVF1-huPrP1-227FLAG228-253 and SVF1-huPrP1-227HIS228-253 (lane 3), SVF1-huPrP1-
227HIS228-253 and SFV1-LRP::FLAG (lane 2) or SVF1-huPrP1-227HIS228-253 and SFV1-
Hsp60::FLAG (lane 1) were harvested 48 h post transfection., purified by IMAC, analyzed on 
a 12% PAA-SDS gel, blotted and developed with a monoclonal anti-FLAG-antibody (M2). 
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Fig. 3.  Identification of PrP/PrP interaction domains in the yeast two-hybrid system (S. 
cerevisiae). Yeast cells containing the reporter plasmid pSH18-34 were co-transformed with 
prey plasmids pJG-GST (row 1 and 2), pJG-GST::PrP23-230 (row 3), pJG-GST::PrP∆GP 
(row 4), pJG-GST::GP52-93 (row 5), pJG-GST::PrP23-50 (row 6) and pJG-GST::PrP90-230 
(row 7) as well as the bait plasmids pSH-GST (row 1), pSH-GST::huPrP23-230 (rows 2 and 
3), pSH-GST::PrP∆GP (row 4), pSH-GST::PrP52-93 (row 5), pSH-GST::PrP23-50 (row 6) 
and pSH-GST::PrP90-230 (row 7). Each of three transformants were resuspended in TE, 
dotted on X-gal-supplemented plates and incubated at 30°C for 3 days (-galactosidase 
assay).  
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Fig. 4.  Influence of additional octarepeats on the PrP/PrP interaction behaviour. Yeast cells 
encompassing the reporter plasmid pSH18-34 were co-transformed with prey plasmids pJG-
GST (rows 1 and 2), pJG-GST::PrP23-230 (rows 3, 7, 8 and 9), pJG-GST::PrP+2OR (row 4), 
pJG-GST::PrP+5OR (row 5), pJG-GST::PrP+9OR (row 6) as well as the bait plasmids pSH-
GST (row 1), pSH-GST::PrP23-230 (row 2 and 3), pSH-GST::PrP+2OR (rows 4 and 7), pSH-
GST::PrP+5OR (rows 5 and 8), pSH-GST::PrP+9OR (rows 6 and 9) (-galactosidase assay). 
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Fig. 5.  Influence of the GSS-mutation P102L, the polymorphism M129V and the mutation 
D178N on the PrP/PrP interaction behaviour analyzed in the yeast two-hybrid system. Yeast 
cells containing the reporter plasmid pSH18-34 were co-transformed with prey plasmids pJG-
GST (rows 1 and 2), pJG-GST::PrP23-230 (rows 3, 4, 6 and 8), pJG-GST::PrP-P102L (row 
5), pJG-GST::PrP-M129V (row 7), and pJG-GST::PrP+9OR (row 9) as well as the bait 
plasmids pSH-GST (row 1), pSH-GST::PrP23-230 (rows 2 and 3), pSH-GST::PrP-P102L 
(rows 4 and 5), pSH-GST::PrP-M129V (rows 6 and 7), pSH-GST::PrP-D178N (row 8) and 
pSH-GST::PrP+9OR (row 9) (-galactosidase assay).  
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Fig. 6. Interaction analysis of PrP of different species in the yeast-two-hybrid system. The 
bait plasmids pSH-GST (row 1), pSH-GST::huPrP23-230 (rows 2 and 3), pSH-
GST::bovPrP25-242 (rows 4-6), pSH-GST::shPrP25-234 (AQ) (rows 7-10) and pSH-
GST::haPrP (rows 11-14) were co-transformed with the reporter-plasmid pSH18-34 and the 
prey-plasmids pJG-GST (rows 1, 2, 4, 7 and 11), pJG-GST::huPrP23-230 (rows 3, 6, 10 and 
13), pJG-GST::bovPrP25-242 (rows 5, 9 and 14) and pJG-GST::shPrP25-234 (AQ) (row 8) 
(-galactosidase assay).  
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Abbreviations 
aa amino acid 
Ab antibody 
Ach(R) acetylcholine (receptor) 
AD Alzheimer’s disease 
AmB amphotericin B 
APC antigen presenting cell 
APP amyloid precursor protein 
APS ammonium persulfate 
ATP adenosine triphosphate 
BD binding domain 
BHK baby hamster kidney 
boPrP bovine PrP 
bp base pair 
BSA bovine serum albumine 
BSE bovine spongiforme encephalopathy 
CD circular dichroism  
cDNA complementary (to mRNA) DNA 
CFTR cystic fibrosis transmembrane regulator 
CHO chinese hamster ovary 
CJD Creutzfeldt-Jakob disease 
CLDs caveolae-like domains 
CWD chronic wasting disease  
Cy2 carbocyanine  
Cy3 indocarbocyanine 
DAPI 4-6-diamidine-2-phenylindole 
DS-500 dextran sulfate 500 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
Dpl doppel  
ECM extracellular matrix 
e.g. for example [Lat.: exempli gratia] 
EHS Engelbreth-Holm-Swarm 
ER endoplasmic reticulum 
FACscans Fluorescence-activated cell scans 
FCS fetal calf serum 
FFI fatal familial insomnia 
FGF(R) fibroblast growth factor (receptor) 
FITC fluorescein isothiocyanate 
GAG glycosaminoglycan 
gal-3 galectin-3 
GFAP glial fibrillary acidic protein 
GPI glycosyl phosphatidylinositol 
GSS Gerstmann-Sträussler-Scheinker syndrome 
GST glutathione S-transferase 
h hour 
haPrP hamster PrP 
HPA-23 heteropolyanion 23 
Hsp heat shock protein 
HSPG heparan sulfate proteoglycan 
Abbreviations 186
huPrP human PrP 
IDX 4‘-iodo-4‘-deoxy-doxorubicin 
i.e. that is [Lat.: id est] 
IF immunofluorescence 
kb kilo bases 
kDa kilo Dalton 
LR laminin receptor 
LRP laminin receptor precursor 
LRS lymphoreticular system 
mAb monoclonal Ab 
MAFF ministery of agriculture, fisheries and food 
min minutes 
moPrP mouse PrP 
mRNA messenger RNA 
M molar 
MHC major histocompatibility complex 
MW molecular weight 
N2a murine neuroblastoma cells 
NMR nuclear magnetic resonance  
NT2 human teratocarcinoma cells 
PAA polyacrylamide 
pAb polyclonal Ab 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PIPLC phosphatidylinositol-specific phospholipase C  
PK proteinase K 
PrPc cellular prion protein 
PrP-CAA prion protein cerebral amyloid angiopathy 
Pli PrP ligand 
PrPSc prion scrapie (pathogenic isoform of PrPc)  
rec. recombinant 
rER rough endoplasmic reticulum 
RNA ribonucleic acid 
rpm rotations per minute 
SDS sodium dodecyl sulfate 
SFV Semliki Forest virus 
SP54 pentosan polysulfate 
TEMED N,N,N',N'-tetramethylethylendiamine 
TGN trans-Golgi network 
TMAO trimethylamine-N-oxide 
TMD transmembrane domain 
TNF(R) tumor necrosis factor (receptor) 
TSE transmissible spongiforme encephalopathy 
UK United Kingdom 
vCJD (new) variant CJD 
VEE Venezuelan equine encephalitis virus 
VLA-6 very late activation antigen-6 
X-gal 5-bromo-4-chloro-3-indoyl--D-galactopyranoside 
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